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Dermal fibroblasts arise from a multipotent progenitor, forming two clear populations: the 
papillary (upper) dermis and the reticular/pre-adipocyte (lower) dermis. The contribution of 
each population to hair follicle formation (papillary) and early wound healing (reticular/pre-
adipocyte) has been well characterised in the developing mouse dermis. Recent work has 
identified markers of fibroblast heterogeneity in human dermis. Transforming growth factor-
β1 (TGF-β1) promotes fibroblast-to-myofibroblast differentiation, characterised by the 
expression of α-smooth muscle actin (α-SMA). Myofibroblasts are important for successful 
wound healing but have also been associated with skin abnormalities including 
hypertrophic/keloid scarring and systemic sclerosis. Normal human dermal fibroblasts 
(NHDF), treated with TGF-β1, were assayed for differentiation, proliferation and cell shape 
using the Operetta imaging system. One donor NHDF, derived from female 64-year-old breast 
skin, expressed decreased levels of α-SMA protein. Added to a skin reconstitution assay, this 
donor NHDF failed to support epidermal stratification. The gene expression profile of this 
donor NHDF was determined using the Agilent microarray system. Four gene candidates 
(Asporin, ASPN; C-X-C motif chemokine ligand 1, CXCL1; Insulin-like growth factor 1, IGF1; and 
Wnt family member 4, WNT4) were chosen based on expression values and validated by 
TaqMan qPCR. Successful knockdown of IGF1 and WNT4 was achieved using MISSION shRNA-
based lentiviral treatment. Fibroblast IGF1 knockdown (shIGF1) increased α-SMA mRNA and 
protein expression; no effect was seen with fibroblast WNT4 knockdown (shWNT4). shWNT4 
increased epidermal stratification in skin reconstitution assays; no effect was seen with 
shIGF1. Here I have characterised NHDF phenotype and gene expression with regard to 
population heterogeneity. This work highlights the role of IGF-1 signalling on α-SMA 
expression and dermal fibroblast fate. Targeting IGF/Wnt signalling could provide therapeutic 
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Given the different roles of fibroblasts, not only in skin development and ageing but also in 
skin wounding and fibrosis, it is important to characterise fibroblast populations. This work 
aimed to examine whether functionally distinct human dermal fibroblasts can be maintained 
in culture. I wished to expand on the current understanding of fibroblast heterogeneity by 
identifying signalling pathways involved. The modification of fibroblast populations could 
have therapeutic and cosmetic benefits and is therefore of great interest to this field of 
biology.  
 
1.1 Skin structure 
The skin can be divided into three layers: the epidermis, dermis and hypodermis. The 
epidermis is composed of stratified epithelial cells and forms the outer layer of the skin. Below 
the epidermis is the dermis, separated by a basement membrane (Figure 1). The dermis can 
be divided into distinct layers. The papillary dermis is below the basement membrane, while 
the reticular dermis is located below the papillary dermis and above the hypodermis (Harper 
and Grove, 1979; Watt, 2014). Formed of adipocyte precursors and adipocytes, the 
hypodermis also contains arteries and veins which extend into the dermis as a vascular 
network (Festa et al., 2011; Driskell et al., 2014). In close association with this vascular 
network is a specialised type of fibroblast known as a pericyte (Paquet-Fifield et al., 2009).  
 
The dermis is rich in extracellular matrix (ECM) proteins primarily, collagen, elastin and 
proteoglycan. Fibroblasts within the dermis produce these ECM proteins. It is the production 
and arrangement of these components that give skin its structure, providing resistance to 
mechanical stress (Tomasek et al., 2002; Kalluri and Zeisberg, 2006). The papillary dermis is 
comprised of disorganised collagen fibres, compared with well-organised collagen bundles 
found in the reticular dermis (Sorrell and Caplan, 2004; Rognoni and Watt, 2018). Fibroblast 
density is greater in the papillary dermis while spacing between fibroblasts is greater in the 





Figure 1. Composition of mouse dorsal skin. The epidermis forms a continuous layer separated from the dermis 
by the basement membrane. Fibroblasts reside in the papillary dermis (PD), reticular dermis (RD) and 
hypodermis. The dermal papilla is associated with the follicle bulb, while the sebaceous gland is associated with 
the follicle shaft. The arrector pili muscle connects the follicle bulge to the interfollicular epidermis. Taken from 
Lynch and Watt (2018). 
 
Keratinocytes are kept in a self-renewing state in the basal layer of the epidermis through 
interactions with the stem cell niche (Fuchs, 2009). Autocrine and paracrine signalling, as well 
as adhesion to the basement membrane, form this niche. Stem cells interact with the 
basement membrane through integrin binding to ECM proteins. Integrin links intracellular 
keratin fibrils with the basement membrane at hemidesmosomes. Integrins α2β1 and α3β1 
link intracellular actin fibrils with the basement membrane at focal adhesions (Watt, 2002). 
Introduction 
 20 
Keratinocytes undergo terminal differentiation forming stratified layers of the epithelium. 
During this process the keratinocyte-basement membrane interaction changes and 
keratinocytes move through the suprabasal layers to the epidermal surface. The 
differentiated cells eventually form the stratum corneum, the outermost layer, which 
protects the skin from water loss (Simpson, Patel and Green, 2011).  
  
Melanocytes and Langerhans cells also reside in the epidermis as well as T lymphocytes; 
primarily, γδ T cells in mouse epidermis and αβ T cells in human epidermis (Foster et al., 1990). 
Melanocytes provide protection from UV damage through production of the pigment melanin 
(Gilchrest, 2013). Langerhans cells and T cells provide protection from infection during wound 
healing (Havran and Jameson, 2010).  
 
The skin contains sweat glands (apocrine and eccrine), as well as hair follicles with associated 
arrector pili muscles (APM) and sebaceous glands. Fibroblast subtypes form the APM as well 
as the hair follicle dermal sheath (Fujiwara et al., 2011; Driskell et al., 2013). Present at the 
base of the hair follicle is a condensate of fibroblasts known as the dermal papilla. The dermal 
papilla has the same developmental origin as papillary fibroblasts and controls the hair 
growth cycle (Jahoda, Reynolds and Oliver, 1993; Chi, Enshell-Seijffers and Morgan, 2010). 
Undulations in the basement membrane, separating the epidermis and dermis, are found in 
human skin. Known as rete ridges, these undulations are not present in mouse skin (Watt and 
Fujiwara, 2011).  
 
1.2 Skin ageing 
Young human skin is well vascularised and has thick epidermal and dermal layers, as well as 
organised ECM proteins. In aged human skin there is a reduction in the number of dermal 
fibroblasts as well as a reduction in the abundance and organisation of ECM proteins (Yaar, 
Eller and Gilchrest, 2002). Thinning of the papillary dermis and loss of rete ridges occurs with 





Figure 2. Loss of rete ridge height in ageing human skin. Abdominal skin from three Caucasian donors aged 30, 
53 and 66 years old. Scale bar: 100 µm. Taken from Giangreco et al., (2010). 
 
Through a better understanding of fibroblast heterogeneity and ECM production, thinning of 
the skin, and the appearance of wrinkles with age, may be reduced or prevented. Altering 
dermal fibroblast/myofibroblast populations could provide therapeutic benefit for fibrotic 
skin disorders, such as hypertrophic/keloid scarring (Ashcroft, Syed and Bayat, 2013; Sriram, 
Bigliardi and Bigliardi-Qi, 2015) and systemic sclerosis (SSc) (Varga and Abraham, 2007; Beyer, 
Distler and Distler, 2012). While great progress has been made in identifying markers of 
mouse dermal fibroblast populations, only recently have robust human fibroblast population 
markers been found. Research in this field will benefit from an improved understanding of 




1.3 Populations of dermal fibroblasts 
1.3.1 Mouse fibroblast heterogeneity 
Studies by Driskell et al., (2013) and Rinkevich et al., (2015) have addressed fibroblast 
heterogeneity in mouse dorsal skin. At embryonic day 12.5 (E12.5) a common fibroblast 
progenitor population can be found in the developing skin. By E16.5, two different fibroblast 
progenitor populations exist: papillary and reticular. These give rise to the dermal papilla and 
papillary fibroblasts as well as the reticular fibroblasts and adipocyte precursors. Conclusions 
reached through the use of lineage tracing technique and the identification of population-
specific markers.  
 
Platelet-derived growth factor receptor-α (Pdgfr-α) was used as a marker of mouse dermal 
fibroblasts from E12.5 onwards (Driskell et al., 2013). From E18.5, fibroblasts of the upper 
dermis expressed leucine-rich repeats and immunoglobulin-like domains protein 1 (Lrig1) 
while those of the lower dermis expressed delta-like homologue 1 (Dlk1). Flow cytometry-
sorted PDGFRα-H2B-eGFP postnatal day two (P2) cells injected into nude BALB/c mice 
showed cluster of differentiation 26 (CD26+) and stem-cell antigen 1 (Sca1-) fibroblasts in the 
upper dermis, while Dlk1+ Sca1+ and Dlk1- Sca1+ fibroblasts formed the hypodermal layer 
(Driskell et al., 2013). CD26 expression was associated with the upper dermis in developing 
mouse skin characterised until P2 (Figure 3).  
 
Flow cytometry-sorted CD26+ cells from aged mice (six-eight weeks of age) enriched for a 
population of dermal fibroblasts expressing engrailed 1 (En1). CD26+ cells were associated 
with the lower dermis in adult mouse skin (Rinkevich et al., 2015). En1+ cells were located in 
the upper dermis at E12.5 and in both the upper and lower dermis at P1 (Rinkevich et al., 
2015). It was further shown that En1- cells were required for development and regeneration 
in foetal mouse dermis, and that En1- cell density decreased to E18.5. From E14.5 onwards 
the density of En1+ cells increased, and En1+ fibroblasts were associated with scar formation 





Figure 3. Fibroblast heterogeneity in developing mouse dermis. Arising from a common progenitor at embryonic 
day 12.5 (E12.5), fibroblasts develop into multiple populations. Two distinct populations are associated with the 
dermal papilla (Awl/Auchene as well as Zigzag hair follicles), in addition to fibroblasts of the papillary dermis and 
reticular dermis/hypodermis at postnatal day two (P2). Adipocyte precursor cells and mature adipocytes arise 
from reticular/hypodermal progenitors, while cells comprising the arrector pili muscle (APM) arise from the 
papillary dermal progenitors. All mouse fibroblasts express platelet-derived growth factor receptor-α (Pdgfr-α). 
Papillary fibroblasts express leucine-rich repeats and immunoglobulin-like domains protein 1 (Lrig1). Reticular 
fibroblasts express delta-like homologue 1 (Dlk1). Adipocyte precursors express cluster of differentiation 24 
(CD24) and stem-cell antigen 1 (Sca1). Taken from Lynch and Watt (2018). 
 
These findings highlight the roles of different fibroblast populations during development and 
wound healing in mouse dorsal skin. Papillary fibroblasts (Lrig1+) were responsible for hair 
follicle regeneration while reticular fibroblasts (Dlk1+) were responsible for early wound 
healing, in P2 mice. Lower lineage dermal fibroblasts expressing α-smooth muscle actin (α-
SMA), were shown to support initial wound repair (Driskell et al., 2013; Rognoni et al., 2016). 
Despite changes in the expression of population-specific markers during development and 




1.3.2 Human fibroblast heterogeneity 
CD90, also known as thymocyte antigen 1 (Thy1), is a glycoprotein found on the surface of 
human fibroblasts. It is used to label fibroblasts in whole tissue and for the isolation of 
fibroblasts from digested dermis (Saalbach et al., 1997; Kisselbach et al., 2009). This approach, 
however, assumes that CD90 labels all human fibroblast populations equally. CD90 is known 
to label other cells including human mesenchymal (Haack-Sorensen et al., 2008), 
haematopoietic (Araki et al., 2007) and epidermal stem cells (Nakamura et al., 2006). While 
population markers identified in mouse dermis do not readily translate to human dermis, 
progress has been made in better understanding human dermal fibroblast heterogeneity. 
Recent publications have identified population-specific markers in vivo (Philippeos et al., 
2018; Tabib et al., 2018; Korosec et al., 2019).  
 
Podoplanin (Pdpn) was found to be a marker of human papillary fibroblasts while 
transglutaminase 2 (Tgm2) was found to be a marker of human reticular fibroblasts, both in 
vivo and in vitro. Matrix Gla protein (Mgp), despite labelling human reticular fibroblasts in 
vivo, was not expressed in vitro (Janson et al., 2012). Cultured to high passage (15-20), human 
papillary fibroblasts lost Pdpn expression and gained Tgm2 expression, similar to expression 
in low passage (three-six) human reticular fibroblasts (Janson et al., 2013). In contrast to this, 
Pdpn was only expressed in the lower dermis of neonatal foreskin (Driskell et al., 2013).  
 
Through the use of single-cell RNASeq and immunofluorescent labelling, two distinct 
populations of human fibroblasts were identified (Tabib et al., 2018). Secreted frizzled related 
protein 2 (Sfrp2) and dipeptidyl peptidase 4 (Dpp4; also known as CD26) stained the 
cytoplasm of small, spindle-shaped cells. The Sfrp2+ Dpp4+ population identified the largest 
fibroblast cluster. Flavin containing monooxygenase 1 (Fmo1) stained cells with large nuclei 
and lymphocyte specific protein 1 (Lsp1) stained the cytoplasm of the same cells. The Fmo1+ 
Lsp1+ population identified the second largest human fibroblast cluster. As well as differences 
in morphology, Sfrp2+ fibroblasts were located in close proximity to bundles of collagen 
protein while Fmo1+ fibroblasts were located in interstitial and perivascular locations, 
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indicative of human fibroblast heterogeneity (Tabib et al., 2018). CD26 was expressed in 
fibroblasts of the upper dermis in neonatal foreskin (Driskell et al., 2013).  
 
Work by Philippeos et al., (2018) identified markers of upper and lower human dermis. CD39 
was expressed in the papillary layer and CD36 was expressed in the reticular fibroblast/pre-
adipocyte layer. CD90+ CD39+ fibroblasts supported significantly increased epidermal 
thickness in skin reconstitution assays, compared with CD90+ CD36+ fibroblasts. CD39 and 
collagen 6α5 both labelled fibroblasts of the papillary dermis; however, expression of both 
was lost in culture. Despite marker loss, functional differences in papillary and reticular 
fibroblasts remained. CD90+ CD36+ fibroblasts expressed genes associated with ECM 
components (including collagen 1α2, collagen 11α1 and fibronectin 1) and inflammatory 
mediators (including interleukin 6). Single-cell RNASeq displayed five human dermal 
fibroblast subpopulations, with the CD39+ population associating with components of the 
Wnt signalling pathway: Wnt family member 5a, R-spondin 1 and lymphoid enhancer factor 
(LEF)1 (Philippeos et al., 2018). CD26 was found to be expressed in the lower dermis of human 
adult skin.  
 
Most recently, Korosec et al., (2019) having separated human dermis into layers (superficial, 
upper, and lower) found that fibroblast activation protein (FAP) identified different fibroblast 
populations. FAP+ CD90- fibroblasts were indicative of the papillary layer and FAP- CD90+ 
fibroblasts were indicative of the reticular/pre-adipocyte layer. Papillary fibroblasts 
expressed PDPN and netrin 1 and did not readily form adipocytes. Whereas reticular 
fibroblasts expressed genes ACTA2 (actin α2; α-SMA), MGP, peroxisome proliferator 
activated receptor-γ (PPARγ) and CD36; with a high propensity to form adipocytes (Korosec 
et al., 2019).  
 
From work in both mouse and human dermis it is clear that distinct populations of fibroblasts 
exist. Some of the cell surface markers identified, while expressed in vivo, are not expressed 
in vitro. There is also some degree of dynamism in surface marker expression. Markers 
present in foetal dermis are not necessarily present in postnatal dermis, as was the case with 
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CD26 expression in mouse. CD26 was expressed in the upper dermis at E16.5 but it was 
expressed in both the upper and lower dermis after P2 (Driskell et al., 2013; Rinkevich et al., 
2015).  
 
Furthermore, there is evidence of positional memory in both mouse and human fibroblasts. 
Rinkevich et al., (2015) found that transplantation of En1+ (scar-associated) fibroblasts from 
mouse dorsal skin to the mouse oral cavity caused the formation of scar tissue resembling 
that of the dorsal region. Comparing 50 human primary fibroblasts, isolated from 16 different 
donors using 10 different anatomical regions, Chang et al., (2002) showed that fibroblast gene 
expression patterns clustered according to the site of origin. Anatomical region was the cause 
of the observed variation in gene expression, despite differences in donor type, fibroblast 
passage number and the presence or absence of serum in the culture medium. Expression of 
homeobox (HOX) genes was used to accurately predict the site of origin of adult human 
fibroblasts (Chang et al., 2002). 
 
The precise contribution of different fibroblast populations and subpopulations in 
homeostatic, disease and wound healing environments remains unknown. To what extent 
this process is governed by the surrounding ECM, as well as autocrine/paracrine signalling, is 
still to be determined. 
 
1.4 Wnt/β-catenin signalling 
Wnt signalling is necessary for both formation of the epidermis and maintenance of 
keratinocyte self-renewal. Binding of Wnt to the cell surface receptor Frizzled and co-
receptors Low-density lipoprotein receptor-related protein (LRP)5/6, activates Dishevelled 
(Tamai et al., 2000). Dishevelled inhibits glycogen synthase kinase-3β, allowing translocation 
of β-catenin into the nucleus. β-catenin binds transcription factors T cell factor (TCF) and LEF, 
causing transcription of Wnt target genes (Henderson and Fagotto, 2002). Both dermal Wnt 
signalling, and the effect of epidermal Wnt signalling on dermal fibroblasts have been studied 
in mouse skin; with epidermal Wnt signalling known to affect dermal fibroblast fate (Rognoni 




Tamoxifen-induced overexpression of N-terminally truncated β-catenin, in basal layer 
(keratin 14-expressing) keratinocytes caused the formation of ectopic hair follicles in 
transgenic mice (K14ΔNβ-cateninER) (Lo Celso, Prowse and Watt, 2004). Using the same 
transgenic mice, β-catenin was shown to convert adult dermal fibroblasts to a neonatal state 
(Collins, Kretzschmar and Watt, 2011). Microarray-based gene expression analysis was used 
to determine differences between mouse dermal fibroblasts associated with cycling hair 
follicles. The gene expression profile of fibroblasts associated with ectopic hair follicles was 
most similar to that of fibroblasts associated with neonatal hair follicles. Prolonged β-catenin 
expression caused an increase in fibroblast proliferation similar to mouse neonatal dermis, 
and the remodelling of mature collagen to subtypes associated with neonatal dermal 
fibroblasts. The population of fibroblasts affected were located adjacent to the epidermal 
junctional zone: a region between the bulge (lower hair follicle; below sebaceous gland), the 
infundibulum (lower hair follicle; above sebaceous gland), and the sebaceous gland. This work 
indicates a role for paracrine β-catenin signalling on mouse fibroblast phenotype (Collins, 
Kretzschmar and Watt, 2011).  
 
Using K14ΔNβ-cateninER transgenic mice, β-catenin overexpression in basal keratinocytes 
was found to remodel the underlying dermis through paracrine signalling (Lichtenberger, 
Mastrogiannaki and Watt, 2016). Sonic hedgehog (Shh) and transforming growth factor-β 
(TGF-β) were upregulated in the epidermis taken from ectopic hair follicle-associated skin and 
neonatal skin. Fibroblasts isolated from adult mouse skin showed an increase in proliferation 
with Shh treatment and a decrease in proliferation with TGF-β2 treatment. Epidermal TGF-β2 
affected the lower lineage of fibroblasts with TGF-β receptor inhibition causing reticular 
fibroblast proliferation, differentiation and ECM production. Epidermal Shh stimulated 
proliferation of the upper fibroblast lineage, independent of TGF-β. Use of signalling pathway 
inhibitors in mice labelled for papillary or reticular fibroblasts enabled these findings.  
 
Shown to impact on dermal cell fate, further work involving epidermal β-catenin signalling 
focused on adipocyte formation in mouse dermis. Using adult (P60) transgenic mice (K14ΔNβ-
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cateninER), tamoxifen-induced ectopic hair follicle formation caused adipocyte neogenesis in 
the upper dermis (Donati et al., 2014). Expression of stable, N-terminally truncated β-catenin 
in basal keratinocytes (K14Cre/CatnbFlox(ex3)/+) of mouse dorsal skin showed an increase in 
adipocyte density compared with wild-type mouse skin (P1). Mouse 3T3 (fibroblast) cells also 
underwent adipogenesis at a faster rate and to a greater extent when treated with adipogenic 
medium supplemented with K14Cre/CatnbFlox(ex3)/+ conditioned medium, compared with 
wild-type keratinocyte conditioned medium (Donati et al., 2014). This indicated that 
epidermal β-catenin signalling affected pre-adipocyte/adipocyte formation in adult mouse 
skin through paracrine signalling. Stabilising β-catenin in lower dermal fibroblasts of the 
developing mouse skin (E16.5-P2) reduced formation of mature adipocytes; introduced 
fibrotic lesions in the adipocyte layer and disrupted hair follicle cycling via autocrine signalling 
(Mastrogiannaki et al., 2016).  
 
These studies demonstrate how fibroblast populations respond differently to environmental 
cues. Understanding the signalling pathways responsible for this plasticity is key to 
discovering targets that can be used for therapeutic applications; such as reducing tissue 
fibrosis in abnormal wound healing and contractile scars.  
 
1.5 Myofibroblast differentiation 
Myofibroblast differentiation is a two-stage process with the formation of proto-
myofibroblasts, from fibroblasts, as an intermediary step (Figure 4). Proto-myofibroblasts 
express stress fibres and the fibronectin splice variant ectodomain A (ED-A) (Serini et al., 
1998; Hinz, 2010). Addition of TGF-β1 increases production of fibronectin ED-A, and with 
further mechanical force causes the formation of myofibroblasts. Myofibroblasts are defined 
by the expression of stress fibre-containing α-SMA (Darby, Skalli and Gabbiani, 1990). Binding 
of fibronectin ED-A to the terminals of α-SMA stress fibres allows transmission of contractile 
force at mature focal adhesions. It is this transmission of contractile force that allows 




The ability of myofibroblasts to migrate through, and remodel, the ECM is particularly 
important in wound healing (Vedrenne et al., 2012). Fibroblasts/myofibroblasts are recruited 
to the wound edge by chemokines released by macrophages and other immune cells. 
Contraction of the ECM by myofibroblasts allows the remodelling of wound tissue. 
Dysregulation of this process however, can lead to either hypertrophic or keloid scarring (Lee 
et al., 2004; Jumper, Paus and Bayat, 2015).  
 
 
Figure 4. Fibroblast-to-myofibroblast differentiation. Mechanical tension is sufficient to cause formation of 
proto-myofibroblasts. TGF-β1 increases expression of the fibronectin splice variant, ectodomain A (ED-A). 
Fibroblasts contain cortical actin but no stress fibres or adhesion complexes, in vivo. Proto-myofibroblasts 
contain cytoplasmic actin and early adhesion complexes. Myofibroblasts contain α-smooth muscle actin as well 
as fibronexus (in vivo) or focal adhesions (in vitro). Taken from Tomasek et al., (2002). 
 
Recent work by Plikus et al., (2017) showed the formation of adipocytes from myofibroblasts. 
Myofibroblasts were previously thought to be terminally differentiated. Successful formation 
of adipocytes in mouse wound healing was dependent on both bone morphogenic protein 
(BMP) signalling and the close proximity of myofibroblasts to newly formed hair follicles. 
Keratinocyte expression of BMP antagonist noggin, or deletion of BMP receptor 1A, in 
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transgenic mice prevented myofibroblast-adipocyte conversion in hair-bearing wounds 
(Plikus et al., 2017). Treatment of human fibroblasts with inhibitors of BMP (Dorsomorphin 
and LDN-193189) and TGF-β (SB-431542) signalling, in combination with forskolin (cyclic 
adenosine monophosphate signalling inducer), caused successful conversion to brown 
adipocytes (Takeda et al., 2017). This work highlights the role of BMP/TGF-β signalling on 
fibroblast/myofibroblast fate, and the potential to modify populations of dermal cells.  
 
1.6 TGF-β signalling  
TGF-β is a cytokine produced by many cells including fibroblasts, as well as keratinocytes, and 
in the case of wound healing, macrophages and platelets (Massagué, 1987). TGF-β exists as 
isoforms 1, 2 and 3. It is bound to ECM proteins in the dermis in a latent form. Two latent 
complexes exist, one small and one large. TGF-β bound to latency associated protein (LAP) is 
known as the small latent complex. Latent TGF-β binding protein (LTBP) bound to the small 
latent complex forms what is known as the large latent complex (Saharinen and Keski-Oja, 
2000). 
 
Activated TGF-β binds to the cell membrane TGF-β receptor (TGF-βR) II. Binding to TGF-βR II 
allows recruitment of TGF-βR I (ALK5) and serine/threonine phosphorylation (Wrana et al., 
1994). The phosphorylated TGF-βR subsequently phosphorylates small mothers against 
decapentaplegic (Smad)2/3 (also known as receptor-mediated Smad protein; R-Smad), 
recruited to the TGF-βR complex by Smad anchor for receptor activation (Tsukazaki et al., 
1998). Phosphorylated R-Smad binds Smad4 (also known as common partner Smad protein; 
Co-Smad) and this heteromeric complex causes transcription of TGF-β target genes. This 
process forms the canonical TGF-β signalling pathway, as shown in Figure 5. Non-canonical 
TGF-β signalling occurs via the activation of various kinases including extracellular signal-
regulated kinase (ERK); c-Jun N-terminal kinase (JNK); p38 mitogen-activated protein kinase 
(p38 MAPK) and protein kinase A (PKA) (Moustakas and Heldin, 2005). 
 
Other R-Smad proteins include Smad1, 5 and 8 associated with BMP signalling. Smad6 and 7 
are known as inhibitory Smad proteins. Smad6/7 prevents the binding of phosphorylated R-
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Smad to Co-Smad and any subsequent gene transcription. While Smad6 inhibits BMP-
mediated Smad signalling, Smad7 acts on both BMP and TGF-β-mediated Smad signalling 
(Massagué, Seoane and Wotton, 2005). 
 
 
Figure 5. Human canonical and non-canonical TGF-β signalling. TGF-β is bound to latency associated protein 
(LAP) and latent TGF-β binding protein (LTBP) in the ECM (A). Stimuli cause the cleavage of TGF-β from the 
latency proteins (B). TGF-β binds TGF-β receptor (TGF-βR) II allowing recruitment of TGF-βR I (ALK5) and receptor 
phosphorylation (C). Phosphorylated R-Smad binds Smad4 (D) resulting in the transcription of TGF-β target 
genes (E). Signalling via Smad proteins is known as canonical TGF-β signalling. TGF-βR degradation and recycling 
occurs via caveolin-mediated and clathrin-mediated endocytosis, respectively (F). Non-canonical TGF-β 
signalling can be induced by growth factors, stress or inflammation and occurs via the activation of various 




1.7 Thesis objectives 
There is good evidence that distinct fibroblast populations are present in both mouse and 
human dermis. Despite population-specific marker loss upon extraction of fibroblasts from 
human dermis, the populations retain their functional differences when grown in culture. The 
aim of my project was to compare commercially available human dermal fibroblasts from 
different adult donors and to see if they exhibited functional differences (see Chapter 3); 
regulating myofibroblast differentiation using agonists/inhibitors of the TGF-β signalling 
pathway. Having found that one human fibroblast donor (derived from female 64-year-old 
breast skin) showed impaired α-SMA protein expression, I went on to identify candidate 
genes responsible for this impairment (see Chapter 4). I then validated these genes using in 
vitro skin reconstitution assays and shRNA-based gene knockdown (see Chapter 5). I wished 
to understand the starting population of human fibroblasts, following extraction from the 
dermis, and if there were subpopulations present. I hypothesise that the characterisation of 
diverse human primary fibroblasts can provide insight into myofibroblast differentiation 
mechanisms. 
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2 Materials and methods 
2.1 Research ethics 
Human skin samples were obtained from consenting patients undergoing plastic surgery 
(Department of Plastic and Reconstructive Surgery, St. George’s Hospital), in collaboration 
with Mark Soldin and Tanya Shaw. All samples were collected and processed in compliance 
with the UK Human Tissue Act (Human Tissue Authority #12121), ethically approved by the 
UK National Research Ethics Service (Research Ethics Committee #14/NS/1073). 
 
2.2 Cell culture 
2.2.1 Human fibroblast culture 
Normal human dermal fibroblasts (NHDF) were cultured in phenol red-free, low glucose 
Dulbecco’s modified Eagle medium (DMEM, Sigma-Aldrich). DMEM was supplemented with 
10% foetal bovine serum (FBS, Sigma-Aldrich); 450 µg/ml L-glutamine, 100 U/ml penicillin and 
100 μg/ml streptomycin (Sigma-Aldrich). Referred to as complete DMEM. NHDF were 
cultured in complete DMEM at 37°C in 5% CO2 (~18% O2) (Newby, Marks and Lyall, 2005; 
Martinez et al., 2008). Cells were passaged 1:3 every four days using 0.05% trypsin-
ethylenediaminetetraacetic acid (trypsin-EDTA, Sigma-Aldrich). NHDF were expanded to 
passage five and stored in liquid nitrogen using Nunc cryogenic tubes (Thermo Scientific). Cells 
were stored in freeze medium comprised of 50% FBS, 45% complete DMEM and 5% dimethyl 
sulfoxide (DMSO, Sigma-Aldrich). NHDF were used in experiments up until passage 10. 
 
Commercially sourced fibroblasts 
Cryopreserved NHDF were purchased from PromoCell (C-12302) at passage two. The NHDF 
were enzyme-extracted (dispase and collagenase) from breast skin of four female donors. 
Donors were aged 19 (NHDF-c19, Lot: 4032503.1), 24 (NHDF-c24, Lot: 4081903.2), 64 (NHDF-
c64a, Lot: 4012203.1) and 64 (NHDF-c64b, Lot: 3102301.3) years old. CD90+ cells were sorted 
by PromoCell using flow cytometry technique and CD90 antibody (BioLegend, 328112). For 
further details see Appendix 8.1 (Table 5). 
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Isolation of fibroblasts from whole skin 
Full thickness skin was sterilised using surgical solution (Ecolab) diluted 1:10 in double distilled 
water (ddH2O), then washed twice with 70% ethanol solution (Sigma-Aldrich). Skin was 
removed of adipose tissue and washed twice with phosphate buffered saline (PBS, Sigma-
Aldrich). Skin was cut using 5 mm punch biopsies (Medisave) and incubated in dispase 
(Corning) diluted 2:1 in PBS, in a shaking water bath at 37°C for 1 h. Epidermis was removed 
from the skin using sterile forceps. The remaining dermis was digested using a whole skin 
dissociation kit (Miltenyi Biotec) in a shaking water bath at 37°C, overnight. The cell 
suspension was passed through a 70 µm cell strainer (Corning) and collected in a 50 ml 
polypropylene tube (Thermo Scientific), centrifuged at 300 x g for 10 min. The cell pellet was 
resuspended in complete DMEM and added to a T25 flask at passage zero. Three punch 
biopsies would typically give a yield of 1 x 106 cells. Freshly-isolated NHDF were named based 
on gender, age and location e.g. female donor, 22 years old, breast skin: NHDF-F22Br. For 
further details see Appendix 8.1 (Table 5). 
 
2.2.2 3T3 J2 cell culture 
Mouse 3T3 (J2 clone) cells (Rheinwald and Green, 1975), were used as a feeder layer for the 
culture of human neonatal foreskin-derived keratinocytes (Km strain; see Chapter 2.2.3). J2 
cells were cultured in phenol red, high glucose DMEM (Life Tech) at 37°C in 5% CO2. DMEM 
was supplemented with 10% bovine serum (Life Tech), 100 U/ml penicillin and 100 μg/ml 
streptomycin. J2 cells were thawed from a frozen working bank. Cells were designated 
‘passage one’ and used up until passage 12 as a keratinocyte feeder layer. J2 cells were 
passaged weekly with the medium changed every four days. J2 cells were seeded at 5 x 105 
cells/T175 flask for routine culture and at 3.6 x 106 cells/T175 flask for use as a feeder layer. 
J2 cells were inactivated for use as a feeder layer through treatment with 4 µg/ml mitomycin 
C (Sigma-Aldrich) for 2 h at 37°C in 5% CO2. 
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2.2.3 Human keratinocyte culture 
Human neonatal foreskin-derived keratinocytes (Km strain) were cultured for use in skin 
reconstitution assays only. Km cells were grown in medium consisting of three parts DMEM 
and one-part Ham’s F12 medium supplemented with 10-4 M adenine (FAD, Life Tech), at 37°C 
in 5% CO2. Medium was further supplemented with 10% FBS (Life Tech), 450 µg/ml L-
glutamine, 1.8 µM calcium chloride (Sigma-Aldrich), 5 µg/ml insulin (Sigma-Aldrich), 0.5 µg/ml 
hydrocortisone (Thermo Scientific), 10-10 M cholera toxin (Sigma-Aldrich), 10 ng/ml epidermal 
growth factor (EGF, PeproTech); 100 U/ml penicillin and 100 μg/ml streptomycin. Referred to 
as complete FAD (Rheinwald and Green, 1975). Km cells were thawed at passage four and 
cultured in complete FAD on inactivated J2 cells. Medium was changed every two days and 
Km cells were passaged weekly. J2 cells were first removed from the culture flask using 0.02% 
EDTA (Life Tech), followed by washing once with PBS. Keratinocytes were then collected using 
0.05% trypsin-EDTA and passed through a 40 µm cell strainer (Corning). Km cells were added 
to an inactivated feeder layer at 4 x 105 cells/T175 flask. Km cells were used in skin 
reconstitution experiments up until passage eight. 
 
2.2.4 HEK293 cell culture 
Human embryonic kidney (HEK)293 cells were used for the production of packaged lentiviral 
particles only. HEK293 cells were cultured in phenol red, high glucose DMEM at 37°C in 5% 
CO2. DMEM was supplemented with 10% FBS, 900 µg/ml L-glutamine; 100 U/ml penicillin and 
100 μg/ml streptomycin. HEK293 cells were passaged every three days and seeded at 2 x 106 
cells/T175 flask. HEK293 cells were used for the amplification and packaging of lentiviral 
particles, from plasmid DNA, for shRNA-based gene knockdown (see Chapter 2.8). 
 
2.3 Operetta high-content imaging 
Normal human dermal fibroblasts (NHDF), both commercially sourced and isolated in-house, 
were assayed for cell number, differentiation, proliferation and shape using the Operetta 
imaging platform. NHDF were assayed for lipid droplet formation following treatment with 
adipogenic medium. Immunofluorescence was quantified using the Harmony analysis 
software to measure NHDF phenotype. 
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2.3.1 Fibroblast phenotype assay 
NHDF were washed once with PBS and removed from the cell culture flask using 0.05% 
trypsin-EDTA. Cells were pelleted at 300 x g for 3 min in centrifuge tubes, resuspended in 
complete DMEM (10% serum) and counted using a haemocytometer. Cells were seeded at 
3000 cells/well in complete DMEM in a 96-well microplate (Greiner). Each well contained 200 
µl cell suspension with a different row for each donor NHDF. NHDF were incubated at 37°C in 
5% CO2 for 24 h. Following this, the medium was removed from each well and NHDF were 
equilibrated in low (1%) serum DMEM for 24 h. NHDF were treated in triplicate with low (1%) 
serum DMEM with or without agonist/inhibitor, for 24 h at 37°C. 10 µM 5-ethynyl-2’-
deoxyuridine (EdU, Invitrogen) (Figure 6) was added to the 96-well microplates 30 min prior 
to fixing cells. Cells were fixed using 4% paraformaldehyde (PFA, Sigma-Aldrich) in PBS, for 15 
min at room temperature. 
 
 
Figure 6. Detection of EdU and BrdU. Both EdU (left) and BrdU (5-bromo-2'-deoxyuridine) (right) are 
incorporated during DNA replication. While EdU is detected using Click-iT Alexa Fluor azide technique, BrdU 
requires DNA denaturation for the necessary antibody labelling. Image taken from manufacturer’s protocol. 
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Agonists/inhibitors of the fibroblast growth factor (FGF), hedgehog (Hh), and TGF-β signalling 
pathways were used in the initial NHDF phenotype experiments, based on concentrations 
used by of a former postdoc (Lichtenberger, Mastrogiannaki and Watt, 2016). FGF2 (20 ng/ml, 
R&D Systems) and FGF5 (10 ng/ml, R&D Systems) are both agonists of the FGF pathway. 
PD170374 (2 µM; Tocris) is an FGF receptor inhibitor (Lichtenberger, Mastrogiannaki and 
Watt, 2016). Smoothened agonist (SAG, 100 nM, Tocris) is an agonist of the Hh pathway (Chen 
et al., 2002). IPI4182 (0.5 µM, Infinity Pharmaceuticals; compound 32) and cyclopamine (5 
µM, Tocris) are both Hh/Smoothened inhibitors (Taipale et al., 2000; Tremblay et al., 2009). 
TGF-β1 (10 ng/ml, R&D Systems) and TGF-β2 (10 ng/ml, R&D Systems) are both agonists of 
the TGF-β pathway. LY2157299 (2 µM, Selleckchem) and RepSox (25 µM, Tocris) are both TGF-
βR I inhibitors (Gellibert et al., 2004; Herbertz et al., 2015). 
 
Fixed cells were washed twice with PBS and permeabilised using 0.2% Triton X-100 in PBS for 
5 min. They were then washed twice with PBS and blocked for 1 h 30 with blocking buffer 
(10% bovine serum albumin (Sigma-Aldrich), 0.25% fish skin gelatin (Sigma-Aldrich) in PBS). 
Cells were washed twice with PBS and stained using the Click-iT EdU imaging kit (Invitrogen). 
This was done according to manufacturer’s instructions, though half the recommended 
volume of Alexa Fluor 488 was used; incubated for 1 h 30. Cells were washed twice with PBS 
and incubated in α-actin 1A4 primary antibody (Santa Cruz Biotechnology, sc-32251, 1:300 in 
blocking buffer), overnight at 4°C. Cells were washed twice with PBS and incubated in Alexa 
Fluor 594 secondary antibody (Invitrogen, A21203, 1:1000 in blocking buffer) for 1 h 30, with 
CellMask deep red plasma membrane stain (1:1000; Invitrogen). After a final wash with PBS, 
cells were stored at 4°C in PBS containing NucBlue reagent (Invitrogen). All staining was 
performed at room temperature except where stated. 
 
NHDF were imaged at 10x magnification using the Operetta Mark1 high content imaging 
system (Perkin Elmer). Using the Harmony software (v.4.1, Perkin Elmer), NHDF were assayed 
for differentiation (percentage α-SMA positive), proliferation (percentage EdU positive) and 
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shape (percentage spindle-shaped). For a description of the analysis pipelines used and for 
details of the spindle-shaped classification, see Appendix 8.2. 
 
Measure of cell viability 
An MTT (3-4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide) assay was used to ensure 
NHDF were viable for the agonist/inhibitor concentrations used in the fibroblast phenotype 
assay. NHDF-c19 were seeded in complete DMEM at 3000 cells/well in a clear 96-well 
microplate. NHDF-c19 were incubated at 37°C in 5% CO2 for 24 h. Following this, NHDF were 
incubated in low (1%) serum DMEM for 24 h. NHDF were treated in duplicate with low (1%) 
serum DMEM with or without agonist/inhibitor (0-10 µM) and incubated at 37°C in 5% CO2 
for 24 h. Culture medium was then replaced with 100 µl/well low (1%) serum DMEM. 10 µl 
MTT stock solution (12 mM in PBS, Sigma-Aldrich) was added to each well and incubated at 
37°C for 4 h. 85 µl/well was then removed and 50 µl DMSO was added to each well. Following 
a further incubation at 37°C for 10 min, absorbance was measured at 560 nm using the 
Promega GloMax discover microplate reader. 
 
2.3.2 Fibroblast adipogenesis assay 
NHDF were seeded at 10000 cells/well in 96-well microplates and cultured for four days in 
complete DMEM. Medium was replaced with complete DMEM for control conditions, and 
with adipogenic medium for treated conditions, in triplicate wells. Adipogenic medium 
consisted of base medium (StemXVivo) with adipogenic supplement (1:100, StemXVivo). Each 
experiment ran for two weeks from the addition of the adipogenic medium, with medium 
replaced every four days. After two weeks, cells were fixed with 4% PFA at room temperature 
for 15 min.  
 
Fixed cells were washed twice with PBS and stained using CellMask deep red and LipidTOX 
green neutral lipid stain (Invitrogen). Both CellMask and LipidTOX were diluted 1:1000 in PBS 
and incubated for 30 min. Stained cells were stored in PBS containing NucBlue and imaged 
using the Operetta. The formation of lipid droplets (percentage LipidTOX positive) was 
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compared between enzyme-derived and explant-derived NHDF-F44B (female 40-year-old 
back skin), M50F (male 50-year-old face skin) and F60Br (female 60-year-old breast skin). The 
formation of lipid droplets in PromoCell NHDF-c19, c24, c64a and c64b was also measured.  
 
2.4 Molecular biology techniques 
RNA was extracted from NHDF and then converted to cDNA through reverse transcription 
process. Gene expression of NHDF was determined using cDNA and TaqMan qPCR technique. 
 
2.4.1 RNA extraction 
To extract RNA from NHDF, cells were washed once with PBS and lysed using 350 µl buffer 
RLT (RNeasy mini kit, Qiagen) with β-mercaptoethanol (β-ME, Thermo Scientific), diluted 
1:100. An equal volume of 70% ethanol was added to each sample and loaded into 
microcentrifuge columns. Contents were centrifuged at 8000 x g and flow-through was 
discarded. The columns were washed with buffer RW1 followed by buffer RPE, centrifuged 
for 15 sec. Columns were centrifuged for 2 min to dry the membranes. RNA was eluted in 
nuclease-free water, centrifuged for 1 min. The RNA concentration was measured using a 
NanoDrop 2000 spectrophotometer (Thermo Scientific).  
 
2.4.2 Reverse transcription 
The QuantiTect reverse transcription kit (Qiagen) was used to generate cDNA from RNA. 300 
ng RNA from each sample was incubated with Wipeout buffer at 42°C to remove any genomic 
DNA. QuantiScript reverse transcriptase, reverse transcription (RT) buffer, RT primer mix, and 
nuclease-free water were added to the RNA. RNA was incubated at 42°C for 15 min (to form 
cDNA) followed by 95°C for 3 min (to stop the RT reaction).  
 
2.4.3 qPCR reaction 
The cDNA was diluted 1:6 in ddH2O and 2 µl was loaded into quadruplicate wells of a 384-well 
PCR plate (Bio-Rad). 8 µl TaqMan fast universal PCR 2X master mix, TaqMan gene expression 
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assay 20X (Table 1) and ddH2O was added to each well. Plates were sealed with Microseal B 
adhesive seals (Bio-Rad). Reactions were run using the TaqMan Fast protocol (95°C for 20 sec, 
then 50 cycles of 95°C for 1 sec and 60°C for 20 sec), on the CFX384 touch real-time PCR 
detection system (Bio-Rad). Data were displayed as quantitation cycle (Cq) values. Cq values 
for genes of interest were normalised to Cq values for reference genes, to give the ΔCq of 
each of the samples. ΔCq expression of each gene of interest was achieved by raising 2 to the 
power of -ΔCq. ΔCq expression values from (TGF-β1, low serum) treated NHDF samples were 
normalised to the ΔCq expression values from (low serum) non-treated NHDF samples, to give 
ΔΔCq expression (Livak and Schmittgen, 2001). ΔCq expression was used to determine gene 
expression with or without TGF-β1 treatment, while ΔΔCq expression was used to determine 
the effect of TGF-β1 treatment on gene expression.  
 
Table 1. List of TaqMan qPCR gene expression assays. PPIA, RPS18 and TBP used as reference genes. 
Gene Gene ID Assay # 
Actin α2/α-SMA ACTA2 Hs00426835_g1 
Asporin ASPN Hs01550901_m1 
C-X-C motif chemokine ligand 1 CXCL1 Hs00236937_m1 
Insulin-like growth factor 1 IGF1 Hs01547656_m1 
Peptidylprolyl isomerase A PPIA Hs04194521_s1 
Ribosomal protein S18 RPS18 Hs01375212_g1 
TATA-box binding protein TBP Hs00427620_m1 
Wnt family member 4 WNT4 Hs01573505_m1 
 
2.5 Agilent gene expression microarray 
The Agilent microarray system was used to determine NHDF gene expression profiles, 
following the fibroblast phenotype experiments. R was used to compare normalised 
expression values of four donor NHDF, non-treated (low serum DMEM) and TGF-β1 treated 
(in low serum DMEM), at 12 h and 24 h timepoints.  
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2.5.1 RNA extraction 
NHDF were seeded into 6-well microplates at 40000 cells/well. NHDF-F22Br (female 22-year-
old breast skin), M50F (male 50-year-old face skin), F60Br (female 60-year-old breast skin) 
and PromoCell NHDF-c64a (female 64-year-old breast skin, donor A) were cultured in 
complete DMEM for four days. NHDF were equilibrated in low (1%) serum DMEM for 24 h 
and treated with or without TGF-β1 (10 ng/ml) in low (1%) serum DMEM for a further 12 h or 
24 h. Following incubation, cells were washed once with PBS and lysed with buffer RLT and β-
ME as described previously (see Chapter 2.4.1). RNA was extracted using the RNeasy mini kit 
protocol. Each experiment was carried out three times (n=3), with passage number increasing 
accordingly. RNA concentration and integrity were measured using the Bioanalyser 2100 
(Agilent) and RNA 6000 Nano kit (Agilent) according to the manufacturer’s instructions. 
 
2.5.2 Production of labelled cRNA 
One colour Quick-Amp labelling kit (Agilent) was used to derive cyanine 3-cytidine 
triphosphate (Cy3-CTP) labelled cRNA from the extracted RNA. One colour RNA spike-in kit 
(Agilent) was used to monitor sample amplification and labelling efficiency. Spike-in mix was 
diluted with dilution buffer (1:20, 1:25 and then 1:10) to give a 1:5000 dilution overall. For 
each sample 300 ng total RNA was used; universal human reference RNA (Agilent) was added 
as a positive control. 7.3 µl sample was added to 3.0 µl diluted spike-in mix and 1.2 µl T7 
promoter primer to give a total reaction volume of 11.5 µl/sample. Samples were incubated 
at 65°C for 10 min to denature primer and template, and then at 4°C for 5 min. RNA was 
converted to cDNA using the cDNA mix (Quick-Amp, Table 2); 8.5 µl was added to each sample 
to give 20 µl total volume. Reactions were incubated at 40°C for 2 h, 65°C for 15 min, and 
then 4°C for 5 min. cDNA was converted to labelled cRNA using the transcription mix (Quick-
Amp, Table 2); 60 µl was added to each sample to give 80 µl total volume. Reactions were 
incubated at 40°C for 2 h. 
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Table 2. Quick-Amp labelling kit mix for production of Cy3-CTP cRNA. Abbreviations: cyanine 3-cytidine 
triphosphate (Cy3-CTP), dithiothreitol (DTT), deoxynucleotide triphosphates (dNTP), Moloney murine leukaemia 
virus-reverse transcriptase (MMLV-RT), nucleotide triphosphates (NTP) and polyethylene glycol (PEG). 
cDNA mix (1 reaction) Transcription mix (1 reaction) 
4 µl first strand buffer 5X 20 µl transcription buffer 4X 
2 µl DTT (0.1 M) 15.3 µl nuclease-free water 
1 µl dNTP (10 mM) 8 µl NTP mix 
1 µl MMLV-RT 6.4 µl PEG (50%) 
0.5 µl RNaseOUT 6 µl DTT (0.1 M) 
 2.4 µl Cy3-CTP 
 0.8 µl T7 RNA polymerase 
 0.6 µl inorganic pyrophosphatase 
 0.5 µl RNaseOUT 
 
20 µl nuclease-free water was added to labelled cRNA to give 100 µl final sample volume. 
Labelled cRNA was extracted using the Qiagen RNeasy mini kit. The procedure was followed 
as before (see Chapter 2.4.1) except buffer RW1 was excluded. cRNA was eluted in nuclease-
free water through centrifugation. The concentration of cRNA was measured using a 
NanoDrop 2000: RNA absorbance was measured at 260 nm, Cy3 dye absorbance was 
measured at 550 nm. 
 
2.5.3 Sample fragmentation and hybridisation 
Using the gene expression hybridisation kit (Agilent), the following components were added 
to a 0.5 ml microcentrifuge tube: Cy3-labelled cRNA (600 ng) made up to 19 µl with nuclease-
free water; 5 µl 10X blocking agent, and 1 µl 25X fragmentation buffer. Sample preparations 
were mixed, collected and incubated at 60°C for 30 min to fragment the cRNA, then placed 
on ice for 1 min. The fragmentation reaction was stopped by adding 25 µl 2X hybridisation 
buffer Hi-RPM. Sample preparations were mixed by pipetting and then centrifuged at 8000 x 
g for 1 min. A gasket slide was loaded into a SureHyb chamber base (Agilent). 40 µl 
hybridisation sample was dispensed into the gasket well and a SurePrint microarray (Agilent) 
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was lowered (active side down) onto the gasket slide. A SureHyb chamber cover (Agilent) was 
added to the array, gasket slide and chamber base; held in place by a clamp assembly. Each 
assembled array was incubated in a rotisserie oven at 65°C for 17 h at 10 rpm to allow 
hybridisation. 
 
2.5.4 Array preparation and data extraction 
The hybridisation assembly was disassembled following incubation. The gasket sandwich was 
added to gene expression wash buffer 1 (Agilent): gasket slides were removed from each 
array and added to a slide rack in wash buffer 1, incubated at room temperature for 1 min. 
Arrays were washed in wash buffer 2 (Agilent) at 37°C for 1 min. Arrays were incubated in 
acetonitrile (Sigma-Aldrich) at room temperature for 10 sec, dried and covered with ozone 
protection covers (Agilent). Arrays were imaged using the Agilent G2565BA microarray 
scanner system. G2567AA feature extraction software (v.9.5.1; Agilent) was used to extract 
data and check data quality. All three experiments were run using the SurePrint G3 Human 
GE 8x60K V2 kit (Agilent). Array barcodes were as follows: experiment 1 – 253949444653 and 
253949444654; experiment 2 – 253949447257 and 253949447258; experiment 3 – 
253949447259 and 253949447260. Each experiment was divided across two arrays, one with 
12 h TGF-β1 treated samples and one with 24 h TGF-β1 treated samples. Six arrays were used 
in total (Table 3). 
 
Table 3. Agilent SurePrint microarray layout. 12 h and 24 h non-treated (CTL) and treated (TGF) samples from 
four NHDF (F22Br, M50F, F60Br and c64a). Three experiments in total (n=3) loaded onto six independent arrays. 
Barcode end Array 1-1 Array 1-2 Array 1-3 Array 1-4 
-53/57/59 F22Br CTL 12 h M50F TGF 12 h c64a CTL 12 h F60Br TGF 12 h 
-54/58/60 F22Br CTL 24 h M50F TGF 24 h c64a CTL 24 h F60Br TGF 24 h 
Barcode end Array 2-1 Array 2-2 Array 2-3 Array 2-4 
-53/57/59 F22Br CTL 12 h M50F TGF 12 h c64a CTL 12 h F60Br TGF 12 h 
-54/58/60 F22Br CTL 24 h M50F TGF 24 h c64a CTL 24 h F60Br TGF 24 h 
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Gene expression values were normalised using Agilent GeneSpring GX software (v.14.8) and 
imported into R (v.3.5.1) (Ihaka and Gentleman, 1996). R scripts were developed in RStudio 
(v.1.0.153) that allowed the comparison of gene expression values for different NHDF 
treatments (non-treated – CTL, TGF-β1 treated – TGF) at both timepoints (12 h and 24 h). 
Genes with a log fold change (logFC) +/-2 and adjusted p value<0.05 were considered 
differentially expressed. The molecular signatures database (v.6.2) was used to investigate 
gene ontology (GO) terms (Ashburner et al., 2000) associated with differentially expressed 
genes (Collection 5: GO gene sets) (Subramanian et al., 2005; Liberzon et al., 2011), see 
Chapter 4.1.2. Qiagen Ingenuity Pathway Analysis (IPA) software (v.01-08) was used to 
determine causal networks (Krämer et al., 2014), see Chapter 4.1.3. 
 
2.6 Fluidigm qPCR gene expression 
The Fluidigm qPCR system allowed the measurement of 96 TaqMan assays from 96 cDNA 
samples. This was used to validate the results from the Agilent gene expression microarray. 
The Fluidigm SINGuLAR analysis toolset was used to display sample variation and distribution. 
 
The same RNA that was used in the microarray (isolated from NHDF treated for 24 h with or 
without TGF-β1) was used in the Fluidigm high-throughput qPCR analysis (three experiments 
in total). RNA isolated from the same NHDF donors, treated independently for 12 h with or 
without TGF-β1 (10 ng/ml; PeproTech), was also used (two experiments in total). RNA 
concentration was measured using the Bioanalyser 2100 and the RNA 6000 Nano kit (see 
Chapter 2.5.1). 
 
2.6.1 Reverse transcription of RNA 
SuperScript III first-strand synthesis SuperMix kit (Thermo Scientific) was used to convert RNA 
to cDNA. 300 ng RNA was used for each of the samples. 10 µl reverse transcriptase 2X reaction 
mix (oligo(dT)20, random hexamers, MgCl2 and dNTPs) and 2 µl reverse transcriptase enzyme 
mix (SuperScript III reverse transcriptase and RNaseOUT) was added to each sample. 
Reactions were made up to 20 µl total volume with nuclease-free water. All samples were 
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incubated at 25°C for 10 min, then 50°C for 30 min, followed by 85°C for 5 min. Samples were 
placed on ice and 1 µl (2 U) E. coli RNase H was added to each sample to remove any mRNA 
from RNA-DNA hybrids. Samples were incubated at 37°C for 20 min. 
 
2.6.2 TaqMan assay preamplification 
To create the preamplification solution, TaqMan gene expression assays 20X were pooled and 
diluted using 1X Tris-EDTA buffer to give 0.2X the original assay concentration. The PreAmp 
reaction mix was made by mixing the following (for one reaction): 2.5 µl 2X TaqMan PreAmp 
master mix (Thermo Scientific) and 1.25 µl 0.2X pooled TaqMan assays. 1.25 µl cDNA was 
added to each reaction to give 5 µl final volume. Each sample was then incubated at 95°C for 
10 min; followed by 14 cycles of 95°C for 15 sec and 60°C for 4 min. Each PreAmp template 
was diluted 1:5 using 20 µl 1X Tris-EDTA. 
 
2.6.3 TaqMan assay and NHDF sample preparation 
To create the 10X assay preparation, 4 µl 20X TaqMan assay was added to 4 µl 2X assay 
loading reagent (Fluidigm); 8 µl/reaction total volume. Samples were prepared by adding 8 µl 
TaqMan universal PCR 2X master mix (Thermo Scientific) to 0.8 µl 20X gene expression sample 
loading reagent (Fluidigm) and 7.2 µl cDNA; 16 µl/reaction total volume. 
 
2.6.4 Array preparation and data extraction 
For the qPCR process a 96.96 dynamic array integrated fluidic circuit (IFC) was used. The array 
was primed with the BioMark IFC controller HX (Fluidigm) using control line fluid, injected into 
each accumulator. Once primed, the array was removed from the IFC controller HX. 5 µl 
TaqMan assay and 5 µl NHDF sample preparation were added to the relevant inlets on the 
array (Figure 7). 40 samples and eight standards were plated in duplicate wells. The 96:96 
array was then loaded (with assays and samples) using the BioMark IFC Controller HX and run 
on the BioMark System. Cq values for each target gene were processed using the Fluidigm 
real-time PCR analysis software (v.4.1.3). Results were represented as ΔCq expression.  
 
Materials and methods 
 46 
 
Figure 7. Fluidigm 96.96 dynamic array integrated fluidic circuit. Used for high-throughput TaqMan qPCR. 96:96 
array was primed with control line fluid injected into the accumulators. 96 TaqMan gene expression assays were 
loaded into the assay inlets. Samples and standards were loaded in duplicate into the sample inlets. Image taken 
from manufacturer’s protocol. 
 
Using the Fluidigm SINGuLAR analysis toolset I was able to generate principal component 
analysis (PCA) and violin plots. PCA plots are used to show dataset variation. Reduced to two 
principal components (PC1 and 2), it was possible to observe NHDF sample clustering based 
on expression values. Violin plots are used to show dataset distribution. Sorted on ANOVA p 
value, it was possible to compare histograms of different genes, of different NHDF groups. 
Unimodal distribution indicates no detectable variation (except intrinsic noise). Bimodal 
distribution (‘violin-like’) indicates a difference in expression within grouped NHDF samples.  
 
Gene expression assays were chosen for genes which were differentially expressed in the 
Agilent microarray experiment. Assay groups of interest included: ECM proteins, fibroblast 
markers, Hh/TGF-β/Wnt signalling, inflammation and redox biology. For a list of the 96 
TaqMan gene expression assays used in the Fluidigm qPCR experiment see Appendix 8.5. 
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2.7 Skin reconstitution assay 
Skin reconstitution models were used to determine the ability of NHDF to support epidermal 
stratification. NHDF were injected into irradiated, decellularised dermis. Keratinocytes were 
then seeded onto the surface. The skin models were grown at the air-liquid interface for two 
weeks, fixed, embedded and sectioned. The thickness of the epidermis was then determined.  
 
2.7.1 Preparation of de-epidermised dermis 
Full thickness skin (female 33-year-old abdomen skin, Watt Lab) was sterilised, removed of 
adipose tissue and washed as described previously (see Chapter 2.2.1). Though the skin 
contained hair follicles, care was taken to avoid the use of skin with obvious hair shafts. Skin 
was incubated in dispase (Corning) diluted 2:1 in PBS, in a shaking water bath at 37°C, for 1 h. 
Epidermis was removed from the skin using sterile forceps. Dermis was cut into 1 cm x 1 cm 
squares. All of the processed dermis was added to a 50 ml polypropylene tube and irradiated 
with a single dose of 60 Gy for 20 min. Irradiated dermis was freeze-thawed (in liquid nitrogen 
and then at room temperature) 10 times to lyse any remaining cells, referred to as de-
epidermised dermis (DED) (Rikimaru, Molès and Watt, 1997).  
 
2.7.2 Addition of NHDF and keratinocytes 
DEDs were chosen for their similarity in shape and size, washed with PBS to remove lysed cell 
debris, and placed in 6-well microplate Millicell hanging inserts (Millipore). NHDF were 
pelleted at 5 x 105 and resuspended in 30 µl complete DMEM. Cell suspension was injected 
below the apical surface of the DED using a 0.3 ml insulin syringe and needle (Becton 
Dickinson). NHDF-containing DEDs were cultured in 3 ml/well complete DMEM for 24 h 
(below the air-liquid interface). Human neonatal foreskin-derived keratinocytes (Km strain) 
were pelleted at 1 x 106 and resuspended in 30 µl complete FAD. Cell suspension was added 
onto the apical surface of NHDF-containing DEDs. Skin models were cultured in 2 ml/well 
complete FAD for two weeks (above the air-liquid interface). FAD medium was changed every 
two days for the first week and then every day for the second week to allow epidermal 
stratification. NHDF-F22Br, M50F, F60Br and c64a were assayed alongside a control (no 
NHDF). The same strain of human neonatal foreskin-derived keratinocytes (Km strain) was 
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used for each skin model, passage six-eight. Each experiment was carried out three times 
(n=3) with one DED injected for each NHDF used.  
 
2.7.3 Processing of skin models 
Skin models were removed from 6-well microplates and fixed in 10% formalin (Sigma-Aldrich), 
overnight at 4°C. Skin models were next incubated in 70% ethanol at 4°C for 5 h. The Excelsior 
AS tissue processor (Thermo Scientific) was run overnight, with each skin model placed in a 
histology cassette (Simport). The processing protocol was as follows: 90% ethanol, then 95% 
ethanol, and three lots of 100% ethanol (60 min each, 30°C). Three lots of xylene (60 min 
each, 30°C) and three lots of paraffin wax (80 min each, 62°C). Each sample was halved using 
a scalpel and placed cut-surface down into a mould tray. The tray was filled with liquid 
paraffin wax using the HistoStar embedding machine (Thermo Scientific) and the cassette 
base was added on top. Blocks were allowed to cool for 20 min and then removed from their 
trays. All sections were cut using the Microm HM 355S (Thermo Scientific). 8 µm sections 
were collected in a 42°C water bath and mounted on Menzel-Gläser polysine glass slides 
(Thermo Scientific). Mounted sections were baked at 60°C overnight.  
 
2.7.4 Haematoxylin and eosin staining 
Haematoxylin and eosin (H&E) staining was used to measure epidermal thickness. Sections 
were first removed of paraffin wax using two separate immersions in xylene (Thermo 
Scientific) for 2 min. Sections were rehydrated using two separate immersions in 100% 
ethanol for 2 min, followed by immersion in 70% ethanol for 2 min. Immersed in cold running 
water for 2 min and stained with haematoxylin Gill No.3 solution (Sigma-Aldrich) for 4 min. 
1% acid alcohol (Sigma-Aldrich) for 5 sec, was used to remove cytoplasmic staining. Sections 
were transferred back to cold running water for 3 min. After staining with 1% eosin Y solution 
(Sigma-Aldrich) for 4 min, sections were immersed in cold running water for 5 sec and then 
in 70% ethanol for 5 sec. Sections were treated twice with 100% ethanol for 2 min then 
treated twice with xylene for 2 min. Slides were towel-dried and covered with Menzel-Gläser 
24 x 60 mm coverslips (Thermo Scientific) using DPX mountant (Sigma-Aldrich). Sections were 
imaged using the NanoZoomer 2.0RS (Hamamatsu Photonics) at 20x magnification. Two slides 
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for each skin reconstitution model, containing four sections/slide, were imaged using 
Hamamatsu Photonics NDP.scan (v.3.2.4). Images were stored as NDPI files and converted to 
.tif files using an image processing pipeline (Mishra et al., 2017).  
 
2.7.5 Immunofluorescent labelling 
As well as H&E staining, skin model sections were also labelled with fluorescent-conjugated 
antibodies. Sections were first removed of paraffin wax through two separate immersions in 
xylene for 5 min. Sections were then rehydrated with 100% ethanol for 3 min, 90% ethanol 
for 1 min and 80% ethanol for 1 min. Washed in cold running water for 2 min, slides were 
next added to 1X citrate buffer (4.8 g sodium tribasic citrate in 2 l ddH2O, pH 6) at 100°C for 
15 min, to expose antigens. Slides were added to warm 1X citrate buffer for a further 15 min, 
washed once with PBS and air-dried. 0.2% Triton X-100 in PBS was used to permeabilise 
sections, incubated for 5 min at room temperature. Blocking buffer (10% bovine serum 
albumin, 0.25% fish skin gelatin in PBS) was used to prevent any non-specific binding; 
incubated for 1 h at room temperature. Sections were incubated overnight at 4°C in primary 
antibody: keratin 14 (BioLegend, chicken, 906001) and vimentin (Cell Signaling, rabbit, 
D21H3), 1:200 in blocking buffer.  
 
Primary antibody was removed, and sections were washed 3 x 5 min in PBS (0.05% Tween 20, 
Sigma-Aldrich) at room temperature. Sections were incubated for 1 h at room temperature 
in secondary antibody: goat 488 anti-chicken (Invitrogen, A11039) and goat 555 anti-rabbit 
(Invitrogen, A21428), 1:500 in blocking buffer with 0.2 µg/ml 4ʹ,6-diamidino-2-phenylindole 
(DAPI, Invitrogen). Secondary antibody was removed, and sections were washed 3 x 5 min in 
PBS (0.05% Tween 20). Slides were air-dried and ProLong gold antifade reagent (Invitrogen) 
was used to mount coverslips. Skin reconstitution sections were imaged at 20x magnification 
using the Nikon A1 upright confocal microscope. Images were processed using ImageJ 
(v.2.0.0, US National Institutes of Health) (Schindelin et al., 2012).  
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2.8 shRNA-based gene knockdown 
Candidate genes were chosen based on expression values from the Agilent microarray 
system, validated using the Fluidigm qPCR system. shRNA-based lentiviral treatment of NHDF 
was used to measure the effect of candidate gene knockdown on cell phenotype, gene 
expression and epidermal stratification. 
  
MISSION shRNA-encoding plasmid DNA was purchased from Sigma-Aldrich for the 
knockdown of four gene targets: ASPN (clone NM_017680.3-1300s1c1), CXCL1 (clone 
NM_001511.1-323s1c1), IGF1 (clone NM_000618.2-598s1c1) and WNT4 (clone 
NM_030761.3-651s1c1). Each of the four clones targeted the gene coding region and used a 
pLKO.1 puromycin backbone (Figure 8). A control shRNA-encoding plasmid (SHC016, Sigma-
Aldrich), containing a non-coding insert in a pLKO.1 puromycin backbone, was used to 
normalise target gene expression. 
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Figure 8. A vector map of the MISSION shRNA-encoding plasmid. Sequence insert, targeting the gene coding 
region (ASPN, CXCL1, IGF1 and WNT4), encode for shRNA-based knockdown. Successfully targeted cells resist 
puromycin-induced cell death. Abbreviations: central polypurine tract (cppt), human phosphoglycerate kinase 
eukaryotic promoter (hPGK), puromycin resistance gene (puroR), 3’ self-inactivating long terminal repeat 
(SIN/3’LTR), f1 origin of replication (f1 ori), ampicillin resistance gene (ampR), pUC origin of replication (pUC ori), 
5’ long terminal repeat (5’LTR), RNA packaging signal (Psi) and rev response element (RPE). Image taken from 
manufacturer’s protocol. 
 
2.8.1 shRNA-encoding plasmid amplification 
2 µl plasmid DNA was added to 14 µl One shot TOP10 E. coli (Invitrogen) in separate 
microcentrifuge tubes. After incubation on ice for 30 min, bacteria were heat shocked at 42°C 
for 30 sec then incubated on ice for a further 2 min. S.O.C. medium (Invitrogen) was added to 
each reaction to give a final volume of 1 ml, and then incubated at 37°C for 1 h. Bacteria were 
added to lysogeny broth (LB) agar (Sigma-Aldrich) in 10 cm petri dishes (Corning) with 
ampicillin selection (100 µg/ml). Petri dishes were placed lid down in a convection oven and 
incubated at 37°C, overnight. 
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One colony per construct was added to 6 ml LB broth (Sigma-Aldrich) with ampicillin, in a 50 
ml polypropylene tube, using a sterile pipette tip. Cultures were incubated at 37°C for 6 h at 
180 rpm. The LB broth culture was added to 200 ml LB broth with ampicillin in a conical flask 
and incubated at 37°C overnight, at 180 rpm. The bacterial cell suspension was centrifuged at 
4°C for 45 min at 1500 x g. Supernatant was discarded and pellets for individual plasmids were 
collected. Plasmids were purified using the Nucleobond Xtra midi plus EF kit (Thermo 
Scientific), according to the manufacturer’s instructions. Each plasmid was resuspended in 
ddH2O. Plasmid concentration was measured using a NanoDrop 2000. Plasmid concentration 
was between 7.9 and 10.4 µg/µl for all except the IGF1 target plasmid (0.33 µg/µl). All yields 
were sufficient for lentiviral production. 
 
2.8.2 Lentiviral production using HEK293 cells 
For each of the five plasmids, 60 µl jetPRIME transfection reagent was mixed with 500 µl 
jetPRIME buffer (Polyplus Transfection). The volume of plasmid required to give 15 µg total 
mass was added to plasmids psPAX2 (11.25 µg total mass, Addgene) and pMD2g (2.75 µg total 
mass, Addgene). The jetPRIME mixture was added to plasmids then incubated at room 
temperature for 20 min. Medium was changed on HEK293 cells, seeded 24 h prior at 11 x 106 
cells/T175 flask, and 1 ml plasmid mix was added to each flask. Medium was discarded after 
24 h incubation with jetPRIME and plasmids. However, it was collected twice for the following 
48 h. The conditioned medium was passed through a 0.45 μm vacuum filter (Corning) and 1X 
Lenti-X concentrator (Clontech Laboratories) was added; stored at 4°C for 48 h. Medium was 
centrifuged at 4°C for 45 min at 1500 x g. The lentivirus pellet was re-suspended in 1 ml PBS 
and 100 μl was aliquoted across 12 microcentrifuge tubes for each target. 
 
2.8.3 Lentiviral infection of NHDF 
A cytotoxicity test was used to determine the optimum antibiotic concentration for NHDF-
c19 killing, following culture in complete DMEM with puromycin for three days. At a 
concentration of 1 µg/ml in complete DMEM there were no viable NHDF-c19. Six T75 flasks 
seeded with 5 x 105 NHDF in complete DMEM were used for lentiviral infection. NHDF were 
grown for four days and medium was then changed to 7 ml complete DMEM with 7 µl 
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polybrene (1:1000; Sigma-Aldrich). 50 µl lentivirus was added to five of the six T75 flasks with 
the sixth T75 flask acting as a control to ensure selection with puromycin. Medium was 
changed after 16 h lentiviral treatment, and NHDF were cultured in complete DMEM for 8 h 
before the addition of 1 µg/ml puromycin (Thermo Scientific). Complete cell killing was 
observed in non-targeted, puromycin-treated NHDF after three days. 
 
2.8.4 Targeted NHDF in functional experiments 
RNA was extracted from targeted NHDF to measure gene expression, described previously 
(see Chapter 2.4). Targeted NHDF were assayed for proliferation, differentiation and shape 
using the same antibody labelling approach as described in the NHDF phenotype assay (see 
Chapter 2.3.1). Targeted NHDF were also injected into skin reconstitution models (female 61-
year-old abdomen skin, Watt Lab) to measure the effect of fibroblast gene knockdown on 
epidermal thickness, described previously (see Chapter 2.7). The same strain of human 
neonatal foreskin-derived keratinocytes (Km strain) was used for each skin model, passage 
six-eight. This skin reconstitution experiment was carried out once, with one DED injected for 
each of the four targeted-NHDF used. 
 
2.9 Statistical tests 
Data, as mean and standard deviation, were tested for normal distribution using the 
D’Agostino & Pearson normality test. One-way ANOVA or two-way ANOVA were used to 
compare sample groups; as stated in each figure legend. When comparing with control 
samples, Dunnett’s test for multiple comparisons was used. When comparing all samples, 
Tukey’s test for multiple comparisons was used. Difference was significant if p<0.05. All 




3 Fibroblast phenotype 
Some of the first experiments I carried out were on commercially sourced NHDF. Cell number, 
differentiation, proliferation and shape were measured following treatment with 
agonists/inhibitors of the FGF, Hedgehog (Hh) and TGF-β pathways. Experiments were carried 
out to better understand the starting population of these primary NHDF. 
 
3.1 Operetta high-content imaging of NHDF 
3000 cells were added to individual wells of a 96-well microplate in complete DMEM. NHDF 
were incubated for 24 h at 37°C in 5% CO2, before changing to low (1%) serum DMEM and 
incubating for a further 24 h. NHDF were treated in triplicate wells with agonist/inhibitor for 
24 h in low (1%) serum DMEM. EdU was added 30 min prior to fixing with 4% PFA. Cells were 
stained for EdU and then incubated at 4°C overnight with α-actin 1A4 primary antibody. NHDF 
were stained with Alexa Fluor 594 secondary antibody, along with CellMask deep red (plasma 
membrane) and NucBlue (nucleus) stain. 96-well microplates were imaged using the Operetta 
platform and immunofluorescence was quantified using the Harmony software. For an 
overview of the image analysis process see Figure 9. For a description of the analysis pipelines 
used and for details of the spindle-shaped classification, see Appendix 8.2. 
 
Continuing on from the work of a former Watt Lab postdoc (Lichtenberger, Mastrogiannaki 
and Watt, 2016), I was interested to see how NHDF were affected by agonists/inhibitors of 
the FGF (Figure 10), Hh (Figure 11) and TGF-β1 (Figure 12) signalling pathways. Values were 
averaged for each condition (triplicate wells; one microplate, n=1). Values were then 
averaged for each experiment/microplate (n=3). Experiments were seeded on different 
weeks, with NHDF passage number increasing accordingly. NHDF were used in experiments 




Figure 9. NHDF phenotype workflow. NHDF were treated in triplicate wells with different agonist/inhibitor in low serum DMEM (in this case TGF-β1 and the TGF-βR I inhibitor, 
RepSox). Experiments were carried out three times (n=3) where stated, with NHDF passage number increasing accordingly. (1) Input image with NucBlue (blue), EdU (green), 
α-SMA (orange) and CellMask (red). The analysis pipeline detected cell nucleus based on NucBlue (2) and cell cytoplasm based on CellMask (3). Having removed partial cells 
on the image border (4), it was possible to train the software to identify proliferating cells (5A), differentiating cells (5B) and spindle-shaped cells (5C); positive cells shown 
in green. Images are of NHDF-c64b (female 64-year-old breast skin, donor B), non-treated (low serum DMEM). Scale bar: 200 µm. 
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3.1.1 Fibroblast growth factor pathway modification 
 
Figure 10. Treatment of NHDF with FGF pathway agonists/inhibitors. NHDF as control (low serum DMEM) or 
treated with FGF2 (20 ng/ml), FGF5 (10 ng/ml) or PD170374 (2 µM) in low serum DMEM. (A) Total number of 
cells analysed. (B) Percentage of cells expressing α-SMA. (C) Percentage of cells stained for EdU. (D) Percentage 
of spindle-shaped cells. PromoCell NHDF-c19 (female 19-year-old breast skin); c24 (female 24-year-old breast 
skin); c64a (female 64-year-old breast skin, donor A) and c64b (female 64-year-old breast skin, donor B). Error 
bars represent SD of mean values; n=3. Two-way ANOVA comparing NHDF treatment with own control (A-D) 
(Dunnett’s *p<0.05, **p<0.01). Two-way ANOVA comparing NHDF-c64a with other similarly treated NHDF (% α-
SMA positive comparison [B] only, Tukey’s #p<0.05). 
 
There was no significant difference in cell number between treatments for each of the four 
NHDF (Figure 10A). There was no significant difference in the percentage of α-SMA positive 
cells (Figure 10B) with treatment. The proportion of NHDF expressing α-SMA was very low for 
NHDF-c64a (non-significant, Tukey’s) when compared with the other three NHDF, for each 
condition. FGF2 and FGF5 showed a similar percentage of EdU positive cells to that of the 
control (Figure 10C). The concentration of FGF2 used was twice that of FGF5 (20 ng/ml 
compared with 10 ng/ml). Increasing the concentration of FGF5 to 20 ng/ml gave similar levels 



























































































































PD173074, significantly reduced the percentage of EdU positive cells compared to that of the 
control. Treatment with PD173074 reduced the percentage of spindle-shaped cells, with 
NHDF-c64a and c64b showing a significant reduction (Figure 10D). The percentage of spindle-
shaped cells was used as a readout of cell morphology. Small, spindle, elongated cells were 
separated from large, round, shortened cells and displayed as a percentage of the total cells 
analysed (for further details see Appendix 8.2.3). 
 
3.1.2 Hedgehog pathway modification 
 
Figure 11. Treatment of NHDF with Hh pathway agonists/inhibitors. NHDF as control (low serum DMEM) or 
treated with SAG (100 nM), IPI4182 (0.5 µM) or cyclopamine (5 µM) in low serum DMEM. (A) Total number of 
cells analysed. (B) Percentage of cells expressing α-SMA. (C) Percentage of cells stained for EdU. (D) Percentage 
of spindle-shaped cells. PromoCell NHDF-c19 (female 19-year-old breast skin); c24 (female 24-year-old breast 
skin); c64a (female 64-year-old breast skin, donor A) and c64b (female 64-year-old breast skin, donor B). Error 
bars represent SD of mean values; n=3. Two-way ANOVA comparing NHDF treatment with own control (A-D) 
(Dunnett’s *p<0.05, **p<0.01). Two-way ANOVA comparing NHDF-c64a with other similarly treated NHDF (% α-



































































































































Smoothened agonist (SAG) is an agonist of the Hh pathway. IPI4182 and cyclopamine are both 
Hh/Smoothened inhibitors. There was no significant difference in cell number between 
treatments, for each of the NHDF (Figure 11A). The cell number of NHDF-c64a was lower than 
the other three NHDF, for each of the treatments. Treatment with agonist/inhibitor had no 
effect on the percentage of α-SMA positive cells (Figure 11B). The percentage of α-SMA 
positive NHDF-c64a was significantly lower in control and SAG conditions, compared with the 
other three donor NHDF (Tukey’s). Treatment with SAG had no effect on the percentage of 
EdU positive cells. Treatment with Hh/Smoothened inhibitors decreased the percentage of 
EdU positive cells (non-significant) (Figure 11C). IPI4182 increased the percentage of spindle-
shaped cells, with a significant increase in percentage for NHDF-c64b (Figure 11D). 
 
3.1.3 Transforming growth factor-β pathway modification 
 
Figure 12. Treatment of NHDF with TGF-β pathway agonists/inhibitors. NHDF as control (low serum DMEM) or 
treated with TGF-β1 (10 ng/ml), LY2157299 (2 µM) or RepSox (25 µM) in low serum DMEM. (A) Total number of 
cells analysed. (B) Percentage of cells expressing α-SMA. (C) Percentage of cells stained for EdU. (D) Percentage 
of spindle-shaped cells. PromoCell NHDF-c19 (female 19-year-old breast skin); c24 (female 24-year-old breast 





































































































































bars represent SD of mean values; n=3. Two-way ANOVA comparing NHDF treatment with own control (A-D) 
(Dunnett’s *p<0.05, **p<0.01). Two-way ANOVA comparing NHDF-c64a with other similarly treated NHDF (% α-
SMA positive comparison [B] only, Tukey’s #p<0.05). 
 
There was no significant difference in cell number between treatments, for each of the NHDF 
(Figure 12A). As with the two previous assays there were lower numbers of NHDF-c64a 
compared with the other three donor NHDF. There was no notable increase in the percentage 
of α-SMA positive cells with TGF-β1 and only a small decrease with TGF-βR I inhibitors, 
LY2157299 and RepSox (Figure 12B). The percentage of α-SMA positive NHDF-c64a was 
significantly lower with TGF-β1 treatment, compared with other NHDF (Tukey’s). The 
percentage of EdU positive cells was increased by treatment with TGF-β1 and decreased by 
TGF-βR inhibition, but the effects were not significant (Figure 12C). There was a reduction in 
the percentage of spindle-shaped cells with TGF-β1 treatment compared with control, which 
was significantly reduced for NHDF-c64b. TGF-βR inhibition reduced the percentage of 
spindle-shaped cells to control levels (Figure 12D). 
 
While FGF receptor inhibition significantly reduced the percentage of proliferating cells, there 
was little effect of FGF2/FGF5 treatment on fibroblast proliferation, differentiation or shape. 
Treatment with SAG did not significantly alter fibroblast proliferation, differentiation or shape 
at the concentration used. Increasing the concentration of SAG (0.5 µM) had little effect on 
each of the readouts (data not shown). It is worth noting that NHDF-c64a, as well as having a 
lower percentage of α-SMA positive cells also had a higher percentage of spindle-shaped cells, 
compared with the other three donor NHDF. NHDF-c64a could therefore be characterised as 
having a higher proportion of small, spindle, elongated cells which did not undergo 
myofibroblast differentiation. 
 
Measure of cell viability 
An MTT assay was used to ensure that NHDF were viable for the agonist/inhibitor 
concentrations used above. Metabolically active cells are able to convert MTT to an insoluble 
formazan, which when dissolved in DMSO gives a blue-purple solution (Mosmann, 1983). The 
absorbance of this solution was measured at 560 nm using the Promega GloMax discover 
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microplate reader. NHDF-c19 were metabolically active at the concentrations of 
agonist/inhibitor used (Figure 13). At the highest dose (10 µM) both SAG and IPI4182 caused 
a reduction in NHDF-c19 viability, however this was at a concentration more than tenfold 
higher than the concentration used in the initial Hh pathway phenotype assay. 
 
 
Figure 13. Effect of agonist/inhibitor concentration on NHDF-c19 viability. Absorbance measured at 560 nm 
across agonist/inhibitor concentrations (0-10 µM). Error bars represent SD of mean. Duplicate absorbance 
values; n=1. PD170374: FGF receptor inhibitor. Smoothened agonist (SAG): Hh pathway agonist. Cyclopamine 
and IPI4182: Hh/Smoothened inhibitors. LY2157299: TGF-βR I inhibitor. 
 
3.1.4 Duration of TGF-β treatment 
TGF-β is known to induce myofibroblast differentiation and the expression of α-SMA protein 
(Desmoulière et al., 1993). Since there was no significant effect of agonists of the FGF and Hh 
pathways in the initial phenotype assay, I chose to focus on the effect of TGF-β signalling on 
NHDF populations. This decision was further supported by results obtained from NHDF 
treatment with TGF-β for different timepoints (Figure 14 and Figure 15). The NHDF used in 
this experiment were from three separate donor skin biopsies, isolated in-house. They were 
either isolated through enzyme digestion (ENZ) or they were explant-derived (EXP). No 
statistical tests were performed on these experiments since they represent only n=1, 
triplicate wells (single 96-well microplate). 
 
























Figure 14. Effect of incubation time on NHDF number and differentiation. NHDF cultured for 24 h or 48 h 
following treatment with agonist/inhibitor. NHDF as control (low serum DMEM) or treated with TGF-β1 (10 
ng/ml), LY2157299 (2 µM) or RepSox (25 µM) in low serum DMEM. Total number of cells analysed, 24 h (A) and 
48 h (B). Percentage of cells expressing α-SMA, 24 h (C) and 48 h (D). Female 44-year-old back skin (F44B), male 
50-year-old face skin (M50F), female 60-year-old breast skin (F60Br). NHDF isolated through enzyme (ENZ) or 
explant (EXP) technique. Error bars represent SD of triplicate wells; n=1. 
 
NHDF were seeded at 3000 cells/well in a 96-well microplate. NHDF were equilibrated in low 
(1%) serum DMEM and then treated with TGF-β1 or TGF-βR I inhibitor. One plate was fixed 
after 24 h (Figure 14A) and one plate was fixed after 48 h (Figure 14B) culture. Higher numbers 
of NHDF were observed after 48 h compared with 24 h. There was no difference in cell 
number between agonist/inhibitor treatments and no obvious effect of NHDF derivation 
technique on cell number. Treatment with TGF-β1 increased the number of cells compared 
with control in both 24 h, and 48 h cultures. The percentage of α-SMA positive cells was 
similar in both experiments and with different NHDF derivation techniques (Figure 14C-D). 













































































































































Figure 15. Effect of incubation time on NHDF proliferation and shape. NHDF cultured for 24 h or 48 h following 
treatment with agonist/inhibitor. NHDF as control (low serum DMEM) or treated with TGF-β1 (10 ng/ml), 
LY2157299 (2 µM) or RepSox (25 µM) in low serum DMEM. Percentage of EdU stained cells, 24 h (A) and 48 h 
(B). Percentage of spindle-shaped cells, 24 h (C) and 48 h (D). Female 44-year-old back skin (F44B), male 50-year-
old face skin (M50F), female 60-year-old breast skin (F60Br). NHDF isolated through enzyme (ENZ) or explant 
(EXP) technique. Error bars represent SD of triplicate wells; n=1. 
 
TGF-β1 caused an increase in the percentage of EdU positive cells at 24 h. The percentage of 
EdU positive cells was reduced by RepSox or LY2157299 (Figure 15A). The percentage of EdU 
positive cells was much higher at 24 h than 48 h (Figure 15B). LY2157299 had a greater effect 
on NHDF proliferation than RepSox at the concentrations used. The reduction in percentage 
of spindle-shaped cells, with TGF-β1 treatment, was greater at 48 h (Figure 15C-D). Inhibition 
of TGF-β1 gave a percentage of spindle-shaped cells similar to that of the control. Treatment 
duration of 24 h was chosen for experiments going forward. 
 
3.1.5 Treatment with TGF-β isoforms 
NHDF were treated with different isoforms of TGF-β to determine the effect on cell 















































































































































experiment was carried out on two separate 96-well microplates (Figure 16 and Figure 17). 
Here, I would observe how adult dermal fibroblasts were affected by TGF-β2 and if that 
response was similar to treatment with TGF-β1. Choice of NHDF was based on availability (see 
Appendix 8.1) using NHDF of similar, if not identical, passage number. Here I used NHDF-c24 
and c64a (described previously, PromoCell) alongside enzyme-derived NHDF from female 27-
year-old abdomen skin (F27Ab), female 44-year-old back skin (F44B) and female 48-year-old 
abdomen skin (F48Ab). No statistical tests were performed on these experiments since they 
represent only n=1, triplicate wells (single 96-well microplate). 
 
 
Figure 16. Effect of TGF-β isoform on cell phenotype. NHDF as control (low serum DMEM) or treated with TGF-
β1 (10 ng/ml), TGF-β2 (10 ng/ml) or RepSox (25 µM) in low serum DMEM. (A) Total number of cells analysed. 
(B) Percentage of cells expressing α-SMA. (C) Percentage of cells stained for EdU. (D) Percentage of spindle-
shaped cells. PromoCell NHDF-c24 and c64a. Enzyme-extracted NHDF: female 27-year-old abdomen skin 
(F27Ab), female 44-year-old back skin (F44B) and female 48-year-old abdomen skin (F48Ab). Error bars 
represent SD of triplicate wells; n=1. 
 
Cell number increased with TGF-β treatment (Figure 16A). Both TGF-β isoforms had a similar 




























































































































to control. As seen previously, TGF-β caused an increase in the percentage of α-SMA positive 
cells (Figure 16B), an increase in the percentage of EdU positive cells (Figure 16C), and a 
decrease in the percentage of spindle-shaped cells (Figure 16D) compared with control. Cell 
number for each of the treatments was highest for F27Ab and lowest for c64a. Interestingly, 
the percentage of α-SMA expressing NHDF was very low in the non-sorted NHDF (F27Ab, 
F44B, F48Ab) compared with NHDF-c24 (CD90+ sorted). 
 
 
Figure 17. Effect of TGF-β isoform inhibition on cell phenotype. NHDF as control (low serum DMEM) or treated 
with TGF-β1 (10 ng/ml), TGF-β2 (10 ng/ml) or RepSox (25 µM) in low serum DMEM. (A) Total number of cells 
analysed. (B) Percentage of cells expressing α-SMA. (C) Percentage of cells stained for EdU. (D) Percentage of 
spindle-shaped cells. PromoCell NHDF-c24 and c64a. Enzyme-extracted NHDF: female 27-year-old abdomen skin 
(F27Ab), female 44-year-old back skin (F44B) and female 48-year-old abdomen skin (F48Ab). Error bars 
represent SD of triplicate wells; n=1. 
 
NHDF-c64a had the lowest number of cells/well; there was an inverse correlation between 




























































































































































treatment with different isoforms did not affect the percentage of EdU-labelled cells (Figure 
17C) or the percentage of spindle-shaped cells (Figure 17D). The percentage of α-SMA positive 
cells was low for all donors except for NHDF-c24. Treatment with RepSox alone did not cause 
a reduction in the percentage of α-SMA positive cells (Figure 17B). Treatment with TGF-β1 
isoform was chosen for experiments going forward. 
 
3.1.6 Treatment with DMSO 
In the above experiments the control did not contain DMSO, despite RepSox having been 
reconstituted in DMSO. To each ml of low (1%) serum DMEM, 5 µl TGF-β (stock concentration 
2 µg/ml, PBS) and 2.5 µl RepSox (stock concentration 10 mM, DMSO) was added (previously). 
To determine the effect of DMSO on NHDF, cells were treated with low (1%) serum DMEM 
control; DMSO; RepSox; or TGF-β1 and RepSox in low (1%) serum DMEM (Figure 18). No 
statistical tests were performed on these experiments since they represent only n=1, 





Figure 18. Effect of DMSO on NHDF phenotype. NHDF as control (low serum DMEM) or treated with DMSO (2 
µl/ml), RepSox (25 µM), or TGF-β1 (10 ng/ml) and RepSox in low serum DMEM. (A) The total number of cells 
used in the analysis pipeline. (B) The percentage of total cells that express α-SMA. (C) The percentage of total 
cells that stained for EdU. (D) The percentage of total cells that are spindle-shaped. PromoCell NHDF-c19 (female 
19-year-old breast skin); c24 (female 24-year-old breast skin); c64a (female 64-year-old breast skin, donor A) 
and c64b (female 64-year-old breast skin, donor B). Error bars represent SD of mean values; n=1. 
 
Cell number was reduced with RepSox treatment, compared with the other three treatments 
(Figure 18A). The percentage of α-SMA positive cells was similar for each treatment of NHDF, 
compared with control (Figure 18B). RepSox increased the percentage of EdU positive cells 
compared with control and with DMSO; this was most pronounced in the case of NHDF-c19 
(Figure 18C). There was no difference in the percentage of spindle-shaped cells across each 
treatment (Figure 18D). The effects of treatment on NHDF phenotype (shown previously), 








































































































































3.1.7 NHDF phenotype with TGF-β1 treatment 
Effect of TGF-β1 and RepSox treatment on PromoCell NHDF-c19 (female 19-year-old breast 
skin); c24 (female 24-year-old breast skin); c64a (female 64-year-old breast skin, donor A) and 
c64b (female 64-year-old breast skin, donor B). This experiment was repeated with both the 
agonist and inhibitor combined (TGF-β1 & RepSox). 
 
 
Figure 19. NHDF phenotype. NHDF treated with TGF-β1 (10 ng/ml) and RepSox (25 µM) in low serum DMEM and 
assayed for cell number (A), differentiation (% α-SMA positive, B), proliferation (% EdU positive, C) and shape 
(% Spindle-shaped, D). Fluorescence intensity thresholding was based on the maximum signal in NHDF lacking 
the respective label (B, C). PromoCell NHDF-c19 (female 19-year-old breast skin); c24 (female 24-year-old breast 
skin); c64a (female 64-year-old breast skin, donor A) and c64b (female 64-year-old breast skin, donor B). Error 
bars represent SD of mean values; three 96-well microplates (n=3). Two-way ANOVA comparing NHDF treatment 
with own control (A-D) (Dunnett’s *p<0.05, **p<0.01). Two-way ANOVA comparing NHDF-c64a with other 

















































































































































Figure 19 shows the results for the NHDF phenotype assay carried out using PromoCell NHDF. 
NHDF were treated with TGF-β1 and RepSox and cultured for 24 h. Cell number, EdU staining, 
α-SMA expression and NHDF morphology were measured. There was no significant difference 
in cell number for each treatment of NHDF (Figure 19A). Addition of RepSox reduced cell 
number in each of the NHDF. TGF-β1 caused an increase in the percentage of α-SMA positive 
cells, and treatment with RepSox prevented this increase (Figure 19B). NHDF-c64a showed a 
low percentage of α-SMA positive cells in all four conditions, however this was non-significant 
compared with the other NHDF (Tukey’s). Treatment with TGF-β1 significantly increased the 
percentage of EdU positive cells (NHDF-c24, c64a, c64b) (Figure 19C). Treatment with TGF-β1 
significantly reduced the percentage of spindle-shaped cells in all four NHDF (Figure 19D). 
With RepSox treatment the percentage of spindle-shaped cells was similar to that of the 
control, except in the case of NHDF-c19 which showed an increased proportion of spindle-
shaped cells. 
 
3.2 Adipogenesis assay 
NHDF were characterised for their ability to form lipid droplets. Papillary fibroblasts reside in 
the upper dermis while reticular fibroblasts/pre-adipocytes reside in the lower dermis. Given 
the proximity of the reticular/pre-adipocyte population to the hypodermis, it is plausible that 
they more readily form lipid droplets (Jahoda and Gilmore, 2016; Mastrogiannaki et al., 2016). 
I was interested to investigate if NHDF-c64a had an altered capacity for adipogenesis 
compared with other PromoCell NHDF; perhaps indicative of a difference in NHDF population 
densities between PromoCell donors. I was also interested to find out if NHDF derivation 




3.2.1 Comparison of enzyme and explant-derived NHDF 
 
Figure 20. Effect of adipogenic medium on enzyme and explant-derived NHDF. Female 44-year-old back skin 
(F44B), male 50-year-old face skin (M50F), female 60-year-old breast skin (F60Br). NHDF isolated through 
enzyme (ENZ) or explant (EXP) technique. (A) Percentage LipidTOX positive cells as a measure of NHDF lipid 
droplet formation. (B) Confluent NHDF cultured in adipogenic medium stained for NucBlue (blue), LipidTOX 
(green) and CD90/Thy1 (red). Left to right: F44B EXP, M50F EXP and F60Br EXP. 20x magnification. Scale bar: 100 
µm. Two-way ANOVA comparing NHDF within treatments. Tukey’s multiple comparisons test. Error bars 
represent SD of mean; n=3. *p<0.05; **p<0.01, ***p<0.001. 
 
Choice of NHDF was based on availability (see Appendix 8.1) using NHDF of similar, if not 
identical, passage number. The NHDF used in this adipogenesis experiment were from three 
separate donor skin biopsies, isolated in-house. They were either isolated through enzyme 
digestion (ENZ) or they were explant-derived (EXP). These were the same NHDF as used in 
Figure 14 and Figure 15. NHDF were seeded in 96-well microplates at 10000 cells/well and 
grown for four days until confluent. Cultured with complete DMEM or adipogenic medium, 
the medium was changed every four days. The experiment was completed after two weeks 
from the point of first adding adipogenic medium. Fixed with 4% PFA, NHDF were stained 
with LipidTOX green which stains lipid droplets. Fluorescence intensity was measured using 
the Operetta platform and the percentage of LipidTOX positive cells was calculated using the 
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Harmony software. The percentage of LipidTOX positive cells was higher in cultures grown in 
adipogenic medium than in complete DMEM (Figure 20A). The percentage of LipidTOX 
positive cells was higher in explant-derived NHDF than in enzyme-derived NHDF; perhaps 
indicating that this explant-derivation technique selected for a lower lineage fibroblast 
population. While this difference between ENZ and EXP-derived NHDF was not significant for 
NHDF-F60Br, it was significant for F44B and M50F. Images show confluent NHDF cultures 
stained for the pan-fibroblast marker CD90 (BD Biosciences, 550402, 1:300) and LipidTOX 
green (Figure 20B). 
 
3.2.2 Comparison of PromoCell NHDF 
 
Figure 21. Effect of adipogenic medium on PromoCell NHDF. NHDF-c19 (female 19-year-old breast skin); c24 
(female 24-year-old breast skin); c64a (female 64-year-old breast skin, donor A) and c64b (female 64-year-old 
breast skin, donor B). (A) Percentage LipidTOX positive cells as a measure of NHDF lipid droplet formation. (B) 
Confluent NHDF cultured in adipogenic medium stained for NucBlue (blue), LipidTOX (green) and CellMask (red). 
Top panel left to right: NHDF-c19, c24, c64a and c64b in adipogenic medium. Bottom panel: corresponding 
LipidTOX positive cells (green), LipidTOX negative cells (red). 10x magnification. Scale bar: 200 µm. Two-way 





NHDF-c19 showed a significantly higher percentage of LipidTOX positive cells, compared to 
the other three NHDF, when cultured in adipogenic medium (Figure 21A). There was no 
difference in the percentage of LipidTOX positive cells between the remaining three NHDF. 
Figure 21B displays LipidTOX positive (green) and LipidTOX negative (red) cells. Populations 
were determined using the LipidTOX analysis pipeline (see Appendix 8.2.2). 
 
3.3 Discussion: fibroblast phenotype 
3.3.1 NHDF characterisation 
Early experiments used CD90+ sorted, commercially sourced NHDF from four donors. Donor 
fibroblasts were from female 19-year-old breast skin (c19); female 24-year-old breast skin 
(c24); female 64-year-old breast skin donor A (c64a) and female 64-year-old breast skin donor 
B (c64b). Having worked previously with the Operetta high-content imaging system as part of 
the Human Induced Pluripotent Stem Cell Initiative (Leha et al., 2016; Kilpinen et al., 2017), I 
was keen to use a similar approach to determine NHDF phenotype.  
 
Work by Lichtenberger, Mastrogiannaki and Watt (2016) had investigated FGF, Hh and TGF-β 
signalling within the dermis of transgenic mice treated with tamoxifen to cause epidermal β-
catenin overexpression (Lo Celso, Prowse and Watt, 2004). It was found that the papillary 
dermis could be expanded with Hh activation and that the reticular dermis could be expanded 
with TGF-βR I inhibition (RepSox) (Lichtenberger, Mastrogiannaki and Watt, 2016).  
 
An MTT assay showed NHDF were viable at the concentration of agonist/inhibitor used in the 
FGF/Hh/TGF-β phenotype experiments. Despite this, there was no significant effect on NHDF 
number, differentiation, proliferation or shape with agonist treatment. Interestingly, the 
percentage of α-SMA positive NHDF-c64a was consistently low regardless of agonist/inhibitor 
treatment. NHDF-c64a had a lower number of quantifiable cells and a higher percentage of 
spindle-shaped cells, but similar levels of proliferating cells compared with the other three 
PromoCell NHDF. Since α-SMA is expressed in myofibroblasts, and TGF-β is known to promote 
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myofibroblast differentiation (Desmoulière et al., 1993), I chose to focus on this signalling 
pathway for further experiments.  
 
3.3.2 TGF-β treatment 
Lichtenberger, Mastrogiannaki and Watt (2016) showed that with 24 h treatment, TGF-β2 (10 
ng/ml) prevented proliferation while RepSox (25 µM) caused proliferation in fibroblasts 
isolated from adult mouse dorsal skin. Here, I showed that both TGF-β1 and β2 caused NHDF 
proliferation (EdU) and differentiation (α-SMA). Both isoforms also reduced the percentage 
of spindle-shaped NHDF, compared with control (low serum DMEM) conditions. TGF-β1 
treatment duration of 24 h was chosen for experiments going forward. 
 
PromoCell NHDF phenotype was determined with both TGF-β1 and RepSox combined. TGF-
β1 (in low serum DMEM) caused an increase in the percentage of α-SMA positive cells (non-
significant), an increase in the percentage of EdU positive cells (significant) and a decrease in 
the percentage of spindle-shaped cells (significant) compared with control (low serum 
DMEM) conditions; all of which were inhibited with RepSox treatment. NHDF-c64a showed a 
low percentage of α-SMA positive cells (non-significant), compared with the other PromoCell 
NHDF (c19, c24 and c64b). 
 
3.3.3 Lipid droplet formation 
The percentage of LipidTOX positive NHDF-c19 was significantly higher than the remaining 
PromoCell NHDF (c24, c64 and c64b), cultured in adipogenic medium. There was no 
significant difference in lipid droplet formation between NHDF-c24, c64a and c64b. 
Comparing lipid droplet formation in enzyme-derived or explant-derived NHDF, there was a 
higher percentage of LipidTOX positive cells in explant-derived NHDF. The conversion from 
fibroblasts to lipid droplet-containing cells was inefficient for all NHDF tested. 
 
Further work would use adipogenic medium containing inhibitors of BMP/TGF-β signalling 
(Takeda et al., 2017) to better understand NHDF population heterogeneity and adipocyte 
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formation (Plikus et al., 2017). Fibroblasts would be isolated through enzyme-derivation 
method from multiple donors of the same gender and from the same site of origin. Given the 
association of myofibroblasts with fibrotic disorders and aberrant wound healing, 
modification of fibroblast-myofibroblast and myofibroblast-adipocyte fate would be of 
therapeutic benefit (Schmidt and Horsley, 2013; Ebmeier and Horsley, 2015). 
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4 Fibroblast gene expression 
From the fibroblast phenotype experiments I had found that one donor (NHDF-c64a) had a 
low percentage of α-SMA positive cells. This was despite treatment with TGF-β1, known to 
cause myofibroblast differentiation and α-SMA protein expression. I was interested to 
investigate its gene expression profile using Agilent microarray and Fluidigm qPCR setups.  
 
NHDF-F22Br, M50F and F60Br were included in the gene expression experiments for 
comparison. NHDF-F60Br, had previously shown a low percentage of α-SMA positive cells 
(Figure 14, enzyme-derived) and was included as an age-matched donor. F22Br was used as 
a young donor, for comparison. M50F had previously shown a high percentage of α-SMA 
positive cells (Figure 14, enzyme-derived). M50F was sourced from 50-year-old male skin 
taken from the donor’s brow. RNA was extracted from NHDF treated with or without TGF-β1, 
in low (1%) serum DMEM, for 12 h and 24 h.  
 
4.1 Agilent gene expression microarray 
Output files were imported into the GeneSpring software and assigned sample names and 
conditions. GeneSpring was used to baseline transform (median of all samples) and normalise 
(shift to 75th percentile) the data. Normalised values for each of the three independent 
experiments were compared for difference in expression using R scripts.  
 
4.1.1 Hierarchical clustering 
Using RStudio, I was able to perform hierarchical clustering of differentially expressed genes. 
With a log fold change (logFC) +/-2, heatmaps show significantly upregulated gene expression 
(red) and significantly downregulated gene expression (blue) with an adjusted p value<0.05 
(Figure 22).  
 
The R script collected the normalised expression files from each experiment and assigned a 
gene ID to each microarray probe. Designs describing the experimental conditions were 
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added and, using a Bayesian fit, the conditions of interest were chosen e.g. 12 and 24 h, non-
treated NHDF-c64a (six samples) compared with 12 and 24 h, non-treated other NHDF (18 
samples). The second fit provided a contrast of the conditions chosen in the first Bayesian fit. 
Three R scripts were used in total, comparing non-treated NHDF-c64a with other non-treated 
NHDF (‘non-treated’); TGF-β1 treated NHDF-c64a with other TGF-β1 treated NHDF (‘TGF-β1 
treated’); and the effect of TGF-β1 treatment on all four NHDF (‘treated vs non-treated’) (see 
Appendix 8.3). Lists of differentially expressed genes were produced (see Appendix 8.4) and 
used for hierarchical clustering, GO term analysis and causal network analysis (below).  
 
 
Figure 22. Non-treated cells: clustering of genes unique to c64a. n=3, logFC +/-2, adjusted p<0.05. 150 probes 
representing 140 differentially expressed genes; 12 h and 24 h in low serum DMEM (Control). Female 22-year-
old breast skin (F22Br), male 50-year-old face skin (M50F), female 60-year-old breast skin (F60Br) and PromoCell 
NHDF-c64a. 
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Non-treated NHDF-M50F, F60Br and c64a samples grouped on experiment with three 
experiments in total (‘.0’, ‘.1’ and ‘.2’); with each experiment increasing in NHDF passage 
number. From the dendrogram at the top of Figure 22, F22Br is shown on a separate branch 
to M50F and F60Br, indicating that under non-treated conditions F22Br was the least similar 
of these three NHDF for these probes. Both ‘F22Br_Control24().1’ and ‘F60Br_Control24().1’ 
clustered differently for these 150 probes, as shown by the branching of the dendrogram 
away from the same donor samples.  
 
 
Figure 23. TGF-β1 treated cells: clustering of genes unique to c64a. n=3, logFC +/-2, adjusted p<0.05. 126 probes 
representing 115 differentially expressed genes; TGF-β1 for 12 and 24 h in low serum DMEM (Test). Female 22-
year-old breast skin (F22Br), male 50-year-old face skin (M50F), female 60-year-old breast skin (F60Br) and 
PromoCell NHDF-c64a. 
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NHDF treated with TGF-β1 (10 ng/ml) for 12 h or 24 h grouped on duration of treatment, with 
all 12 h treated samples grouping together and all 24 h treated samples grouping together for 
each of the NHDF (Figure 23). This indicates that treatment of NHDF with TGF-β1 had an effect 
on gene expression and that duration of TGF-β1 treatment had a greater effect than NHDF 
passage number. M50F clustered separately to F22Br and F60Br for these 126 probes, shown 
by the dendrogram.  
 
 
Figure 24. Clustering of genes common to all four NHDF. Comparing TGF-β1 treated (Test) with non-treated for 
12 and 24 h. n=3, logFC +/-2, adjusted p<0.05. 230 probes representing 208 differentially expressed genes. 
Female 22-year-old breast skin (F22Br), male 50-year-old face skin (M50F), female 60-year-old breast skin 
(F60Br) and PromoCell NHDF-c64a. 
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Figure 24 shows differentially expressed genes for all four NHDF in response to treatment 
with TGF-β1 in low (1%) serum DMEM. From the dendrogram, it can be seen that M50F 
clustered separately from the female NHDF for these 230 probes.  
 
4.1.2 Gene ontology 
Figure 25 shows the top 10 GO terms for each of the three gene lists. Using the molecular 
signatures database, GO terms were generated for non-treated (Figure 25A), TGF-β1 treated 
(Figure 25B) and treated vs non-treated (Figure 25C) differentially expressed genes.  
 
Non-treated GO terms, for NHDF-c64a gene expression, included ‘regulation of cell 
differentiation’, ‘regulation of cell proliferation’ and ‘extracellular space’. These same GO 
terms were included in the list generated for TGF-β1 treated NHDF-c64a gene expression. 
TGF-β1 treated NHDF-c64a GO terms also included ‘positive regulation of response to 
stimulus’, ‘immune system process’ and ‘defence response’, indicative of an inflammatory 
response. GO terms common across all of the four NHDF assayed, in response to TGF-β1, were 
listed in Figure 25C. The most significant was ‘tissue development’. ‘Regulation of the MAPK 
pathway cascade’ was also included; known for its role in non-canonical TGF-β signalling 
(Moustakas and Heldin, 2005). Cell locomotion was also included, perhaps indicative of a 
migratory response to TGF-β1 in all four NHDF (F22Br, M50F, F60Br, NHDF-c64a).  
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Figure 25. Top 10 GO terms for each treatment condition. (A) GO terms for non-treated (low serum DMEM) 
NHDF-c64a differentially expressed genes. (B) GO terms for TGF-β1 treated (in low serum DMEM) NHDF-c64a 
differentially expressed genes. (C) GO terms for TGF-β1 treated (in low serum DMEM) differentially expressed 
genes common across all four NHDF. Female 22-year-old breast skin, male 50-year-old face skin, female 60-year-
old breast skin and PromoCell NHDF-c64a. 
 
4.1.3 Causal network analysis 
Gene lists for non-treated (NHDF-c64a), TGF-β1 treated (NHDF-c64a) and treated vs non-
treated (NHDF-F22Br, M50F, F60Br, NHDF-c64a) conditions were uploaded to Qiagen 
Ingenuity Pathway Analysis (IPA) software. The software ‘Core Analysis’ function was run for 
each uploaded gene list. Gene expression values (increased logFC measurement – red; 
decreased logFC measurement – green) were overlaid onto nodes using the software 
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‘Molecule Activity Predictor’ function. Predicted interactions are based on published 
datasets, taking into account the logFC and adjusted p value for each of the differentially 
expressed genes uploaded here. Figure 26 shows the top predicted network for non-treated 
NHDF-c64a. Figure 27 shows the top predicted network for TGF-β1 treated NHDF-c64a. Figure 
28 shows the top predicted network for all four NHDF in response to TGF-β1 treatment. 
 
 
Figure 26. Top interaction network for NHDF-c64a, non-treated in low-serum DMEM. Increased gene expression 
(red) and decreased gene expression (green) for each node. Orange indicates predicted activation and blue 
indicates predicted inhibition. Inconsistent interactions and non-predicted interactions (yellow and grey, 








Fibroblast gene expression 
 81 
At the centre of Figure 26 is ERK1/2 signalling, predicted to be activated with non-treated 
NHDF-c64a (low serum DMEM). The network shows involvement of genes of the IGF signalling 
pathway: IGF (upregulated), insulin-like growth factor binding protein (IGFBP)2 
(downregulated) and IGFBP5 (upregulated). WNT is downregulated, shown in green, while 
collagens (αI and type II) are predicted to be activated (orange). Cadherin 2 (CDH2) is shown 
to be upregulated in NHDF-c64a. Alcohol dehydrogenase 1α (ADH1A), 1β (ADH1B) and 1γ 
(ADH1C) also formed part of this top network for non-treated NHDF-c64a. Perhaps indicative 
of ethanol catabolism in the dermis of this donor (Petersen, Cornell and Veech, 1980). 
 
 
Figure 27. Top interaction network for NHDF-c64a, TGF-β1 treated in low-serum DMEM. Increased gene 
expression (red) and decreased gene expression (green) for each node. Orange indicates predicted activation 
and blue indicates predicted inhibition. Inconsistent interactions and non-predicted interactions (yellow and 
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Predicted activation of ERK1/2 is again at the centre of NHDF-c64a network interactions 
(Figure 27). The top signalling network for TGF-β1 treatment (in low serum DMEM), also 
includes chemokines CXCL1-3 and CXCL6, as well as components of the complement system: 
C3, C8 and C8β. Interleukin 17 receptor is predicted to be activated in TGF-β1 treated NHDF-
c64a. Integrin α8 (ITGA8) was downregulated in TGF-β1 treated NHDF-c64a. Of note, IGF is 
upregulated in both the non-treated and treated NHDF-c64a gene expression networks. 
 
 
Figure 28. Top interaction network for all four NHDF, TGF-β1 treated in low serum DMEM. Increased gene 
expression (red) and decreased gene expression (green) for each node. Orange indicates predicted activation 
and blue indicates predicted inhibition. Inconsistent interactions and non-predicted interactions (yellow and 
grey, respectively) also shown. Female 22-year-old breast skin, male 50-year-old face skin, female 60-year-old 
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Whereas before the interaction networks were specific to NHDF-c64a for both non-treated 
(low serum DMEM) and TGF-β1 treated (in low serum DMEM) conditions, here the interaction 
network was derived from the treated vs non-treated gene list. This network shows changes 
in gene expression common to all four NHDF, in response to TGF-β1 (Figure 28). At the centre 
of this network, and therefore the case for NHDF-22Br/M50F/F60Br/c64a, was increased 
expression of early growth response 2 (EGR2). EGR2 is associated with predicted activation of 
serine-threonine protein kinases Raf/Akt and mitogen-activated protein kinase kinase 1-2 
(MAP2K1/2). Maybe suggesting, kinase signalling in all four NHDF as part of the non-canonical 
TGF-β pathway. NADPH oxidase 4 (NOX4) was upregulated for all four NHDF with treatment. 
 
4.1.4 Selecting genes of interest for validation and further analysis 
The highest differentially expressed genes specific to NHDF-c64a, both non-treated (low 
serum DMEM) and TGF-β1 treated (in low serum DMEM), were chosen from the microarray 
experiment as genes of interest for further work. IGF1 was highly upregulated and WNT4 was 
highly downregulated for NHDF-c64a (Table 4). ASPN is an endogenous TGF-β1 inhibitor 
(Maris et al., 2015). Here ASPN was significantly downregulated (adjusted p value<0.05) in 
both non-treated and TGF-β1 treated NHDF-c64a. CXCL1 was significantly upregulated 
(adjusted p value<0.05) in TGF-β1 treated NHDF-c64a only (Table 4). 
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Table 4. Differentially expressed genes unique to NHDF-c64a. Sorted on logFC. Adjusted (Adj.) p value<0.05. 




LogFC Adj. p value Gene name (ID) 
 
LogFC Adj. p value Gene name (ID) 
5.63 2.57E-04 IGF1 
 
4.05 1.23E-02 IGF1 
5.18 4.65E-04 IGF1 
 
4.02 3.75E-02 IGF1 
-2.51 1.21E-03 WNT4 
 
3.18 4.52E-03 CXCL1 
-3.70 2.67E-04 ASPN 
 
2.85 5.51E-03 CXCL1 
-3.79 4.03E-04 ASPN 
 
-2.79 1.86E-03 WNT4 
-5.06 4.45E-06 WNT4 
 
-3.08 1.36E-02 ASPN 
    
-3.24 1.25E-02 ASPN 
    
-3.69 2.49E-02 WNT4 
 
4.1.5 TaqMan qPCR 
The fibroblast phenotype experiments compared PromoCell NHDF (CD90+ sorted). Whereas 
the microarray gene expression experiments compared NHDF-c64a (CD90+ sorted) with other 
NHDF (non-sorted). Here I measured gene expression, of the genes of interest (ASPN, CXCL1, 
IGF1 and WNT4), in NHDF previously used for comparison with NHDF-c64a. These 
experiments were carried out to determine if the NHDF previously used for comparison 
shared similar gene expression profiles, at least for the genes of interest. The NHDF used here 
were: female 22-year-old breast skin (F22Br); male 50-year-old face skin (M50F); female 60-
year-old breast skin (F60Br); PromoCell NHDF-c19 (female 19-year-old breast skin); PromoCell 
NHDF-c24 (female 24-year-old breast skin) and PromoCell NHDF-c64b (female 64-year-old 
breast skin, donor B). ΔCq expression was used to determine gene expression with or without 
TGF-β1 treatment (Figure 29-Figure 30). ΔΔCq expression was used to determine the effect 
of TGF-β1 treatment on gene expression (Figure 31). 
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Figure 29. ΔCq expression in non-treated (low serum DMEM) NHDF. (A) ASPN, (B) CXCL1, (C) IGF1 and (D) WNT4 
expression. Expression relative to reference genes 18S and TBP. Error bars represent SD of mean values from 
three independent experiments (n=3). One-way ANOVA comparing NHDF. Tukey’s test for multiple comparisons. 
*p<0.05, **p<0.01, ***p<0.001. Female 22-year-old breast skin (F22Br); male 50-year-old face skin (M50F); 
female 60-year-old breast skin (F60Br); PromoCell NHDF-c19 (female 19-year-old breast skin); PromoCell NHDF-
c24 (female 24-year-old breast skin) and PromoCell NHDF-c64b (female 64-year-old breast skin, donor B). 
 
Figure 29 shows ΔCq expression values for the four candidate genes in non-treated NHDF-
F22Br, M50F, F60Br, c19, c24 and 64b. Candidate gene expression was normalised against 
reference genes 18S and TBP. ASPN (Figure 29A) and WNT4 (Figure 29D) expression was 
significantly higher in M50F. There was no significant difference in CXCL1 expression between 
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Figure 30. ΔCq expression in TGF-β1 treated (low serum DMEM) NHDF. (A) ASPN, (B) CXCL1, (C) IGF1 and (D) 
WNT4 expression. Expression relative to reference genes 18S and TBP. Error bars represent SD of mean values 
from three independent experiments (n=3). One-way ANOVA comparing NHDF. Tukey’s test for multiple 
comparisons. *p<0.05, **p<0.01, ***p<0.001. Female 22-year-old breast skin (F22Br); male 50-year-old face 
skin (M50F); female 60-year-old breast skin (F60Br); PromoCell NHDF-c19 (female 19-year-old breast skin); 
PromoCell NHDF-c24 (female 24-year-old breast skin) and PromoCell NHDF-c64b (female 64-year-old breast 
skin, donor B). 
 
Figure 30 shows ΔCq expression values for the four candidate genes in TGF-β1 treated NHDF-
F22Br, M50F, F60Br, c19, c24 and 64b. Candidate gene expression was normalised against 
reference genes 18S and TBP. There was no significant difference in ASPN, CXCL1 or IGF1 
expression between NHDF (Figure 30A-C). ASPN expression was highest in M50F. WNT4 
expression was significantly increased in F60Br (Figure 30D). None of the NHDF showed a 
significant difference in candidate gene expression in both non-treated and treated 
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Figure 31. ΔΔCq expression in TGF-β1 treated (low serum DMEM) NHDF. (A) ASPN, (B) CXCL1, (C) IGF1 and (D) 
WNT4 expression. Expression relative to non-treated (low serum DMEM) control, normalised using reference 
genes 18S and TBP. Error bars represent SD of mean values from three independent experiments (n=3). One-
way ANOVA comparing treated expression with control expression. Dunnett’s multiple comparison test. 
*p<0.05, **p<0.01, ***p<0.001. Female 22-year-old breast skin (F22Br); male 50-year-old face skin (M50F); 
female 60-year-old breast skin (F60Br); PromoCell NHDF-c19 (female 19-year-old breast skin); PromoCell NHDF-
c24 (female 24-year-old breast skin) and PromoCell NHDF-c64b (female 64-year-old breast skin, donor B). 
 
Figure 31 shows candidate gene expression for TGF-β1 treated NHDF, relative to non-treated 
control, normalised using reference genes 18S and TBP (ΔΔCq expression). There was no 
significant effect of TGF-β1 treatment on ASPN expression for any of the NHDF, compared 
with non-treated control (Figure 31A). TGF-β1 treatment significantly increased CXCL1 
expression in NHDF-c64b (Figure 31B). Expression of IGF1 was greater in all six NHDF with 
TGF-β1 treatment, compared with non-treated control. TGF-β1 treatment significantly 
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significantly increased WNT4 expression in NHDF-c24 and c64b, compared with non-treated 
control (Figure 31D). 
 
4.2 Fluidigm qPCR gene expression 
The Fluidigm qPCR process was employed to validate the microarray gene expression results. 
Using a 96:96 array it was possible to assay 96 samples/standards using 96 TaqMan probes. 
Samples were split into two batches: 24 samples (n=3) from 24 h TGF-β1 treated (in low serum 
DMEM) and non-treated NHDF (low serum DMEM); as used in the Agilent microarray. 16 
samples (n=2) from 12 h TGF-β1 treated (in low serum DMEM) and non-treated NHDF (low 
serum DMEM); not used in the Agilent microarray. The remaining eight were standards of 
known concentration. Samples and standards were run in duplicate. NHDF-F22Br, M50F, 
F60Br and c64a were used in this experiment. Assay groups of interest included: ECM 
proteins, fibroblast markers, Hh/TGF-β/Wnt signalling, inflammation and redox biology. For a 
list of the 96 TaqMan assays used in the Fluidigm qPCR experiment see Appendix 8.5. 
 
4.2.1 qPCR graphs 
Relative gene expression was determined for each of the samples using PPIA as a reference 
gene. Of all the probes included for use as a potential reference gene (ACTB, B2M, PPIA, 
RPL13, TBP, TCF4 and YKT6), PPIA expression was found to be the most consistent across all 
samples (visualised using GeneSpring software). In other words, PPIA gene expression did not 
change across samples and across treatment conditions. Of the 96 probes used, espin like 
(ESPNL), NADPH oxidase 4 (NOX4), phosphodiesterase 7B (PDE7B), sonic hedgehog (SHH) and 
tumour necrosis factor (TNF) failed (Cq value ≥40). NHDF-F22Br treated with TGF-β1 for 24 h 
(experiment three) failed (insufficient sample concentration - Outlier) and was excluded from 
the analysis. 
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Figure 32. ΔCq expression of target genes, 24 h. (A) ASPN, (B) CXCL1, (C) IGF1 and (D) WNT4 expression relative 
to reference gene (PPIA). Female 22-year-old breast skin (F22Br); male 50-year-old face skin (M50F); female 60-
year-old breast skin (F60Br); PromoCell NHDF-c64a. Error bars represent SD of mean values from three 
independent experiments (n=3). Two-way ANOVA comparing NHDF with NHDF-c64a, non-treated (low serum 
DMEM) or treated with TGF-β1 (in low serum DMEM) for 24 h. Tukey’s multiple comparisons test. *p<0.05, 
**p<0.01, ***p<0.001. 
 
NHDF-c64a showed a lower expression of ASPN compared with the other NHDF (Female 22-
year-old breast skin, male 50-year-old face skin, female 60-year-old breast skin). This was only 
significantly different however, when compared with M50F (Figure 32A). Expression of CXCL1 
and IGF1 was significantly higher in NHDF-c64a (Figure 32B-C). Expression of WNT4 was 
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Figure 33. ΔCq expression of target genes, 12 h. (A) ASPN, (B) CXCL1, (C) IGF1 and (D) WNT4 expression relative 
to reference gene (PPIA). Female 22-year-old breast skin (F22Br); male 50-year-old face skin (M50F); female 60-
year-old breast skin (F60Br); PromoCell NHDF-c64a. Error bars represent SD of mean values from two 
independent experiments (n=2). NHDF non-treated (low serum DMEM) or treated with TGF-β1 (in low serum 
DMEM) for 12 h. 
 
With 12 h treatment, NHDF-c64a showed lower expression of ASPN and WNT4, and higher 
expression of CXCL1 and IGF1 when compared with other NHDF. These results, together with 
Figure 32, validate the gene expression profile of NHDF-c64a which was generated using the 
Agilent microarray (see Chapter 4.1). 
 
4.2.2 Violin plots and principal component analysis 
The SINGuLAR toolset, developed by Fluidigm, was used to generate principal component 
analysis (PCA) plots for NHDF sample clustering. Plots were generated using Cq values from 
NHDF samples, non-treated (low serum DMEM) or treated with TGF-β1 (in low serum DMEM) 
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and F60Br) and Fluidigm 2 (FD2: NHDF-c64a). Samples clustered according to PCA rank of the 
top 24 genes (A). These top 24 genes are shown here as violin plots, ordered on p value (B). 
 
Figure 34A shows a PCA plot of non-treated (low serum DMEM) samples divided into 
populations FD1 and FD2. Samples clustered based on NHDF donor, with NHDF-M50F and 
NHDF-c64a showing the greatest variation (PC1). Figure 34B shows violin plots of the top 24 
genes. These genes are ordered on ANOVA p value for population expression difference. 
WNT4, IGF1 and CXCL6 were the most differentially expressed genes between FD1 and FD2. 
WNT4 through to SEPP1 were significantly different (p<0.05) while genes SOST (p=0.064) 
through to PDPN were not significantly different, for expression. 
 
Figure 35A shows a PCA plot of samples treated with TGF-β1 (in low serum DMEM), divided 
into populations FD1 and FD2. Clustering was similar to that seen in the non-treated samples, 
with NHDF-M50F and NHDF-c64a showing the greatest variation (PC1). Treated samples 
included genes encoding interleukin (IL)1α, IL1β, CXCL2, CXCL1, IL1RN (receptor antagonist), 
IL8 and CXCL6; upregulated in the FD2 population, indicative of an inflammatory response of 
NHDF-c64a with TGF-β1 (Figure 35B). IL1A through to CXCL6 were significantly different 
(p<0.05) while genes CASP1 (p=0.051) through to RGS16 were not significantly different, for 
expression. 
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Figure 34. SINGuLAR analysis of non-treated Cq values. (A) PCA plot of all samples as two populations FD1 (NHDF-
F22Br, M50F, F60Br) and FD2 (NHDF-c64a). (B) Violin plot of the top 24 genes, based on PCA rank, ordered on 
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Figure 35. SINGuLAR analysis of treated Cq values. (A) PCA plot of all samples as two populations FD1 (NHDF-
F22Br, M50F, F60Br) and FD2 (NHDF-c64a). (B) Violin plot of the top 24 genes, based on PCA rank, ordered on 
ANOVA p value.  
FD1
FD2
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4.3 Discussion: fibroblast gene expression 
From the NHDF phenotype experiments, NHDF-c64a was found to have a lower percentage 
of α-SMA positive cells compared with other PromoCell NHDF. This low proportion of α-SMA 
expressing cells was not affected by treatment with agonists/inhibitors of the FGF/Hh/TGF-β 
signalling pathways. I wished to compare the gene expression profiles of NHDF (including 
NHDF-c64a), to better understand this difference in NHDF phenotype.  
 
4.3.1 NHDF-c64a gene expression profile 
NHDF from female 22-year-old breast skin (F22Br); male 50-year-old face skin (M50F); female 
60-year-old breast skin (F60Br) and PromoCell NHDF-c64a were used in the Agilent gene 
expression microarray. NHDF were non-treated (low serum DMEM) and TGF-β1 treated (in 
low serum DMEM) for 12 h and 24 h. Non-treated NHDF-c64a gave 140 significantly 
differentially expressed genes and TGF-β1 treated NHDF-c64a gave 115 significantly 
differentially expressed genes.  
 
Four candidate genes were chosen for further experiments based on the logFC expression 
values. Candidate gene expression was significantly different between NHDF-c64a and NHDF-
F22Br/M50F/F60Br (adjusted p value<0.05). Insulin-like growth factor 1 (IGF1) was 
upregulated in NHDF-c64a, both non-treated (low serum DMEM) and TGF-β1 treated (in low 
serum DMEM). Wnt family member 4 (WNT4) and Asporin (ASPN) were downregulated in 
NHDF-c64a with both treatments. C-X-C motif chemokine ligand 1 (CXCL1) was upregulated 
with TGF-β1 treatment (in low serum DMEM) only.  
 
Ingenuity Pathway Analysis (IPA) software was used to generate causal networks using the 
gene lists generated from the microarray. Central to both non-treated (low serum DMEM) 
and TGF-β1 treated (in low serum DMEM) networks was the predicted activation of ERK1/2, 
specific to NHDF-c64a. IGF was linked with predicted activation of ERK1/2 in both non-treated 
and TGF-β1 treated networks. ASPN and WNT4 were included in the non-treated network, 
while CXCL1 was included in the TGF-β1 treated network, specific to NHDF-c64a. IPA could 
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also be used to determine the upstream regulators of the differentially expressed genes for 
NHDF-c64a. TNF and progesterone (p value overlap: 1.41E-07 and 2.01E-07, respectively) 
were the top upstream regulators, both predicted to be activated in non-treated NHDF-c64a 
(Z-score: 2.155 and 2.275, respectively). It would be interesting to investigate these upstream 
targets of NHDF-c64a gene expression further. The effect of candidate gene knockdown on 
mRNA and protein expression, of both progesterone receptor and TNF-α, could be measured 
using qPCR and western blot technique. 
 
4.3.2 TGF-β1 induces EGR2 and NOX4 expression 
Highly upregulated in all four NHDF (F22Br, M50F, F60Br and PromoCell NHDF-c64a) with 
TGF-β1 treatment (in low serum DMEM) was early growth response 2 (EGR2) expression. 
Known to be upregulated with TGF-β treatment and linked with systemic sclerosis (SSc) (Fang 
et al., 2011), this increase in EGR2 indicates a positive response to TGF-β treatment. NADPH 
oxidase 4 (NOX4) was also highly upregulated with TGF-β1 treatment (in low serum DMEM), 
in all four NHDF tested. Expression of α-SMA protein with TGF-β treatment is known to be 
NOX4-dependent, as part of the oxidative stress response, in both cardiac fibroblasts 
(Cucoranu et al., 2005) and pulmonary fibroblasts (Hecker et al., 2014). TGF-β signalling-
induced NOX4 expression has also been linked with SSc (Piera-Velazquez, Makul and Jiménez, 
2015).  
 
4.3.3 Candidate gene expression in NHDF 
Candidate genes were validated by Fluidigm high-throughput qPCR for NHDF, non-treated 
(low serum DMEM) and treated with TGF-β1 (in low serum DMEM) for 24 h. ASPN expression 
in NHDF-c64a was downregulated compared with other NHDF (F22Br, M50F and F60Br). 
However, this difference in ASPN expression was only significant when comparing NHDF-c64a 
with M50F. CXCL1 and IGF1 expression in NHDF-c64a was significantly upregulated while 
WNT4 was significantly downregulated, compared with other NHDF (F22Br, M50F and F60Br). 
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The SINGuLAR analysis toolset was used to generate PCA and violin plots, displaying sample 
variation and distribution, based on gene expression profiles. PCA plots for both non-treated 
(low serum DMEM) and TGF-β1 (in low serum DMEM) treated conditions (24 h) were 
generated for two populations: Fluidigm 1 (FD1: F22Br, M50F and F60Br) and Fluidigm 2 (FD2: 
c64a). Of the top 24 genes based on PCA rank, 15 were significantly differentially expressed 
between populations for non-treated conditions and 18 were significantly differentially 
expressed between populations for TGF-β1 treated conditions. Non-treated top 24 genes 
included WNT4, IGF1 and ASPN. TGF-β1 treated top 24 genes included WNT4, ASPN, IGF1 and 
CXCL1. Upregulated gene expression of interleukins (IL1α, IL1β, IL1RN and IL8) and 
chemokines (CXCL1, 2 and 6) was also observed with TGF-β1 treatment of NHDF-c64a 
(compared with NHDF-F22Br, M50F and F60Br), indicative of an inflammatory response 
(Gillitzer and Goebeler, 2001). 
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5 Fibroblast functional experiments 
Following the gene expression studies using the Agilent microarray and Fluidigm qPCR setup, 
work was carried out to determine whether candidate genes affected NHDF function. A skin 
reconstitution assay was used to measure the effect of NHDF on epidermal stratification. 
shRNA-based lentiviral treatment was used to measure the effect of gene knockdown on 
fibroblast phenotype, gene expression and epidermal stratification. 
 
5.1 Skin reconstitution assay  
Using a model described by Rikimaru, Molès and Watt (1997) and more recently employed 
by Mishra et al., (2017), I measured epidermal thickness in skin reconstitution assays. De-
epidermised dermis (DED) was injected with NHDF and cultured overnight below the air-liquid 
interface. Keratinocytes were added to the surface of the NHDF-injected DED and cultured 
for two weeks at the air-liquid interface. Skin models were fixed in 10% formalin and then 
processed using the Excelsior AS tissue processor, before embedding in paraffin wax blocks. 
The centre of each organotypic model was sectioned, mounted and subsequently H&E 
stained or labelled with fluorescent antibodies.  
 
5.1.1 H&E stained reconstituted skin sections 
One skin model was used for each of the four NHDF (F22Br, M50F, F60Br and c64a) with a 
control (no NHDF) also used. The skin reconstitution experiment was carried out three times 
in total (n=3). Two slides were used for each skin model with four sections mounted on each 
slide. This gave 30 slides, containing 120 H&E stained sections, in total. Sections were imaged 
using the NanoZoomer 2.0RS at 20x magnification. Images were converted to .tif files and 
batch processed using Python. The Python script made it possible to identify the epidermis 
based on colour gradient (Figure 36). From this, epidermal length and thickness could be 
measured (Mishra et al., 2017). The epidermal thickness of each of the skin models, across 
the three experiments, is shown in Figure 37.  
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Figure 36. Epidermal thickness measurements in skin reconstitution models. (A) Slide overview of four mounted 
H&E sections (2.5x). (B) Apical surface of M50F-injected de-epidermised dermis, seeded with keratinocytes and 
grown at the air-liquid interface for two weeks (20x). (C) Epidermal thickness (25 µm) and length (7691 µm) 
calculated using a Python script that identified epidermis based on colour gradient. (D) Epidermal colour 
separation (left) of the M50F-injected skin reconstitution model (right); scale bar: 500 µm. 
 
Comparing epidermal thickness of the skin models, there was no significant difference 
between control (no NHDF) and NHDF-c64a skin models (Figure 37). NHDF-c64a models had 
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significantly thinner epidermis compared with the other three NHDF (F22Br, M50F and 
F60Br). This indicates an inability of NHDF-c64a to support epidermal growth.  
 
 
Figure 37. Epidermal thickness of NHDF-injected skin reconstitution models. Control (no NHDF); female 22-year-
old breast skin (F22Br); male 50-year-old face skin (M50F); female 60-year-old breast skin (F60Br) and PromoCell 
NHDF-c64a skin models. One-way ANOVA comparing NHDF-c64a with other skin models. Tukey’s multiple 
comparisons. Error bars represent SD of data points; n=3. *p<0.05, **p<0.01, *** p<0.001. 
 
5.1.2 Immunofluorescent labelling of reconstituted human skin 
Immunofluorescent images of skin models were acquired using the Nikon A1 upright confocal 
microscope at 20x magnification. Sections were stained with primary antibodies for keratin 
14 (basal layer keratinocytes) and vimentin (mesenchymal cell marker). Stained with DAPI 
(nuclei) and the appropriate Alexa Fluor secondary antibodies. Representative images for 
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Figure 38. Immunofluorescent skin reconstitution sections. DAPI (white), keratin 14 (basal layer keratinocytes; 
green) and vimentin (mesenchymal cell marker; red). Control (no NHDF); female 22-year-old breast skin (F22Br); 
male 50-year-old face skin (M50F); female 60-year-old breast skin (F60Br) and PromoCell NHDF-c64a. Scale bar: 
200 µm. 
 
As was the case with H&E stained sections, epidermal thickness in immunofluorescent-
labelled NHDF-c64a skin models was most similar to the control (no NHDF). NHDF-c64a skin 
models had thinner epidermis compared with F22Br, M50F and F60Br.  
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5.2 shRNA-mediated gene knockdown 
shRNA-based lentiviral transduction of NHDF was used to determine the effect of gene 
knockdown on NHDF phenotype. A control plasmid was used in addition to the four candidate 
gene plasmids (ASPN, CXCL1, IGF1 and WNT4). SHC016 plasmid (Sigma-Aldrich) contained a 
non-coding insert (referred to here as shControl). NHDF were treated overnight with 
lentivirus followed by incubation with 1 µg/ml puromycin for three days. 
 
5.2.1 Effective knockdown of IGF1 and WNT4 in NHDF 
PromoCell NHDF-c19, PromoCell NHDF-c24, F39Ab (female 39-year-old abdomen skin), 
F43Ab (female 43-year-old abdomen skin), F44Ab (female 44-year-old abdomen skin) and 
F65Ab (female 65-year-old abdomen skin) were used for this experiment. RNA was extracted 
from each targeted NHDF. Candidate gene expression was measured and displayed as 
percentage knockdown. shASPN reduced ASPN gene expression in four of the six NHDF 
(Figure 39A). shCXCL1 reduced CXCL1 gene expression in four of the six NHDF (Figure 39B). 
Gene knockdown was observed in all six NHDF with shIGF1 (Figure 39C) and shWNT4 (Figure 
39D) lentiviral treatment. 
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Figure 39. Effective knockdown of genes IGF1 and WNT4 in NHDF. ASPN (A), CXCL1 (B), IGF1 (C) and WNT4 (D) 
expression in lentiviral-treated NHDF relative to non-coding control (shControl). NHDF-c19, c24, female 39-year-
old abdomen skin (F39Ab), female 43-year-old abdomen skin (F43Ab), female 44-year-old abdomen skin (F44Ab) 
and female 65-year-old abdomen skin (F65Ab). Chart represents % knockdown (1-ΔΔCq expression values *100) 
for each targeted NHDF. 
 
5.2.2 Effect of shRNA knockdown on ACTA2 expression 
Since gene knockdown occurred in all six of the targeted NHDF for shIGF1 and shWNT4, I 
chose to take these two forward. The initial NHDF phenotype experiments using PromoCell 
NHDF and the Operetta imaging system showed that NHDF-c64a had a low percentage of α-
SMA positive cells. NHDF gene expression experiments using the Agilent microarray system 
(validated using the Fluidigm qPCR system) showed that NHDF-c64a had high IGF1 and low 
WNT4 gene expression. I was interested in measuring α-SMA gene expression (ACTA2) 
following IGF1 and WNT4 knockdown in NHDF (Figure 40). There was no effect of WNT4 
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however, caused an increase in the expression of ACTA2 compared with shControl in all six 
NHDF (Figure 40A). 
 
 
Figure 40. α-SMA gene expression levels in lentiviral-treated NHDF. ACTA2 expression in shIGF1 (A) and shWNT4 
(B) targeted NHDF. NHDF-c19, c24, female 39-year-old abdomen skin (F39Ab), female 43-year-old abdomen skin 
(F43Ab), female 44-year-old abdomen skin (F44Ab) and female 65-year-old abdomen skin (F65Ab). Bars 
represent ΔΔCq expression values for each NHDF, relative to non-coding control (shControl; ---), normalised to 
the reference gene (18S). 
 
5.2.3 Effect of shRNA knockdown on NHDF phenotype 
Since IGF1 knockdown in six independent NHDF increased ACTA2 gene expression, I was 
interested to see if α-SMA protein expression was affected also. Targeted NHDF-c19 and 
NHDF-c24 were used (based on availability) in the same phenotype assay as I had used 
previously. 
 
NHDF-c19 and c24 targeted with lentivirus (shControl, shIGF1and shWNT4), were plated in a 
96-well microplate at 3000 cells/well. NHDF were treated with TGF-β1 (in low serum DMEM) 
for 24 h. DAPI (number), α-SMA (differentiation), EdU (proliferation) and CellMask (shape) 
staining was imaged using the Operetta. This experiment was only performed once (n=1). 
Chart represents mean values from three separate 96-well microplates, with NHDF plated on 
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Figure 41. Effect of IGF1 knockdown on NHDF-c19 and NHDF-c24 phenotype. NHDF treated with Control (low 
serum DMEM) and TGF-β1 (10 ng/ml, in low serum DMEM) were assayed for cell number (A), differentiation (% 
α-SMA positive, B); proliferation (% EdU positive, C); and cell shape (% Spindle-shaped, D). Error bars represent 
SD of mean values; n=1, 3x 96-well microplates plated together. 
 
Figure 41A shows no obvious effect of shRNA-based knockdown on cell number. Treatment 
with TGF-β1 increased cell number compared with control medium. The percentage of α-SMA 
positive cells was much higher in NHDF targeted with shIGF1 than with shControl (non-coding 
control). Treatment with TGF-β1 had no effect on the percentage of α-SMA positive cells. 
(Figure 41B). There was no clear effect of IGF1 knockdown on the percentage of EdU positive 
cells. There was a higher percentage of EdU positive cells with TGF-β1 treatment (Figure 41C). 
There was no clear effect of shIGF1 on the percentage of spindle-shaped cells. TGF-β1 
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Figure 42. Effect of WNT4 knockdown on NHDF-c19 and NHDF-c24 phenotype. NHDF treated with Control (low 
serum DMEM) and TGF-β1 (10 ng/ml, in low serum DMEM) were assayed for cell number (A), differentiation (% 
α-SMA positive, B), proliferation (% EdU positive, C) and cell shape (% Spindle-shaped, D). Error bars represent 
SD of mean values; n=1, 3x 96-well microplates plated together. 
 
Targeting NHDF with shWNT4 showed no obvious effect on cell number (Figure 42A). 
Treatment with TGF-β1 had no effect on the percentage of α-SMA positive cells. There was 
no clear effect of WNT4 knockdown on the percentage of α-SMA positive cells. When 
compared with shControl, shWNT4 showed a lower percentage for c19 and a higher 
percentage for c24 (Figure 42B). There was no clear effect of WNT4 knockdown on the 
percentage of EdU positive cells (non-treated, low serum DMEM). Treatment with TGF-β1 
increased the percentage of EdU positive cells (Figure 42C). TGF-β1 treatment reduced the 
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5.2.4 H&E stained shIGF1 and shWNT4 skin models 
Skin reconstitution models were used to ascertain the effect of gene knockdown on epidermal 
growth. Four targeted NHDF were injected into DEDs and keratinocytes were added to the 
apical surface; cultured for two weeks at the air-liquid interface. One skin model was used for 
each NHDF target: F22Br, female 36-year-old breast skin (F36Br), female 44-year-old breast 
skin (F44Br) and F60Br. Control (no NHDF) skin models were also used, two in total. The same 
Python script as before was used to measure the epidermal thickness of H&E stained sections. 
 
 
Figure 43. shRNA-based lentiviral knockdown in skin reconstitution models. (A) Example skin reconstitution 
model images containing targeted (shControl, shIGF1 and shWNT4) NHDF from female 22-year-old breast skin 
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(F22Br) and female 60-year-old breast skin (F60Br). (B) Individual lentiviral-targeted NHDF: F22Br, female 36-
year-old breast skin (F36Br), female 44-year-old breast skin (F44Br) and F60Br. (C) Grouped lentiviral-targeted 
NHDF. One-way ANOVA, Dunnett’s multiple comparisons test compared with shControl. Error bars represent SD 
of data points. *p<0.05, **p<0.01, *** P<0.001. Scale bar: 250 µm. 
 
Figure 43A shows example H&E stained sections from skin reconstitution models. Sections 
were from targeted (shControl, shIGF1 and shWNT4) NHDF, derived from female 22-year-old 
breast skin (F22Br) and female 60-year-old breast skin (F60Br). There was no difference 
between the control (no NHDF) and shControl skin models (Figure 43B-C). Combining 
measurements from all shRNA targets there was no significant difference in epidermal 
thickness with shIGF1. Epidermal thickness in shWNT4 targeted NHDF skin models was 





6.1 Fibroblast functional experiments 
Heterogeneity in both mouse and human dermal fibroblasts has been well characterised in 
vivo. Despite loss of some cell surface markers in vitro, it has been shown that differences in 
fibroblast function are retained. Here I was interested in characterising fibroblast subtypes 
present in commercially sourced fibroblasts, with a view to better understanding the effect 
on function.  
 
In the initial phenotype experiments PromoCell NHDF from female 19-year-old breast skin 
(c19), female 24-year-old breast skin (c24), female 64-year-old breast skin donor A (c64a) and 
female 64-year-old breast skin donor B (c64b) were characterised for cell number, 
differentiation, proliferation and shape. Treatment with TGF-β1 caused a proliferative 
response in NHDF-c64a but had no effect on α-SMA protein expression. Used as a readout of 
myofibroblast differentiation, the proportion of α-SMA positive cells in other NHDF was 
greater than that of NHDF-c64a, both in non-treated (low serum DMEM) and TGF-β1 treated 
(in low serum DMEM) conditions.  
 
I then carried out gene expression profiling of PromoCell NHDF-c64a (CD90+ sorted) and 
other NHDF (non-sorted) to define genes associated with this non-differentiating phenotype. 
Comparing gene expression in non-treated (low serum DMEM) conditions, NHDF-c64a had 
significantly higher expression of IGF1, and significantly lower expression of ASPN and WNT4. 
These same genes were differentially expressed in NHDF-c64a with TGF-β1 treatment (in low 
serum DMEM). NHDF-c64a also had upregulated expression of genes CXCL1-2 and 6 gene in 
response to TGF-β1 treatment (in low serum DMEM). Gene expression results were validated 
using Fluidigm TaqMan qPCR.  
 
6.1.1 shRNA-based lentiviral knockdown of IGF1 and WNT4 
Targeting NHDF with shRNA-based lentivirus, I was able to show knockdown of IGF1 and 
WNT4 in the six NHDF used: PromoCell NHDF-c19, PromoCell NHDF-c24, F39Ab (female 39-
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year-old abdomen skin), F43Ab (female 43-year-old abdomen skin), F44Ab (female 44-year-
old abdomen skin) and F65Ab (female 65-year-old abdomen skin). Knockdown of ASPN and 
CXCL1 was not successful in all of these six NHDF. Knockdown of IGF1 increased both α-SMA 
gene expression (TaqMan qPCR assay, Figure 40) and α-SMA protein expression (Operetta 
phenotype assay, Figure 41). This is understandable given that NHDF-c64a expressed high 
levels of IGF1 mRNA (Agilent/Fluidigm gene expression) and low levels of α-SMA protein 
expression (Operetta phenotype assay).  
 
Knockdown efficiency will differ with different plasmid constructs and target cell types. Here, 
I used one plasmid for each candidate gene as well as a non-coding control (shControl). Each 
of the plasmids used a pLKO.1 puromycin backbone and targeted the gene coding region. I 
took forward only the shRNA-encoding plasmids that targeted all six of the NHDF tested 
(shIGF1 and shWNT4). Averaging the percentage knockdown across all six of the NHDF tested 
(including negative values) gave the following: shASPN, 38.1% knockdown; shCXCL1, 29.9% 
knockdown; shIGF1, 33.6% knockdown; and shWNT4, 74.5% knockdown. Further work would 
validate more than one shRNA-encoding plasmid for each candidate gene, to understand 
better the effect of differences in percentage knockdown.  
 
6.1.2 Epidermal thickness in skin reconstitution models 
Using skin reconstitution models, I was able to show that NHDF-c64a failed to support 
epidermal growth and stratification, compared with other NHDF donors (F22Br, M50F, 
F60Br). Knockdown of IGF1 gene expression in four NHDF had no effect on epidermal 
thickness: F22Br, female 36-year-old breast skin (F36Br), female 44-year-old breast skin 
(F44Br) and F60Br. Knockdown of WNT4 gene expression in the same NHDF resulted in 
significantly thicker epidermis when compared with the non-coding control (shControl). 
Despite WNT4 knockdown having no clear effect on expression of α-SMA protein (Operetta 
phenotype assay, Figure 42), this increase in epidermal thickness in shRNA-targeted skin 





The skin reconstitution models used shIGF1 and shWNT4 targeted NHDF from four donors. 
This experiment was only carried out once. There was no difference in epidermal thickness of 
control (no NHDF) and shControl targeted skin models. To gain a better understanding, of 
how epidermal thickness is altered in shRNA-targeted skin models, the experiment would be 
repeated. If there is no difference in the epidermal thickness of control (no NHDF) and 
shControl skin models it would be evident from the repeat experiments.  
 
6.2 Study limitations 
It is known that fibroblasts exhibit positional memory (Fries et al., 1994) and that the site of 
origin has more of an effect on fibroblast gene expression patterning than donor type, 
passage number, and serum content of the culture medium (Chang et al., 2002; Rinn et al., 
2006). In this research project the donor location from which the NHDF were derived changed 
between experiments. However, where possible, NHDF derived from the same location were 
used in experiments, based on the availability of low passage NHDF. For a full list of the 16 
donor NHDF used in this research project see Appendix 8.1. 
 
Four PromoCell NHDF were sourced from female breast skin, both young (19 years old and 
24 years old) and aged (two donor NHDF aged 64 years old). PromoCell NHDF were 
commercially sorted on CD90+ expression using flow cytometry technique. Only one vial of 
each donor NHDF (passage two) was purchased from PromoCell. The remaining 12 donor 
NHDF used in this research project were isolated in-house and not sorted for marker 
expression. These fibroblasts were enzyme-digested from skin; designated passage zero. All 
NHDF (PromoCell and in-house) were used in experiments up until passage 10. 
 
Care was taken to seed NHDF in experiments at the same passage and under the same 
conditions. Cultured in vitro at 37°C in 5% CO2 (~18% O2), NHDF experienced a higher O2 
concentration than that present in vivo. Rather than culturing NHDF under hyperoxic 
conditions, as was the case here, it would have been better to use physiologically relevant, 




NHDF were regularly cultured in DMEM containing 10% FBS (referred to as complete DMEM). 
NHDF were seeded in experiment microplates and acclimatised at low (1%) serum DMEM for 
24 h prior to treatment with agonist/inhibitor. At no point was the effect of changing from 
10% to 1% FBS measured. Future work would involve the comparison of NHDF treated in 
DMEM containing 10%, 1% and 0.1% FBS to determine the effect on NHDF. Perhaps a 
different response to agonists/inhibitors of the FGF/Hh/TGF-β would have been observed in 
NHDF treated for longer in 0.1% FBS (Armatas et al., 2014; Maris et al., 2015). 
 
NHDF-F22Br, M50F and F60Br were included in the Agilent/Fluidigm gene expression 
experiments for comparison with NHDF-c64a. From the hierarchical clustering performed on 
Agilent gene expression it can be seen that M50F clustered separately to F22Br and F60Br 
when comparing TGF-β1 treated (in low serum) NHDF (Figure 23). When comparing the effect 
of TGF-β1 treatment (in low serum) on all four NHDF assayed, M50F clustered separately from 
the female NHDF (Figure 24). In the Fluidigm PCA plots of both non-treated (low serum 
DMEM) and TGF-β1 treated (in low serum DMEM) NHDF, samples clustered based on NHDF 
donor, with NHDF-M50F and NHDF-c64a showing the greatest variation (PC1). This difference 
in clustering between NHDF-c64a and NHDF-M50F is likely to have been as a result of the 
difference in donor location. Gender and age, as well as hair follicles, skin pigmentation and 
UV exposure (Yaar, Eller and Gilchrest, 2002) will likely impact on fibroblast function, but, to 
a lesser extent than location. Future work would compare fibroblasts derived from the same 
donor location, gender and age. 
 
Using the Operetta imaging system, I initially compared PromoCell NHDF-c19, c24, c64a and 
c64b (Figure 10-Figure 12). NHDF-c64b was shown to have a similar percentage of EdU 
positive cells and a similar percentage of spindle-shaped cells to the remaining NHDF (c19 and 
c24). NHDF-c64b had the highest percentage of α-SMA positive cells, regardless of treatment, 
compared to the other three PromoCell NHDF. It perhaps would have been preferable to 
include NHDF-c64b in the Agilent/Fluidigm gene expression experiments as a positive 
indicator of cells expressing α-SMA protein; hence more likely to undergo myofibroblast 
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differentiation. This would have been more suitable than NHDF-M50F and it would have 
meant inclusion of another CD90+ sorted NHDF alongside NHDF-c64a. 
 
6.3 Future work 
I studied fibroblast phenotype and gene expression, carrying out further experiments to link 
the two. I found that one donor NHDF, NHDF-c64a, had a low percentage of α-SMA positive 
cells. It is known that TGF-β treatment causes myofibroblast differentiation and α-SMA 
protein expression. Here, NHDF-c64a was used as a tool to investigate fibroblast-
myofibroblast fate. Having identified differentially expressed genes in NHDF-c64a, future 
work would investigate the impact of these candidate genes in fibroblast populations, at the 
protein level. 
 
6.3.1 NHDF cell surface markers 
CD90 is a pan-fibroblast marker used to isolate fibroblasts (PromoCell NHDF) from donor 
tissue. The fibroblasts I extracted from donor dermis, however, were not CD90+ sorted. It has 
previously been shown that after multiple passages in vitro, fibroblasts lose the papillary 
marker Pdpn but, maintain the reticular marker Tgm2 (Janson et al., 2013). Staining for 
human CD90, Pdpn and Tgm2 in NHDF using Alexa Fluor-conjugated antibody labelling 
revealed no Pdpn but consistent CD90 and Tgm2 labelling across the four PromoCell NHDF 
(data not shown). Comparing differences in protein concentration of CD90, Pdpn and Tgm2 
in both PromoCell NHDF and in NHDF isolated in-house would be of interest for future work. 
 
With work by Philippeos et al., (2018) and more recently by Korosec et al., (2019) describing 
population-specific markers, it would be interesting to measure expression of my candidate 
genes in papillary/reticular fibroblast populations. Papillary fibroblasts were identified as 
CD39+ (Philippeos et al., 2018) and FAP+ (Korosec et al., 2019). Reticular fibroblasts were 
identified as CD36+ (Philippeos et al., 2018) and FAP- (Korosec et al., 2019). Using a panel of 
NHDF, derived from the same donor location, it would be interesting to investigate whether 
flow cytometry-sorted papillary/reticular populations showed different candidate gene 
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expression (ASPN, CXCL1, IGF1 and WNT4). Published single-cell RNASeq datasets could be 
used alongside this to better understand the contribution of candidate genes in distinct cell 
populations (Tabib et al., 2018; Guerrero-Juarez et al., 2019). Searching different clusters of 
cells for known surface markers, as well as for the four candidate genes, could help elucidate 
the NHDF-c64a cell signalling and cell population profile. 
 
6.3.2 IGF-1 signalling in NHDF 
At the centre of both the non-treated and TGF-β1 treated causal networks (generated using 
IPA) for NHDF-c64a gene expression, was predicted activation of ERK1/2. Canonical TGF-β 
signalling involves receptor phosphorylation of R-Smad and the subsequent activation of TGF-
β target genes (Tsukazaki et al., 1998). ERK is known to be involved in TGF-β non-canonical 
signalling, induced by various factors including growth factors, stress and inflammation 
(Hartsough and Mulder, 1995).  
 
Using western blot technique, it was found that lesional fibroblasts from SSc patients had 
greater p-ERK expression than non-lesional and normal (control) fibroblasts. Treatment with 
β-xyloside, known to inhibit heparin sulphate synthesis, prevented ERK phosphorylation in 
SSc fibroblasts (Chen et al., 2005). Treated with TGF-β1, syndecan 4-/- dermal mouse 
fibroblasts showed reduced expression of p-ERK compared with syndecan 4+/+ fibroblasts. 
Use of siRNA, targeting syndecan 4, in SSc fibroblasts showed a reduction in p-ERK expression. 
These results indicate that syndecan 4 mediates ERK phosphorylation with TGF-β1 treatment 
and that elevated levels of p-ERK in SSc fibroblasts is syndecan 4-dependent (Chen et al., 
2005). Given its role in SSc fibroblasts and its predicted activation in NHDF-c64a causal 
networks, ERK1/2 signalling would be investigated for future work.  
 
Treatment of human foetal fibroblasts with IGF-1 showed increased collagen I and α-SMA 
protein expression compared with non-treated control. This effect was significantly inhibited 
following pre-treatment of fibroblasts with phosphatidylinositol 3-kinase (PI3K) inhibitor 
(LY294002) or IGF-1 receptor antibody (A12) (Chetty, Cao and Nielsen, 2006). Using the 
monoclonal antibody A12, Choi et al., (2009) showed a reduction in pulmonary fibrosis in 
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bleomycin treated mice, compared with control mice. Mouse pulmonary fibroblasts, treated 
with IGF-1, showed greater cell migration and cell survival compared with control. The effect 
of IGF-1 was mediated through insulin receptor substrate-2/PI3K/Akt signalling (Choi et al., 
2009). Moreover, treatment of mouse lung fibroblasts with IGF-1 had no effect on α-SMA 
gene expression (ACTA2) when cultured on stiff substrates (collagen I coated plastic) but 
caused an increase in α-SMA gene expression when cultured on soft substrates (collagen I 
hydrogel). This response on soft substrates was abrogated through treatment with A12 or 
LY294002 (Hung et al., 2013). Treatment of mouse lung fibroblasts with TGF-β1 gave 
significantly higher α-SMA gene expression (ACTA2), compared with serum-free control 
conditions, cultured on stiff substrates. Treatment with IGF-1 and TGF-β1 together did not 
increase ACTA2 gene expression further; nor did treatment alongside antibody A12 cause a 
change in ACTA2 gene expression on stiff substrates (Hung et al., 2013).  
 
With these publications in mind, it would be worth investigating both ERK1/2 and PI3K/Akt 
signalling in the NHDF used in this research project. Western blot technique would be used 
to measure protein concentration in NHDF-c19, c24, c64a and c64b (Operetta phenotype 
assay) as well as NHDF-F22Br, M50F and F60Br (Agilent/Fluidigm gene expression). Inhibitors 
of IGF1 receptor (PQ401), ERK1/2 (PD8059) and PI3K (LY294002) signalling would be used to 
better understand kinase phosphorylation in these NHDF. Western blots would measure 
human fibroblast population markers, as well as CD90, α-SMA and p-SMAD2/3. The same 
could be achieved with the shRNA-based targets, so as to determine any signalling pathway 
crosstalk and the effect of IGF-1/TGF-β treatment on targeted NHDF protein expression.  
 
6.4 Conclusion 
Treatment of CD90+ sorted NHDF with agonists/inhibitors of the TGF-β signalling pathway 
identified one donor, isolated from female 64-year-old breast skin, which did not differentiate 
into myofibroblasts (percentage of α-SMA positive cells). This donor was associated with 
upregulated expression of genes CXCL1 and IGF1, and downregulated expression of genes 
ASPN and WNT4. IGF1 gene knockdown increased the expression of α-SMA mRNA and the 
percentage of α-SMA positive cells, compared with the control. WNT4 gene knockdown did 
Discussion 
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not affect expression of α-SMA but, did result in greater epidermal stratification in skin 
reconstitution models. This work identified differences in dermal fibroblast populations and 
the gene expression profiles associated with those differences. Further work is required to 
understand the mechanism through which the differential gene expression of ASPN, CXCL1, 
IGF1 and WNT4 alters NHDF function. Here I have highlighted a role for IGF-1 signalling in 
adult human dermal fibroblast fate. Targeting the signalling pathways which control human 
myofibroblast differentiation could provide therapeutic benefit for skin disorders involving 
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8.1 NHDF used in this research project 
Four NHDF were commercially sourced from PromoCell (C-12302), while the remaining 12 were isolated in-house (Table 5). All experiments used 
enzyme-derived NHDF only, except in Chapter 3.2.1 where a comparison was made between enzyme and explant-derived NHDF. 
  
Table 5. Details of the NHDF used in this research project. PromoCell NHDF aged 19 (c19, Lot: 4032503.1), 24 (c24, Lot: 4081903.2), 64 donor A (c64a, Lot: 4012203.1) and 
64 donor B (c64b, Lot: 3102301.3) years old. Note: enzyme and explant-derived NHDF from the same donor (*); all other experiments used enzyme-derived NHDF only. NHDF 



















Gender (F/M) F F F F F M F F F F F F F F F F 
Age (years old) 19 24 64 64 44 50 60 27 48 22 39 43 44 65 36 44 
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8.2 Operetta image analysis 
Generated using the Agilent Harmony software, for NHDF characterisation. Measurements of 
NHDF differentiation (% α-SMA positive), proliferation (% EdU positive) (Appendix 8.2.1); 
shape (% Spindle-shaped) and lipid droplet formation (% LipidTOX positive) (Appendix 8.2.2). 
 
8.2.1 Differentiation and proliferation 
α-SMA pipeline  EdU pipeline 
Input Image  Input Image 
Stack Processing : Individual Planes  Stack Processing : Individual Planes 
Flatfield Correction : Basic  Flatfield Correction : Basic 
   
Find Nuclei  Find Nuclei 
Channel : NucBlue  Channel : NucBlue 
Method : M  Method : M 
Diameter : 20.0 μm  Diameter : 20.0 μm 
Splitting Coefficient : 0.3  Splitting Coefficient : 0.3 
Common Threshold : 0.05  Common Threshold : 0.05 
Output Population : Nuclei  Output Population : Nuclei 
   
Calculate Morphology Properties  Calculate Morphology Properties 
Population : Nuclei  Population : Nuclei 
Region : Nucleus  Region : Nucleus 
Method : Standard  Method : Standard 
Area  Area 
Output Properties : Nucleus  Output Properties : Nucleus 
   
Select Population  Select Population 
Population : Nuclei   Population : Nuclei  
Method : Filter by Property  Method : Filter by Property 
Nucleus Area [μm²] : >= 50  Nucleus Area [μm²] : >= 50 
Nucleus Area [μm²] : <= 850  Nucleus Area [μm²] : <= 850 
Boolean Operations : F1 and F2  Boolean Operations : F1 and F2 
Output Population : Nuclei Selected  Output Population : Nuclei Selected 
   
Find Cytoplasm  Find Cytoplasm 
Channel : Alexa 647  Channel : Alexa 647 
Nuclei : Nuclei Selected  Nuclei : Nuclei Selected 
Method : B  Method : B 
Common Threshold : 0.5  Common Threshold : 0.5 
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Individual Threshold : 0.2  Individual Threshold : 0.2 
   
Select Population 2  Select Population 2 
Population : Nuclei Selected   Population : Nuclei Selected  
Method : Common Filters  Method : Common Filters 
Remove Border Objects  Remove Border Objects 
Region : Cell  Region : Cell 
Output Population : Non-border Cells  Output Population : Non-border Cells 
   
Calculate Intensity Properties  Calculate Intensity Properties 
Channel : Alexa 594  Channel : Alexa 488 
Population : Non-border Cells  Population : Non-border Cells 
Region : Cell  Region : Nucleus 
Method : Standard  Method : Standard 
Median  Median 
Contrast  Contrast 
Output Properties : Intensity Cell Alexa 594  Output Properties : Intensity Nucleus Alexa 488 
   
Select Population 3  Select Population 3 
Population : Non-border Cells   Population : Non-border Cells  
Method : Filter by Property  Method : Filter by Property 
Intensity Cell Alexa 594 Median : >= 15  Intensity Nucleus Alexa 488 Median : >= 50 
Intensity Cell Alexa 594 Median : <= 1000  Intensity Nucleus Alexa 488 Median : <= 3000 
Boolean Operations : F1 and F2  Boolean Operations : F1 and F2 
Output Population : Cell Selected  Output Population : Cell Selected 
   
Select Population 4  Select Population 4 
Population : Cell Selected   Population : Cell Selected  
Method : Linear Classifier  Method : Linear Classifier 
Number of Classes : 2  Number of Classes : 2 
Intensity Cell Alexa 594 Median  Intensity Nucleus Alexa 488 Median 
Intensity Cell Alexa 594 Contrast  Intensity Nucleus Alexa 488 Contrast 
Output Population A : Positive  Output Population A : Positive 
Output Population B : Negative  Output Population B : Negative 
 
8.2.2 Shape and lipid droplet formation 
Spindle-shaped pipeline  LipidTOX pipeline 
Input Image  Input Image 
Stack Processing : Individual Planes  Stack Processing : Individual Planes 
Flatfield Correction : Basic  Flatfield Correction : Basic 
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Find Nuclei  Find Nuclei 
Channel : NucBlue  Channel : NucBlue 
Method : M  Method : C 
Diameter : 20.0 μm  Area : > 30 μm² 
Splitting Coefficient : 0.3  Split Factor : 7 
Common Threshold : 0.05  Common Threshold : 0.5 
Output Population : Nuclei  Output Population : Nuclei 
   
Calculate Morphology Properties  Calculate Morphology Properties 
Population : Nuclei  Population : Nuclei 
Region : Nucleus  Region : Nucleus 
Method : Standard  Method : Standard 
Area  Area 
Output Properties : Nucleus  Output Properties : Nucleus 
   
Select Population  Select Population 
Population : Nuclei   Population : Nuclei  
Method : Filter by Property  Method : Filter by Property 
Nucleus Area [μm²] : >= 50  Nucleus Area [μm²] : >= 50 
Nucleus Area [μm²] : <= 850  Nucleus Area [μm²] : <= 850 
Boolean Operations : F1 and F2  Boolean Operations : F1 and F2 
Output Population : Nuclei Selected  Output Population : Nuclei Selected 
   
Find Cytoplasm  Select Population 2 
Channel : Alexa 647  Population : Nuclei Selected  
Nuclei : Nuclei Selected  Method : Common Filters 
Method : B  Remove Border Objects 
Common Threshold : 0.5  Region : Nucleus 
Individual Threshold : 0.2  Output Population : Non-border Nuclei 
   
Select Population 2  Select Region 
Population : Nuclei Selected   Population : Non-border Nuclei  
Method : Common Filters  Region : Nucleus 
Remove Border Objects  Method : Resize Region [μm/px] 
Region : Cell  Outer Border : -2.5 μm 
Output Population : Non-border Cells  Inner Border : 0.5 μm 
  Output Region : Peri-nuclear 
   
Calculate Morphology Properties 2  Calculate Intensity Properties 
Population : Non-border Cells  Channel : Alexa 488 
Region : Cell  Population : Non-border Nuclei 
Method : Standard  Region : Peri-nuclear 
Area  Method : Standard 
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Roundness  Median 
Ratio Width to Length  Contrast 
Output Properties : Morphology Cell  Output Properties : Intensity Peri-nuclear Alexa 488 
   
Select Population 3  Select Population 3 
Population : Non-border Cells   Population : Non-border Nuclei 
Method : Filter by Property  Method : Linear Classifier 
Morphology Cell Area [μm²] : > 400  Number of Classes : 2 
Morphology Cell Area [μm²] : < 16000  Intensity Peri-nuclear Alexa 488 Median 
Boolean Operations : F1 and F2  Intensity Peri-nuclear Alexa 488 Contrast 
Output Population : Cell Selected  Output Population A : Positive 
  Output Population B : Negative 
Select Population 4   
Population : Cell Selected    
Method : Linear Classifier   
Number of Classes : 2   
Morphology Cell Area [μm²]   
Morphology Cell Roundness   
Morphology Cell Ratio Width to Length   
Output Population A : Spindle   
Output Population B : Round   
 
8.2.3 Spindle-shaped classification 
NHDF were characterised as possessing a spindle-shape morphology, using the Agilent 
Harmony software. The analysis pipeline first identified the cell nuclei (NucBlue), and then 
identified the cell cytoplasm (CellMask). The software was used to classify NHDF into spindle-
shaped positive and spindle-shaped negative populations based on individual cell readouts. 
These readouts were: cell area (μm²), cell roundness, and cell ratio width to length. Small, 
spindle, elongated cells were classified as positive (green) for spindle-shape morphology. 





Figure 44. Spindle-shaped classification of PromoCell NHDF, example 1. (Left) Input image with NucBlue (blue) 
EdU (green), α-SMA (orange) and CellMask (red). (Right) Spindle-shaped cells: positive (green) and negative 
(red). Cells on the image border (grey) were excluded. PromoCell NHDF (c19, c24, c64a and c64b) treated with 
low (1%) serum DMEM only. Image represents 1/9 fields of 96-well microplate well. 10x magnification. Scale 




Figure 45. Spindle-shaped classification of PromoCell NHDF, example 2. (Left) Input image with NucBlue (blue) 
EdU (green), α-SMA (orange) and CellMask (red). (Right) Spindle-shaped cells: positive (green) and negative 
(red). Cells on the image border (grey) were excluded. PromoCell NHDF (c19, c24, c64a and c64b) treated with 
low (1%) serum DMEM only. Image represents 1/9 fields of 96-well microplate well. 10x magnification. Scale 
bar: 200 µm.  
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8.3 R scripts 
Used to generate lists of differentially expressed genes (Appendix 8.4). Non-treated (low 
serum DMEM) for NHDF-c64a (Appendix 8.3.1), TGF-β1 treated (in low serum DMEM) for 
NHDF-c64a (Appendix 8.3.2), and treated vs non-treated for all four NHDF (F22Br, M50F, 
F60Br and c64a) in low serum DMEM (Appendix 8.3.3). 
 
8.3.1 Non-treated  
source("https://bioconductor.org/biocLite.R") 
 
run01 <- read_excel("/Desktop/run01.xlsx", skip = 4) 
run01p <- run01[,-1] 
rownames(run01p) <- run01[,1] 
run02 <- read_excel("/Desktop/run02.xlsx", skip = 4) 
run02p <- run02[,-1] 
rownames(run02p) <- run02[,1] 
run03 <- read_excel("/Desktop/run03.xlsx", skip = 4) 
run03p <- run03[,-1] 
rownames(run03p) <- run03[,1] 
 
olisALL = cbind(run01p,run02p,run03p) 
 
olis_norm = olisALL[,c(17:32,50:65,83:98)] 
olis_norm <- olis_norm[, order(colnames(olis_norm))] 
 
olis = olisALL[,c(1:16,34:49,67:82)] 
olis <- olis[, order(colnames(olis))] 
 
design <- cbind(c(1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0), 
c(0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0)) 
 
colnames(design) <- c("restcontrol","c64acontrol") 
numParameters <- ncol(design) 
parameterNames <- colnames(design) 
design 
 
fit <- lmFit(olis_norm, design) 





contrastNames <- c(paste(parameterNames[2],parameterNames[1],sep="-")) 
contrastsMatrix <- makeContrasts(c64acontrol-restcontrol, levels=design) 
rownames(contrastsMatrix) <- parameterNames 
colnames(contrastsMatrix) <- contrastNames 
contrastsMatrix 
 
fit2 <- contrasts.fit(fit,contrasts=contrastsMatrix) 
fit2 <- eBayes(fit2) 
x <- topTable(fit2,number =Inf, genelist = olisALL[,99], p.value=.05,lfc = 2) 
write.table(x,file="/Desktop/File.xls",sep="\t",quote=FALSE,col.names=NA) 
 
SigG <- rownames(x) 
olis_normSigG <- olis_norm[SigG,c(1:6,13:18,25:30,37:42)] 
hmcol<-colorRampPalette(c("blue","white","red")) 
pdf(file = "heatmap2.pdf") 




8.3.2 TGF-β1 treated  
design <- cbind(c(0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1), 
c(0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0)) 
colnames(design) <- c("resttgfb","c64atgfb") 
 
8.3.3 Treated vs non-treated  
design <- cbind(c(1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0), 
c(0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,1)) 




8.4 Gene lists 
Differentially expressed genes unique to NHDF-c64a both non-treated (Table 6) and TGF-β1 
treated (Table 7). Differentially expressed genes for all four NHDF (F22Br, M50F, F60Br and 
c64a) with TGF-β1 treatment (Table 8). 
 
8.4.1 Non-treated 
Table 6. Differentially expressed genes for NHDF-c64a, non-treated (low serum DMEM). 12 and 24 h timepoints 
together; logFC +/-2, adjusted p value<0.05. Sorted on logFC value. 
LogFC Adj. p value Gene name (ID) 
5.63 2.57E-04 insulin like growth factor 1(IGF1) 
5.18 4.65E-04 insulin like growth factor 1(IGF1) 
4.94 1.64E-04 butyrylcholinesterase(BCHE) 
4.75 8.69E-03 PAX8 antisense RNA 1(PAX8-AS1) 
4.69 2.57E-03 p21 protein (Cdc42/Rac)-activated kinase 2 pseudogene(LOC646214) 
4.69 1.34E-04 5-hydroxytryptamine receptor 2B(HTR2B) 
4.64 7.17E-10 synaptotagmin 1(SYT1) 
4.28 3.90E-08 transmembrane protein with EGF like and two follistatin like domains 2(TMEFF2) 
4.18 5.45E-03 C-X-C motif chemokine ligand 6(CXCL6) 
3.95 6.09E-03 late cornified envelope 3D(LCE3D) 
3.71 1.45E-02 interleukin 13 receptor subunit alpha 2(IL13RA2) 
3.66 6.50E-05 pleckstrin homology domain containing A6(PLEKHA6) 
3.66 1.24E-02 insulin like growth factor binding protein 5(IGFBP5) 
3.61 1.02E-02 stathmin 2(STMN2) 
3.58 1.78E-03 PAX8 antisense RNA 1(PAX8-AS1) 
3.49 3.90E-08 keratinocyte proline rich protein(KPRP) 
3.36 1.53E-03 fibronectin leucine rich transmembrane protein 3(FLRT3) 
3.35 5.61E-04 chimerin 2(CHN2) 
3.35 2.73E-04 acid phosphatase 5, tartrate resistant(ACP5) 
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LogFC Adj. p value Gene name (ID) 
3.31 4.62E-04 serum deprivation response(SDPR) 
3.31 2.88E-03 uncharacterized LOC101930246(LOC101930246) 
3.25 1.73E-02 single-minded family bHLH transcription factor 2(SIM2) 
3.22 3.95E-03 calcium homeostasis modulator 3(CALHM3) 
3.18 4.23E-02 cadherin 18(CDH18) 
3.16 2.26E-04 SLIT and NTRK like family member 4(SLITRK4) 
3.16 2.72E-05 olfactory receptor family 7 subfamily D member 2(OR7D2) 
3.14 2.30E-03 bone morphogenetic protein 2(BMP2) 
3.13 5.10E-05 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5(ST8SIA5) 
3.13 3.35E-03 protein phosphatase 2 regulatory subunit Bbeta(PPP2R2B) 
3.12 1.69E-02 family with sequence similarity 19 member A2, C-C motif chemokine like(FAM19A2) 
3.12 1.25E-04 calcium voltage-gated channel auxiliary subunit alpha2delta 3(CACNA2D3) 
3.11 8.29E-03 potassium voltage-gated channel subfamily D member 2(KCND2) 
3.07 6.24E-06 doublecortin like kinase 1(DCLK1) 
3.07 1.61E-03 lnc-CDH2-1 
3.01 4.62E-04 late cornified envelope 2A(LCE2A) 
2.99 1.25E-04 ATP binding cassette subfamily A member 8(ABCA8) 
2.96 3.75E-03 doublecortin like kinase 1(DCLK1) 
2.96 4.82E-04 calmegin(CLGN) 
2.94 1.21E-02 iroquois homeobox 4(IRX4) 
2.92 3.88E-04 neurofilament, light polypeptide(NEFL) 
2.92 6.24E-06 TNF receptor superfamily member 21(TNFRSF21) 
2.92 1.70E-02 CD163 molecule(CD163) 
2.89 1.45E-04 junctophilin 1(JPH1) 
2.88 1.34E-04 sarcoglycan alpha(SGCA) 
2.82 9.63E-03 family with sequence similarity 84 member A(FAM84A) 
2.81 1.67E-09 cytochrome P450 family 3 subfamily A member 5(CYP3A5) 
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LogFC Adj. p value Gene name (ID) 
2.80 1.02E-02 alcohol dehydrogenase 1A (class I), alpha polypeptide(ADH1A) 
2.80 6.87E-03 uncharacterized LOC102725394(LOC102725394) 
2.78 1.39E-02 retinol binding protein 1(RBP1) 
2.77 2.39E-04 uncharacterized LOC653602(LOC653602) 
2.76 4.78E-03 interleukin 7(IL7) 
2.76 2.89E-03 uncharacterized LOC101060810(LOC101060810) 
2.73 1.68E-03 RAB27B, member RAS oncogene family(RAB27B) 
2.69 9.34E-03 natriuretic peptide receptor 1(NPR1) 
2.68 1.13E-03 protocadherin 7(PCDH7) 
2.67 5.64E-06 cytochrome P450 family 3 subfamily A member 7(CYP3A7) 
2.66 1.64E-04 chloride intracellular channel 3(CLIC3) 
2.65 1.79E-02 lnc-C20orf197-3 
2.64 2.59E-02 alcohol dehydrogenase 1C (class I), gamma polypeptide(ADH1C) 
2.63 7.01E-03 angiopoietin like 4(ANGPTL4) 
2.63 1.49E-03 long intergenic non-protein coding RNA 1260(LINC01260) 
2.59 5.19E-03 progestin and adipoQ receptor family member 5(PAQR5) 
2.58 1.07E-02 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3(ATP2A3) 
2.58 4.12E-02 XLOC_l2_012847 
2.57 6.10E-03 anoctamin 4(ANO4) 
2.57 3.19E-03 disrupted in renal carcinoma 3(DIRC3) 
2.56 4.28E-04 B-cell scaffold protein with ankyrin repeats 1(BANK1) 
2.56 4.65E-04 paired box 8(PAX8) 
2.55 3.74E-05 cadherin 2(CDH2) 
2.54 4.38E-06 growth associated protein 43(GAP43) 
2.52 1.80E-03 dipeptidyl peptidase 4(DPP4) 
2.51 4.21E-03 solute carrier family 16 member 6(SLC16A6) 
2.51 3.72E-05 cadherin 2(CDH2) 
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LogFC Adj. p value Gene name (ID) 
2.43 4.86E-04 progesterone receptor(PGR) 
2.39 4.84E-02 calcium voltage-gated channel auxiliary subunit beta 2(CACNB2) 
2.38 1.31E-03 macrophage stimulating 1 receptor(MST1R) 
2.36 1.35E-02 defensin beta 103B(DEFB103B) 
2.36 1.46E-02 galectin 9C(LGALS9C) 
2.35 4.35E-02 transmembrane protein 132E(TMEM132E) 
2.33 1.95E-03 ankyrin repeat domain 2(ANKRD2) 
2.33 5.48E-05 carbohydrate sulfotransferase 11(CHST11) 
2.32 1.18E-02 serpin family B member 7(SERPINB7) 
2.31 9.14E-03 aquaporin 7 pseudogene 3(AQP7P3) 
2.27 4.78E-03 sortilin related receptor 1(SORL1) 
2.27 1.33E-02 C1q and tumour necrosis factor related protein 3(C1QTNF3) 
2.26 9.93E-04 lnc-CCDC152-1 
2.25 1.00E-04 major histocompatibility complex, class II, DP alpha 1(HLA-DPA1) 
2.24 1.62E-02 G protein-coupled receptor class C group 5 member B(GPRC5B) 
2.20 7.01E-03 transmembrane phosphatase with tensin homology pseudogene 1(TPTEP1) 
2.20 3.56E-02 growth hormone regulated TBC protein 1(GRTP1) 
2.20 2.18E-06 alcohol dehydrogenase 1B (class I), beta polypeptide(ADH1B) 
2.20 1.10E-03 long intergenic non-protein coding RNA 906(LINC00906) 
2.18 6.87E-03 chromosome 8 open reading frame 46(C8orf46) 
2.18 1.64E-02 lnc-NR5A2-1 
2.18 2.73E-03 transmembrane protein 130(TMEM130) 
2.15 1.91E-02 doublecortin like kinase 1(DCLK1) 
2.14 2.75E-02 stimulated by retinoic acid 6(STRA6) 
2.14 1.29E-05 immunoglobin superfamily member 21(IGSF21) 
2.14 3.25E-02 ring finger protein 157(RNF157) 
2.13 3.04E-02 dual specificity phosphatase 26 (putative)(DUSP26) 
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LogFC Adj. p value Gene name (ID) 
2.12 1.53E-02 uncharacterized LOC101929756(LOC101929756) 
2.09 1.05E-02 histocompatibility minor serpin domain containing(HMSD) 
2.05 2.30E-03 interleukin 20 receptor subunit beta(IL20RB) 
2.04 2.46E-02 purinergic receptor P2X 5(P2RX5) 
2.03 1.54E-03 WNT1 inducible signalling pathway protein 2(WISP2) 
2.02 1.38E-04 dispatched RND transporter family member 2(DISP2) 
2.02 3.16E-02 long intergenic non-protein coding RNA 1296(LINC01296) 
2.00 3.70E-02 brain and acute leukemia, cytoplasmic(BAALC) 
-2.02 6.09E-03 regulating synaptic membrane exocytosis 3(RIMS3) 
-2.03 2.37E-04 osteomodulin(OMD) 
-2.08 3.04E-02 actin binding LIM protein 1(ABLIM1) 
-2.09 7.74E-03 cadherin 15(CDH15) 
-2.10 1.14E-02 HID1 domain containing(HID1) 
-2.13 3.57E-04 lnc-UMODL1-1 
-2.14 1.59E-02 TFAP2A antisense RNA 1(TFAP2A-AS1) 
-2.17 2.65E-02 paired box 1(PAX1) 
-2.18 3.12E-02 prostate stem cell antigen(PSCA) 
-2.25 7.93E-04 uncharacterized LOC100132077(LOC100132077) 
-2.29 2.39E-04 B-cell CLL/lymphoma 11A(BCL11A) 
-2.30 3.55E-05 aquaporin 1 (Colton blood group)(AQP1) 
-2.32 2.55E-02 EGF like domain multiple 6(EGFL6) 
-2.36 7.82E-03 piezo type mechanosensitive ion channel component 2(PIEZO2) 
-2.42 2.14E-02 RAS guanyl releasing protein 1(RASGRP1) 
-2.43 3.63E-03 espin-like(ESPNL) 
-2.46 1.92E-03 distal-less homeobox 1(DLX1) 
-2.50 4.19E-04 guanylate binding protein 3(GBP3) 
-2.51 1.21E-03 Wnt family member 4(WNT4) 
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LogFC Adj. p value Gene name (ID) 
-2.68 8.23E-03 LIM homeobox 8(LHX8) 
-2.74 5.72E-03 anaphase promoting complex subunit 1(ANAPC1) 
-2.77 2.05E-02 neurotrophic receptor tyrosine kinase 3(NTRK3) 
-2.82 6.19E-03 transcription factor AP-2 alpha(TFAP2A) 
-2.96 1.70E-02 cell adhesion molecule 3(CADM3) 
-3.07 5.18E-05 reticulon 1(RTN1) 
-3.09 3.74E-05 B-cell CLL/lymphoma 11A(BCL11A) 
-3.21 2.57E-04 erythrocyte membrane protein band 4.2(EPB42) 
-3.47 1.14E-03 protein tyrosine phosphatase, receptor type D(PTPRD) 
-3.53 4.19E-04 leucine rich repeat containing 14(LRRC14) 
-3.54 2.35E-03 SIX homeobox 1(SIX1) 
-3.59 6.81E-04 Nik related kinase(NRK) 
-3.62 4.93E-03 SHC adaptor protein 2(SHC2) 
-3.70 2.67E-04 asporin(ASPN) 
-3.74 2.02E-02 seizure related 6 homolog like(SEZ6L) 
-3.76 1.23E-05 long intergenic non-protein coding RNA 1128(LINC01128) 
-3.79 4.03E-04 asporin(ASPN) 
-4.21 1.34E-04 major histocompatibility complex, class I, B(HLA-B) 
-4.96 4.66E-03 insulin like growth factor binding protein 2(IGFBP2) 
-5.06 4.45E-06 Wnt family member 4(WNT4) 
-5.26 3.72E-05 major histocompatibility complex, class I, B(HLA-B) 
-5.30 1.29E-02 Nik related kinase(NRK) 




8.4.2 TGF-β1 treated 
Table 7. Differentially expressed genes for NHDF-c64a, TGF-β1 treated (in low serum DMEM). 12 and 24 h 
timepoints together; logFC +/-2, adjusted p value<0.05. Sorted on logFC value. 
LogFC Adj. p value Gene name (ID) 
5.28 1.10E-03 p21 protein (Cdc42/Rac)-activated kinase 2 pseudogene(LOC646214) 
5.00 6.53E-03 PAX8 antisense RNA 1(PAX8-AS1) 
4.69 2.62E-04 late cornified envelope 3D(LCE3D) 
4.58 2.19E-08 serum amyloid A2(SAA2) 
4.46 5.30E-03 butyrylcholinesterase(BCHE) 
4.34 1.59E-03 C-X-C motif chemokine ligand 6(CXCL6) 
4.31 1.67E-02 serum amyloid A1(SAA1) 
4.05 1.23E-02 insulin like growth factor 1(IGF1) 
4.05 7.40E-03 5-hydroxytryptamine receptor 2B(HTR2B) 
4.02 3.75E-02 insulin like growth factor 1(IGF1) 
3.90 1.24E-03 PAX8 antisense RNA 1(PAX8-AS1) 
3.81 1.26E-04 iroquois homeobox 4(IRX4) 
3.78 1.94E-02 insulin like growth factor binding protein 5(IGFBP5) 
3.53 3.44E-02 interleukin 13 receptor subunit alpha 2(IL13RA2) 
3.47 1.23E-02 single-minded family bHLH transcription factor 2(SIM2) 
3.47 1.49E-02 naked cuticle homolog 2(NKD2) 
3.26 2.79E-03 acid phosphatase 5, tartrate resistant(ACP5) 
3.18 4.52E-03 C-X-C motif chemokine ligand 1(CXCL1) 
3.18 1.86E-03 C-X-C motif chemokine ligand 2(CXCL2) 
3.06 6.04E-03 family with sequence similarity 84 member A(FAM84A) 
3.06 5.59E-03 lnc-C20orf197-3 
3.02 3.09E-02 family with sequence similarity 19 member A2, C-C motif chemokine like(FAM19A2) 
3.02 3.52E-03 calcium voltage-gated channel auxiliary subunit alpha2delta 3(CACNA2D3) 
3.00 2.93E-02 potassium voltage-gated channel subfamily D member 2(KCND2) 
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LogFC Adj. p value Gene name (ID) 
2.90 4.11E-04 long intergenic non-protein coding RNA 1260(LINC01260) 
2.89 3.78E-03 uncharacterized LOC101060810(LOC101060810) 
2.88 1.43E-02 natriuretic peptide receptor 1(NPR1) 
2.88 1.10E-03 chromosome 8 open reading frame 4(C8orf4) 
2.87 2.64E-02 uncharacterized LOC101930246(LOC101930246) 
2.86 4.36E-02 pleckstrin homology domain containing A6(PLEKHA6) 
2.86 4.01E-05 interleukin 1 beta(IL1B) 
2.85 5.51E-03 C-X-C motif chemokine ligand 1(CXCL1) 
2.82 3.34E-02 CD163 molecule(CD163) 
2.80 1.33E-02 calmegin(CLGN) 
2.74 2.16E-04 lnc-CDH2-3 
2.74 2.37E-02 doublecortin like kinase 1(DCLK1) 
2.73 4.14E-03 olfactory receptor family 7 subfamily D member 2(OR7D2) 
2.72 1.41E-02 ATP binding cassette subfamily A member 8(ABCA8) 
2.69 1.16E-03 paired box 8(PAX8) 
2.66 3.09E-02 chimerin 2(CHN2) 
2.66 2.03E-02 teashirt zinc finger homeobox 2(TSHZ2) 
2.65 3.53E-03 C-X-C motif chemokine ligand 2(CXCL2) 
2.65 1.80E-02 uncharacterized LOC102725394(LOC102725394) 
2.62 3.95E-02 complement C8 beta chain(C8B) 
2.55 2.82E-02 nuclear receptor subfamily 0 group B member 1(NR0B1) 
2.52 3.73E-03 dipeptidyl peptidase 4(DPP4) 
2.52 4.44E-02 serum deprivation response(SDPR) 
2.45 6.04E-03 aquaporin 7 pseudogene 3(AQP7P3) 
2.44 2.44E-03 family with sequence similarity 84 member A(FAM84A) 
2.40 3.14E-02 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3(ATP2A3) 
2.38 2.99E-02 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5(ST8SIA5) 
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2.37 2.43E-04 heparan sulfate-glucosamine 3-sulfotransferase 2(HS3ST2) 
2.37 3.05E-02 late cornified envelope 2A(LCE2A) 
2.36 5.76E-03 purinergic receptor P2X 5(P2RX5) 
2.32 4.06E-03 ankyrin repeat domain 65(ANKRD65) 
2.28 9.95E-03 transmembrane phosphatase with tensin homology pseudogene 1(TPTEP1) 
2.28 1.08E-02 protein phosphatase 4 regulatory subunit 4(PPP4R4) 
2.27 6.04E-03 B-cell scaffold protein with ankyrin repeats 1(BANK1) 
2.27 2.19E-02 protocadherin 7(PCDH7) 
2.26 1.36E-02 nuclear receptor binding SET domain protein 1(NSD1) 
2.25 3.97E-02 solute carrier family 16 member 6(SLC16A6) 
2.24 1.36E-02 XLOC_l2_013311 
2.24 3.87E-04 long intergenic non-protein coding RNA 545(LINC00545) 
2.21 1.65E-02 long intergenic non-protein coding RNA 1296(LINC01296) 
2.18 1.20E-03 glycerophosphodiester phosphodiesterase domain containing 3(GDPD3) 
2.16 1.80E-02 long intergenic non-protein coding RNA 1436(LINC01436) 
2.15 1.40E-03 major histocompatibility complex, class II, DP alpha 1(HLA-DPA1) 
2.15 2.34E-02 sarcoglycan alpha(SGCA) 
2.15 1.06E-02 myocardial infarction associated transcript (non-protein coding)(MIAT) 
2.14 4.06E-03 long intergenic non-protein coding RNA 545(LINC00545) 
2.14 2.77E-03 complement C3(C3) 
2.12 3.32E-03 small nucleolar RNA, C/D box 25(SNORD25) 
2.12 6.05E-03 Src-like-adaptor(SLA) 
2.12 3.38E-03 WNT1 inducible signalling pathway protein 2(WISP2) 
2.11 1.86E-02 chromosome 8 open reading frame 46(C8orf46) 
2.10 3.95E-02 ATP binding cassette subfamily C member 9(ABCC9) 
2.10 8.79E-03 FERM domain containing 5(FRMD5) 
2.10 3.81E-02 uncharacterized LOC653602(LOC653602) 
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2.10 2.90E-02 FAM20A, golgi associated secretory pathway pseudokinase(FAM20A) 
2.08 2.01E-02 ankyrin repeat domain 2(ANKRD2) 
2.07 1.64E-02 torsin family 4 member A(TOR4A) 
2.06 1.17E-02 paired like homeodomain 1(PITX1) 
2.05 4.26E-02 XLOC_l2_004950 
2.04 6.24E-03 olfactory receptor family 7 subfamily E member 47 pseudogene(OR7E47P) 
2.02 2.28E-02 macrophage stimulating 1 receptor(MST1R) 
2.01 4.85E-02 fibroblast growth factor 13(FGF13) 
-2.01 1.55E-03 lnc-PRSS42-1 
-2.01 3.12E-03 coiled-coil domain containing 144A(CCDC144A) 
-2.02 4.18E-02 cadherin 15(CDH15) 
-2.03 2.24E-02 HLA complex group 9 (non-protein coding)(HCG9) 
-2.05 4.46E-03 B-cell CLL/lymphoma 11A(BCL11A) 
-2.09 2.57E-02 fibroblast growth factor receptor 2(FGFR2) 
-2.12 2.45E-03 fibrillarin-like 1(FBLL1) 
-2.13 1.26E-02 leucine zipper tumor suppressor 1(LZTS1) 
-2.14 8.15E-04 LY6/PLAUR domain containing 6B(LYPD6B) 
-2.17 4.99E-04 lnc-DEC1-2 
-2.25 1.73E-03 guanylate binding protein 3(GBP3) 
-2.25 1.50E-02 periostin(POSTN) 
-2.29 1.23E-02 piezo type mechanosensitive ion channel component 2(PIEZO2) 
-2.29 1.57E-02 distal-less homeobox 1(DLX1) 
-2.31 4.36E-02 EGF like domain multiple 6(EGFL6) 
-2.37 2.24E-02 B-cell CLL/lymphoma 11A(BCL11A) 
-2.38 1.05E-02 integrin subunit alpha 8(ITGA8) 
-2.42 2.32E-02 paired box 1(PAX1) 
-2.43 1.80E-02 mesenchyme homeobox 2(MEOX2) 
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-2.53 4.45E-02 protein tyrosine phosphatase, receptor type D(PTPRD) 
-2.55 1.65E-02 RAS guanyl releasing protein 1(RASGRP1) 
-2.76 7.30E-05 espin-like(ESPNL) 
-2.79 1.86E-03 Wnt family member 4(WNT4) 
-2.80 2.74E-02 long intergenic non-protein coding RNA 1060(LINC01060) 
-2.85 4.60E-02 keratin 17(KRT17) 
-2.93 1.27E-02 LIM homeobox 8(LHX8) 
-3.03 1.24E-03 erythrocyte membrane protein band 4.2(EPB42) 
-3.08 1.36E-02 asporin(ASPN) 
-3.17 6.04E-03 long intergenic non-protein coding RNA 1060(LINC01060) 
-3.24 1.25E-02 asporin(ASPN) 
-3.26 1.89E-02 SHC adaptor protein 2(SHC2) 
-3.29 1.03E-02 SIX homeobox 1(SIX1) 
-3.34 4.22E-03 long intergenic non-protein coding RNA 1128(LINC01128) 
-3.69 2.49E-02 Wnt family member 4(WNT4) 
-3.76 3.31E-04 leucine rich repeat containing 14(LRRC14) 
-4.18 3.87E-04 major histocompatibility complex, class I, B(HLA-B) 
-4.70 1.52E-03 major histocompatibility complex, class I, B(HLA-B) 
-5.10 5.30E-03 insulin like growth factor binding protein 2(IGFBP2) 
-5.36 3.32E-03 hyaluronan and proteoglycan link protein 1(HAPLN1) 




8.4.3 Treated vs non-treated 
Table 8. Differentially expressed genes for all four NHDF, TGF-β1 treated (in low serum DMEM). NHDF-F22Br, 
M50F, F60Br and c64a. 12 and 24 h timepoints together; logFC +/-2, adjusted p value<0.05. Sorted on logFC. 
LogFC Adj. p value Gene name (ID) 
6.84 1.71E-21 KN motif and ankyrin repeat domains 4(KANK4) 
6.69 1.57E-20 KN motif and ankyrin repeat domains 4(KANK4) 
5.69 5.66E-26 early growth response 2(EGR2) 
4.93 7.53E-15 low density lipoprotein receptor class A domain containing 4(LDLRAD4) 
4.83 2.66E-19 claudin 14(CLDN14) 
4.77 4.83E-15 tetraspanin 2(TSPAN2) 
4.55 1.58E-20 adhesion molecule with Ig like domain 2(AMIGO2) 
4.49 1.64E-22 interleukin 11(IL11) 
4.37 3.24E-22 lnc-RP11-625H11.1.1-3 
4.23 3.24E-32 basic helix-loop-helix family member e40(BHLHE40) 
4.18 8.48E-15 frizzled class receptor 8(FZD8) 
4.08 2.51E-17 POU class 3 homeobox 2(POU3F2) 
4.06 1.50E-12 BTB domain containing 11(BTBD11) 
3.95 8.65E-22 NADPH oxidase 4(NOX4) 
3.63 1.99E-14 inhibitor of DNA binding 1, HLH protein(ID1) 
3.62 1.84E-27 NADPH oxidase 4(NOX4) 
3.62 4.35E-13 sphingosine-1-phosphate receptor 5(S1PR5) 
3.62 6.22E-18 heparin binding EGF like growth factor(HBEGF) 
3.56 1.17E-16 SRY-box 9(SOX9) 
3.56 1.12E-13 leukemia inhibitory factor(LIF) 
3.55 4.27E-28 xylosyltransferase 1(XYLT1) 
3.51 5.73E-23 prostate transmembrane protein, androgen induced 1(PMEPA1) 
3.50 5.85E-16 inhibitor of DNA binding 3, HLH protein(ID3) 
3.44 3.69E-24 POU class 3 homeobox 2(POU3F2) 
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3.40 1.17E-07 sclerostin(SOST) 
3.38 2.62E-14 tetraspanin 13(TSPAN13) 
3.32 4.88E-15 synapse differentiation inducing 1(SYNDIG1) 
3.32 7.98E-22 NADPH oxidase 4(NOX4) 
3.28 1.29E-19 growth differentiation factor 6(GDF6) 
3.28 1.11E-10 long intergenic non-protein coding RNA 1013(LINC01013) 
3.20 7.17E-20 dishevelled binding antagonist of beta catenin 1(DACT1) 
3.20 2.93E-15 interleukin 21 receptor(IL21R) 
3.16 4.15E-10 long intergenic non-protein coding RNA 1013(LINC01013) 
3.15 3.48E-18 syndecan 1(SDC1) 
3.14 3.10E-13 uncharacterized LOC79160(LOC79160) 
3.12 5.43E-10 long intergenic non-protein coding RNA 1013(LINC01013) 
3.08 1.49E-15 stathmin domain containing 1(STMND1) 
3.04 3.91E-11 spermatogenesis associated 17(SPATA17) 
3.03 7.26E-14 PBX/knotted 1 homeobox 2(PKNOX2) 
3.03 6.05E-09 transglutaminase 2(TGM2) 
2.93 1.55E-16 WNT1 inducible signalling pathway protein 1(WISP1) 
2.91 2.52E-04 forkhead box S1(FOXS1) 
2.91 1.16E-08 lnc-PRICKLE2-3 
2.91 4.04E-06 hyaluronan synthase 1(HAS1) 
2.89 2.89E-05 MyoD family inhibitor(MDFI) 
2.87 9.01E-10 archaelysin family metallopeptidase 1(AMZ1) 
2.83 4.53E-07 exostosin like glycosyltransferase 1(EXTL1) 
2.80 7.55E-17 MIR503 host gene(MIR503HG) 
2.80 7.96E-16 MIR503 host gene(MIR503HG) 
2.79 7.40E-10 phosphatidic acid phosphatase type 2 domain containing 1A(PPAPDC1A) 
2.78 1.17E-16 colony stimulating factor 1 receptor(CSF1R) 
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2.76 1.43E-10 long intergenic non-protein coding RNA 1013(LINC01013) 
2.75 7.37E-09 collagen type X alpha 1 chain(COL10A1) 
2.74 2.22E-12 RAS like family 11 member B(RASL11B) 
2.74 4.09E-07 TNF alpha induced protein 6(TNFAIP6) 
2.68 2.41E-11 LY6/PLAUR domain containing 1(LYPD1) 
2.67 3.21E-19 annexin A8-like 1(ANXA8L1) 
2.64 9.53E-10 chromosome 15 open reading frame 48(C15orf48) 
2.60 5.97E-07 cadherin EGF LAG seven-pass G-type receptor 1(CELSR1) 
2.59 1.20E-16 PC-esterase domain containing 1B(PCED1B) 
2.55 3.02E-10 F2R like trypsin receptor 1(F2RL1) 
2.54 1.42E-08 stimulated by retinoic acid 6(STRA6) 
2.52 6.70E-16 immediate early response 3(IER3) 
2.51 4.64E-10 opioid binding protein/cell adhesion molecule like(OPCML) 
2.51 9.90E-22 cysteine and glycine rich protein 2(CSRP2) 
2.50 6.93E-13 EFR3 homolog B(EFR3B) 
2.49 3.12E-08 dual specificity phosphatase 26 (putative)(DUSP26) 
2.48 4.90E-09 leucine rich repeat neuronal 3(LRRN3) 
2.48 3.33E-13 JunB proto-oncogene, AP-1 transcription factor subunit(JUNB) 
2.43 1.25E-13 scleraxis bHLH transcription factor(SCX) 
2.43 2.97E-15 immediate early response 3(IER3) 
2.42 9.45E-10 long intergenic non-protein coding RNA 1013(LINC01013) 
2.42 2.61E-14 uncharacterized LOC102724849(LOC102724849) 
2.41 4.65E-12 diacylglycerol kinase iota(DGKI) 
2.39 1.37E-13 fibronectin type III domain containing 1(FNDC1) 
2.37 9.77E-11 muscle related coiled-coil protein(MURC) 
2.37 9.52E-10 carbohydrate sulfotransferase 11(CHST11) 
2.37 1.84E-11 solute carrier family 19 member 2(SLC19A2) 
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2.34 4.83E-09 SLAM family member 8(SLAMF8) 
2.34 7.53E-15 transglutaminase 2(TGM2) 
2.33 1.12E-03 galanin and GMAP prepropeptide(GAL) 
2.33 3.93E-10 NIPA like domain containing 4(NIPAL4) 
2.31 4.27E-28 follistatin like 3(FSTL3) 
2.29 2.32E-16 RELT tumour necrosis factor receptor(RELT) 
2.29 6.23E-14 sterile alpha motif domain containing 11(SAMD11) 
2.29 1.90E-11 protocadherin 19(PCDH19) 
2.27 5.14E-17 collagen type VII alpha 1 chain(COL7A1) 
2.26 5.00E-10 inhibin beta A subunit(INHBA) 
2.25 1.75E-11 calbindin 2(CALB2) 
2.24 7.67E-03 peptidase inhibitor 16(PI16) 
2.24 2.84E-04 C-X-C motif chemokine ligand 5(CXCL5) 
2.23 3.61E-14 PC-esterase domain containing 1B(PCED1B) 
2.21 1.98E-19 ADAM metallopeptidase domain 19(ADAM19) 
2.19 4.74E-03 growth differentiation factor 10(GDF10) 
2.19 1.46E-07 leukocyte cell derived chemotaxin 2(LECT2) 
2.18 9.66E-11 pleckstrin 2(PLEK2) 
2.17 1.59E-11 connective tissue growth factor(CTGF) 
2.17 4.69E-12 long intergenic non-protein coding RNA 862(LINC00862) 
2.17 1.31E-08 Src-like-adaptor(SLA) 
2.15 3.21E-19 SMAD family member 7(SMAD7) 
2.15 6.16E-22 protein phosphatase 1 regulatory subunit 13 like(PPP1R13L) 
2.12 2.96E-09 collagen type IV alpha 1 chain(COL4A1) 
2.11 2.80E-22 paired like homeodomain 2(PITX2) 
2.10 1.16E-08 uncharacterized LOC102724849(LOC102724849) 
2.09 6.58E-17 spindle apparatus coiled-coil protein 1(SPDL1) 
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2.09 4.17E-06 growth arrest specific 7(GAS7) 
2.09 1.41E-08 C-X-C motif chemokine receptor 5(CXCR5) 
2.07 1.24E-11 tensin 1(TNS1) 
2.07 2.67E-14 tumour protein p53 inducible protein 3(TP53I3) 
2.07 2.33E-10 atypical chemokine receptor 3(ACKR3) 
2.06 1.71E-21 sphingosine kinase 1(SPHK1) 
2.06 9.89E-08 5-hydroxytryptamine receptor 2A(HTR2A) 
2.06 2.71E-06 endothelial cell specific molecule 1(ESM1) 
2.06 3.46E-07 distal-less homeobox 2(DLX2) 
2.06 1.57E-12 MICAL C-terminal like(MICALCL) 
2.05 2.35E-06 long intergenic non-protein coding RNA 673(LINC00673) 
2.04 9.18E-10 stathmin domain containing 1(STMND1) 
2.03 3.48E-18 spindle apparatus coiled-coil protein 1(SPDL1) 
2.03 7.77E-05 matrix metallopeptidase 10(MMP10) 
2.02 1.64E-03 serum amyloid A2(SAA2) 
2.02 4.91E-04 uncharacterized LOC389332(LOC389332) 
2.02 1.29E-11 snail family transcriptional repressor 1(SNAI1) 
2.01 2.05E-16 phosphoribosyl pyrophosphate synthetase 1-like 1(PRPS1L1) 
-2.00 5.30E-04 polypeptide N-acetylgalactosaminyltransferase 15(GALNT15) 
-2.01 6.22E-03 R-spondin 3(RSPO3) 
-2.02 3.08E-04 serpin family B member 2(SERPINB2) 
-2.02 1.63E-09 chromosome 1 open reading frame 21(C1orf21) 
-2.04 5.06E-10 NOVA alternative splicing regulator 1(NOVA1) 
-2.04 5.80E-08 adenosine A2b receptor(ADORA2B) 
-2.04 6.32E-08 mitochondria localized glutamic acid rich protein(MGARP) 
-2.05 4.04E-11 caspase 4, apoptosis-related cysteine peptidase pseudogene(LOC643733) 
-2.08 4.04E-11 ring finger protein 144B(RNF144B) 
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-2.08 9.93E-09 phosphodiesterase 7B(PDE7B) 
-2.08 3.55E-09 lnc-HRH4-7 
-2.08 4.36E-10 transmembrane protein 26(TMEM26) 
-2.08 1.35E-13 APC down-regulated 1(APCDD1) 
-2.09 1.37E-07 CNKSR family member 3(CNKSR3) 
-2.09 5.23E-06 fibroblast growth factor 13(FGF13) 
-2.10 3.06E-15 guanylate binding protein 2(GBP2) 
-2.10 6.79E-18 CNKSR family member 3(CNKSR3) 
-2.11 3.71E-13 LRRN4 C-terminal like(LRRN4CL) 
-2.11 3.04E-11 ADP ribosylation factor like GTPase 4C(ARL4C) 
-2.12 3.14E-06 ETS variant 1(ETV1) 
-2.13 4.01E-16 immunoglobulin superfamily member 10(IGSF10) 
-2.13 8.86E-12 ecto-NOX disulfide-thiol exchanger 1(ENOX1) 
-2.13 1.11E-11 interleukin 6 receptor(IL6R) 
-2.14 4.74E-06 mesoderm specific transcript(MEST) 
-2.14 7.68E-09 coiled-coil domain containing 170(CCDC170) 
-2.15 4.53E-03 ankyrin 1(ANK1) 
-2.16 4.09E-13 interferon induced protein with tetratricopeptide repeats 2(IFIT2) 
-2.18 3.18E-13 nuclear factor, erythroid 2(NFE2) 
-2.19 1.03E-09 coiled-coil domain containing 102B(CCDC102B) 
-2.20 7.27E-15 sprouty RTK signalling antagonist 1(SPRY1) 
-2.20 2.05E-15 heat shock protein family B (small) member 3(HSPB3) 
-2.21 3.55E-05 doublecortin like kinase 1(DCLK1) 
-2.21 2.48E-14 toll like receptor 3(TLR3) 
-2.21 6.69E-08 monoamine oxidase A(MAOA) 
-2.22 5.05E-08 caspase 1(CASP1) 
-2.22 1.21E-04 fibronectin leucine rich transmembrane protein 3(FLRT3) 
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-2.24 5.91E-12 purinergic receptor P2X 7(P2RX7) 
-2.24 9.00E-05 receptor interacting serine/threonine kinase 4(RIPK4) 
-2.26 2.27E-10 breast carcinoma amplified sequence 1(BCAS1) 
-2.26 1.95E-10 chromosome 1 open reading frame 167(C1orf167) 
-2.26 3.80E-18 regulator of calcineurin 2(RCAN2) 
-2.27 1.74E-05 serum deprivation response(SDPR) 
-2.27 6.32E-07 angiomotin(AMOT) 
-2.29 2.29E-17 transmembrane and tetratricopeptide repeat containing 1(TMTC1) 
-2.30 2.25E-07 roundabout guidance receptor 2(ROBO2) 
-2.31 1.72E-12 acyl-CoA synthetase short-chain family member 1(ACSS1) 
-2.31 1.85E-08 kinesin family member 5C(KIF5C) 
-2.32 2.17E-07 potassium voltage-gated channel subfamily B member 1(KCNB1) 
-2.32 2.29E-08 atypical chemokine receptor 4(ACKR4) 
-2.33 1.08E-15 long intergenic non-protein coding RNA 341(LINC00341) 
-2.33 1.87E-08 cathepsin C(CTSC) 
-2.33 7.86E-11 coiled-coil domain containing 102B(CCDC102B) 
-2.35 5.32E-07 annexin A3(ANXA3) 
-2.35 2.40E-14 cadherin related family member 3(CDHR3) 
-2.37 9.55E-15 GTPase, IMAP family member 2(GIMAP2) 
-2.37 1.09E-06 potassium voltage-gated channel subfamily J member 2(KCNJ2) 
-2.38 2.17E-15 armadillo repeat containing 4(ARMC4) 
-2.38 6.38E-12 lnc-SMC1B-2 
-2.39 1.11E-10 uncharacterized LOC101928188(LOC101928188) 
-2.40 8.03E-15 death associated protein kinase 1(DAPK1) 
-2.40 4.70E-22 odd-skipped related transciption factor 2(OSR2) 
-2.42 3.08E-09 uncharacterized LOC101929174(LOC101929174) 
-2.43 5.07E-08 uncharacterized LOC101929641(LOC101929641) 
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-2.43 5.93E-04 family with sequence similarity 65 member B(FAM65B) 
-2.43 9.38E-07 nuclear receptor subfamily 0 group B member 1(NR0B1) 
-2.43 6.58E-09 ecotropic viral integration site 2A(EVI2A) 
-2.45 1.69E-10 uncharacterized LOC101929174(LOC101929174) 
-2.45 2.32E-16 solute carrier family 9 member A9(SLC9A9) 
-2.46 4.43E-22 TBC1 domain family member 8(TBC1D8) 
-2.49 3.75E-07 calcium voltage-gated channel auxiliary subunit beta 2(CACNB2) 
-2.49 2.24E-03 ankyrin 1(ANK1) 
-2.49 5.62E-10 reticulon 4 receptor like 1(RTN4RL1) 
-2.50 3.19E-08 microtubule associated protein tau(MAPT) 
-2.51 2.91E-07 mesenchyme homeobox 2(MEOX2) 
-2.56 7.53E-15 secreted and transmembrane 1(SECTM1) 
-2.57 1.08E-05 myelin basic protein(MBP) 
-2.58 4.86E-10 long intergenic non-protein coding RNA 908(LINC00908) 
-2.58 1.17E-16 potassium voltage-gated channel modifier subfamily S member 2(KCNS2) 
-2.58 9.89E-11 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1(ST8SIA1) 
-2.62 6.27E-11 growth differentiation factor 5(GDF5) 
-2.63 1.17E-16 solute carrier family 7 member 14(SLC7A14) 
-2.65 2.70E-09 myosin VIIA and Rab interacting protein(MYRIP) 
-2.68 1.60E-13 signal induced proliferation associated 1 like 2(SIPA1L2) 
-2.71 6.83E-11 keratin associated protein 1-5(KRTAP1-5) 
-2.73 2.95E-07 KIAA1217(KIAA1217) 
-2.75 8.12E-20 RAB7B, member RAS oncogene family(RAB7B) 
-2.77 8.87E-17 RAS like family 11 member A(RASL11A) 
-2.78 2.63E-26 fatty acid hydroxylase domain containing 2(FAXDC2) 
-2.89 1.63E-11 ankyrin repeat domain 33B(ANKRD33B) 
-2.92 8.50E-14 pentraxin 3(PTX3) 
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-2.92 2.82E-05 cadherin 18(CDH18) 
-2.92 5.40E-09 integrin subunit beta 8(ITGB8) 
-2.93 1.03E-11 transmembrane protein 26(TMEM35) 
-2.98 6.44E-06 chromosome 10 open reading frame 105(C10orf105) 
-3.06 2.97E-13 keratin associated protein 1-5(KRTAP1-5) 
-3.09 7.54E-11 semaphorin 3A(SEMA3A) 
-3.09 2.47E-16 long intergenic non-protein coding RNA 908(LINC00908) 
-3.10 4.30E-16 solute carrier family 7 member 14(SLC7A14) 
-3.15 1.75E-11 interferon induced protein with tetratricopeptide repeats 1(IFIT1) 
-3.22 2.37E-06 lipid phosphate phosphatase-related 4(LPPR4) 
-3.27 1.21E-15 sterile alpha motif domain containing 12(SAMD12) 
-3.47 1.66E-11 alcohol dehydrogenase 1C (class I), gamma polypeptide(ADH1C) 
-3.59 4.33E-12 alcohol dehydrogenase 1A (class I), alpha polypeptide(ADH1A) 
-3.68 3.13E-14 peroxisome proliferator activated receptor gamma(PPARG) 
-3.70 5.72E-11 chromosome 11 open reading frame 87(C11orf87) 
-4.17 3.06E-15 periplakin(PPL) 




8.5 TaqMan gene expression assays 
Table 9. TaqMan assays used in the Fluidigm qPCR system. Genes ACTA2 and GLI1 run with multiple assays (*). 
Gene Gene ID Assay # 
actin, alpha 2, smooth muscle, aorta ACTA2* Hs00426835_g1 
actin, alpha 2, smooth muscle, aorta ACTA2* Hs00426835_g1 
actin beta ACTB Hs01060665_g1 
aldo-keto reductase family 1 member C3 AKR1C3 Hs00366267_m1 
adhesion molecule with Ig like domain 2 AMIGO2 Hs01938743_s1 
asporin ASPN Hs01550901_m1 
beta-2-microglobulin B2M Hs00187842_m1 
bone morphogenetic protein 4 BMP4 Hs03676628_s1 
caspase 1 CASP1 Hs00354836_m1 
cadherin 2 CDH2 Hs00983056_m1 
choline dehydrogenase CHDH Hs00294875_m1 
collagen type I alpha 1 chain COL1A1 Hs00164004_m1 
collagen type III alpha 1 chain COL3A1 Hs00943809_m1 
collagen type VI alpha 1 chain COL6A1 Hs00242448_m1 
collagen type VI alpha 3 chain COL6A3 Hs00915125_m1 
collagen type VII alpha 1 chain COL7A1 Hs00164310_m1 
collagen type VIII alpha 2 chain COL8A2 Hs00697025_m1 
catenin beta 1 CTNNB1 Hs00355049_m1 
C-X-C motif chemokine ligand 1 CXCL1 Hs00236937_m1 
C-X-C motif chemokine ligand 2 CXCL2 Hs00601975_m1 
C-X-C motif chemokine ligand 6 CXCL6 Hs00237017_m1 
dishevelled binding antagonist of beta catenin 1 DACT1 Hs00420410_m1 
dickkopf WNT signalling pathway inhibitor 1 DKK1 Hs00183740_m1 
dickkopf WNT signalling pathway inhibitor 3 DKK3 Hs00951307_m1 
dynein axonemal light intermediate chain 1 DNALI1 Hs00185750_m1 
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espin-like ESPNL Hs00811388_m1 
fibrillin 1 FBN1 Hs00171191_m1 
fibroblast growth factor 5 FGF5 Hs03676587_s1 
fibroblast growth factor 7 FGF7 Hs00940253_m1 
fibroblast growth factor 13 FGF13 Hs00182807_m1 
frizzled class receptor 8 FZD8 Hs00259040_s1 
glutamate-cysteine ligase catalytic subunit GCLC Hs00155249_m1 
glutamate-cysteine ligase modifier subunit GCLM Hs00157694_m1 
gliomedin GLDN Hs00738960_m1 
GLI family zinc finger 1 GLI1* Hs00171790_m1 
GLI family zinc finger 1 GLI1* Hs01110766_s1 
GLI family zinc finger 2 GLI2 Hs01119974_m1 
glycogen synthase kinase 3 alpha GSK3A Hs00997938_m1 
glycogen synthase kinase 3 beta GSK3B Hs00275656_m1 
haeme oxygenase 1 HMOX1 Hs01110250_m1 
interferon beta 1 IFNB1 Hs01077956_s1 
insulin like growth factor 1 IGF1 Hs01547656_m1 
interleukin 1 alpha IL1A Hs00174092_m1 
interleukin 1 beta IL1B Hs01555410_m1 
interleukin 1 receptor antagonist IL1RN Hs00893626_m1 
interleukin 6 IL6 Hs00985639_m1 
interleukin 8 IL8 Hs00174103_m1 
involucrin IVL Hs00846307_s1 
kelch like ECH associated protein 1 KEAP1 Hs00202227_m1 
KIT proto-oncogene receptor tyrosine kinase KIT Hs00174029_m1 
keratin 14 KRT14 Hs00265033_m1 
lymphoid enhancer binding factor 1 LEF1 Hs01547250_m1 
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long intergenic non-protein coding RNA 341 LINC00341 Hs00544575_s1 
monoamine oxidase A MAOA Hs00165140_m1 
microtubule associated serine/threonine kinase family member 4 MAST4 Hs00382423_m1 
mesoderm specific transcript MEST Hs00853380_g1 
matrix metallopeptidase 2 MMP2 Hs01548727_m1 
MAS related GPR family member F MRGPRF Hs01936726_s1 
nuclear factor, erythroid 2 like 2 NFE2L2 Hs00975961_g1 
nuclear factor kappa B subunit 1 NFKB1 Hs00765730_m1 
NADPH oxidase 4 NOX4 Hs00418356_m1 
NAD(P)H quinone dehydrogenase 1 NQO1 Hs00168547_m1 
phosphodiesterase 7B PDE7B Hs01054008_m1 
podoplanin PDPN Hs00366766_m1 
progesterone receptor PGR Hs01556702_m1 
periostin POSTN Hs01566734_m1 
peroxisome proliferator activated receptor gamma PPARG Hs01115513_m1 
peptidylprolyl isomerase A PPIA Hs04194521_s1 
peroxiredoxin 1 PRDX1 Hs00602020_mH 
peroxiredoxin 2 PRDX2 Hs00853603_s1 
patched 1 PTCH1 Hs00181117_m1 
protein tyrosine phosphatase, receptor type D PTPRD Hs00369913_m1 
receptor activity modifying protein 1 RAMP1 Hs00195288_m1 
regulator of G-protein signalling 16 RGS16 Hs00892674_m1 
ribosomal protein L13 RPL13 Hs00744303_s1 
secreted and transmembrane 1 SECTM1 Hs00356334_m1 
selenoprotein P, plasma 1 SEPP1 Hs01032845_m1 
SHC adaptor protein 2 SHC2 Hs01044373_m1 
sonic hedgehog SHH Hs00179843_m1 
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superoxide dismutase 1, soluble SOD1 Hs00533490_m1 
sortilin related receptor 1 SORL1 Hs00268342_m1 
sclerostin SOST Hs00228830_m1 
TATA-box binding protein TBP Hs99999910_m1 
transcription factor 3 TCF3 Hs00413032_m1 
transcription factor 4 TCF4 Hs00162613_m1 
transforming growth factor beta 1 TGFB1 Hs00998133_m1 
transglutaminase 1 TGM1 Hs00165929_m1 
Thy-1 cell surface antigen THY1 Hs00264235_m1 
toll like receptor 2 TLR2 Hs01872448_s1 
toll like receptor 3 TLR3 Hs01551078_m1 
tumour necrosis factor TNF Hs00174128_m1 
tenascin XB TNXB Hs00372889_g1 
WNT1 inducible signalling pathway protein 1 WISP1 Hs04234730_m1 
Wnt family member 4 WNT4 Hs01573505_m1 
Wnt family member 5A WNT5A Hs00998537_m1 
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